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Su m m a r y
Cystic Fibrosis (CF) is characterised by disrupted electrolyte and fluid transport 
because of mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) chloride (Cf) channel at epithelial mucosae. This condition is 
associated with a hyper-inflammatory pulmonary phenotype, which is 
exacerbated by chronic and repeated respiratory infections with bacteria such as 
Pseudomonas aeruginosa and Burkholderia cepacia. Coupled with the effects 
of bacterial toxins, an excessive and uncontrolled immune response results in 
the production of copious amounts of mucopurulent sputum, leading to severe 
bronchiectasis and premature death in more than 90 % of patients. Much of the 
tissue destruction is host-derived, mediated by the potent neutrophil 
chemoattractant interleukin (IL)-8.
The aims of this study were to characterise IL-8 production and C f channel 
activity by CF and non-CF airway epithelial cells, following stimulation with 
pharmacological or bacterial agonists, to identify any differences in host 
response that may be linked to the functional expression of CFTR. C f channel 
activity was measured by fluorescence and radioisotopic labelling and the 
production of IL-8 and IL-10 was determined using ELISA. In addition, 
specific pharmacological inhibitors were employed to investigate the 
involvement of mitogen-activated protein (MAP) kinases in cytokine 
production.
It was shown that both P. aeruginosa and B. cepacia modulated C f channel 
activity in the respiratory epithelium, although the effects did not appear to be 
CFTR-dependent. Furthermore, epithelial IL-8 production was increased via 
structural and secreted factors from both P. aeruginosa and B. cepacia, but 
these latter effects were antagonised by MAP kinase inhibitors, implying a role 
for MAP kinases in mediating secretion of this chemokine. In particular, p38 
MAP kinase was required for IL-8 production by CF-cells, suggesting that this 
protein could provide a potential target for therapeutic intervention to 
ameliorate bacterial-derived tissue damage in the CF lung.
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Cystic fibrosis (CF) is the most frequent lethal genetic disorder in the Western 
world, affecting 1 in 2500 live births in Caucasian populations (1). Relatively 
small numbers of other ethnic groups such as the Ashkenazi Jews and American 
Blacks are also affected (2). First described by Dorothy Andersen in children 
with fibrocystic disease of the pancreas (3), CF is a disorder of mucous 
membranes and the exocrine glands in which electrolyte and fluid transport are 
disturbed and this imbalance forms the basis for the ‘sweat-test’, which detects 
excessively high saline concentrations in the sweat and is diagnostic of CF (4). 
Cystic fibrosis results from recessive mutations in the gene encoding a single 
chloride (Cf) channel expressed in apical epithelial membranes (5;6). 
Hypertonic, viscid secretions obstruct the conducting tubes o f a number of 
organs and the clinical consequences of CF range from meconium ileus, 
diabetes, pancreatitis and infertility to life-threatening lung dysfunction (1).
Half a century ago the median survival age was 3-5 years, and malnutrition and 
staphylococcal pneumonia were the predominant causes of death in CF (7;8). 
Gastrointestinal (GI) problems can be managed successfully now after the 
introduction of pancreatic enzyme therapy in the 1950s, although GI symptoms 
still cause significant morbidity. However, chronic and recurrent respiratory 
infections that are the hallmarks of CF cannot be eradicated and, following a 
massive and uncontrolled inflammatory response by the host, eventually lead to 
pulmonary failure and premature death in more than 90 % of CF patients (4). 
Because of the intensive and multidisciplinary research effort during the past 
decade, the figure for life expectancy is approaching 40 years of age (8) and will 
increase as understanding and intervention strategies improve. CF is a 
particularly complex disease, understanding of which requires consideration of
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three fundamental and inter-related elements, namely genetic mutation, 
inflammation and infection. This chapter provides a detailed analysis of the 
three components and examines how they contribute to the pathogenesis of CF.
1.1 The Genetics of CF.
1.1.1 Characterisation of the Disease.
In 1989 the autosomal gene responsible for CF was identified on the long arm 
of chromosome 7 and the encoded protein was named the ‘cystic fibrosis 
transmembrane conductance regulator’, or CFTR (9-11). Since its discovery 
more than 850 recessive mutations have been reported within the gene (CF 
Genetic Analysis Consortium, http://www. zenet. sickkids. on. ca/cftrA and 
approximately 1 in every 25 people of North European extraction is 
heterozygous for a CF gene mutation (2). Disease status is associated with 
genotype and covers a broad range of symptoms (12). Patients with ‘typical’ 
CF, such as those with the most common genotype, cftr AF508 1 AF508, display 
pancreatic insufficiency from an early age and develop severe lung pathology 
that ultimately is fatal (1). At the opposite end of the clinical spectrum are 
patients with ‘atypical’ CF’ who may not be diagnosed until adulthood because 
of less common symptoms (13). These individuals suffer from mild or no 
respiratory or pancreatic disease (12). Most CF patients fall somewhere 
between the two states, although a precise phenotypic profile for each genetic 
combination has not been delineated.
The clinical outcomes in the sweat gland and pancreas can be predicted from a 
known genotype but this ‘genotype: phenotype correlation’ is poor with respect
3
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to the lungs, in part owing to the effects of so-called ‘modifier genes’ which can 
attenuate the severity of lung pathophysiology but which show different activity 
in different individuals (14; 15). It should be emphasised that siblings with CF 
may demonstrate different clinical progression since non-genetic factors can 
alter the outcome of this condition drastically (16-18).
1.1.2 The carrier advantage in CF.
Since CF is such a devastating disease, it is reasonable to speculate why natural 
selection has allowed these mutations to remain in the gene pool. Three main 
hypotheses have been proposed on the basis of heterozygous advantage. 
Escherichia coli and Vibrio cholerae enterotoxins over-activate the CFTR Cl' 
channel in the gut causing massive outpourings of watery stools and severe 
dehydration (19;20). Such episodes are usually fatal in infants and in 
developing countries where hygiene and sanitation are poor. Indeed, diarrhoeal 
disease still poses the single greatest threat to public health worldwide, killing 3 
-  4 million people each year (20). Reduced expression of a functional CFTR 
C f channel because of a heterozygous mutation would decrease the unwanted 
effects of these enterotoxins. Pier et al. have suggested that this selective 
pressure may be compounded by Salmonella typhi, the causative agent of 
typhoid fever, which enters gut epithelial cells by binding to CFTR (21).
A third hypothesis states that non-CF carriers of AF508 are less likely to 
develop bronchial asthma (22). This latter suggestion was proposed on the basis 
that diminished fluid movement across the respiratory epithelium would reduce 
the accumulation of intraluminal inflammatory mediators that usually would 
provoke an asthma attack (22). However, this idea has been challenged (23)
4
Chapter 1: Introduction
because the incidence of asthma related deaths worldwide is relatively low. 
Understanding the different types of mutation in cftr will permit a more 
thorough assessment of these selective pressures and highlight potentially novel 
targets for therapeutic intervention. This understanding requires an appreciation 
of the biosynthetic processing of CFTR.
1.1.3 CFTR Biosynthesis.
In common with the majority of integral membrane proteins, CFTR is fed co- 
translationally into the endoplasmic reticulum (ER) lumen during synthesis at 
the ribosomes of the rough ER, glycosylated in the Golgi complex and inserted 
into the plasma membrane. Incorrectly folded CFTR is targeted for degradation 
via the ubiquitin-26S proteasome pathway (24;25). CFTR is a complex, multi­
domain protein with necessarily slow post-translational processing kinetics 
compared with the kinetics of degradation, and only 20-30% of mature, 
functional CFTR is exported to the plasma membrane successfully (26). This 
efficiency is reduced even further in CF.
1.1.4 Characterisation of CFTR mutations.
Missense, nonsense, ffameshift and mRNA splice mutations in cftr have 5 broad 
molecular consequences, which are discussed in detail in several comprehensive 
references, for example (27-29). These mutation classes are summarised in 
Figure 1.1.
1.1.5 The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
CFTR is known best as a cAMP-regulated Cl* channel expressed at the apical 
epithelial membrane of most tissues (30). However, a picture is evolving of
5
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CFTR as a protein involved in a plethora of physiological processes within the 
cell and the relative contribution of each function of CFTR may need to be 
reassessed.
CFTR is composed of 1480 amino acids and has an approximate molecular 
mass of 170-kDa (10). Two non-identical motifs, each containing a membrane- 
spanning domain (MSD) of 6 transmembrane (TM) a-helices, and a nucleotide 
binding domain (NBD) are joined to form CFTR by a large, highly charged 
cytoplasmic regulatory (R) domain (10) illustrated in Figure 1.2. CFTR 
interacts with other proteins (Figure 1.3), which maintains its position at the 
membrane and mediates its regulation of other ion channels (31-38;48;49) .
CFTR is a member of the ATP-binding cassette (ABC) superfamily of 
membrane transporters, which are found extensively in many organisms ranging 
from bacteria to mammals (39) although CFTR differs from other ABC 
transporters both structurally and functionally. Whilst the NBDs and 6- 
transmembrane-MSDs are defining features of this molecular class, the conjugal 
R-domain is unique to CFTR (10;27). Coupling of the two motifs via the R- 
domain creates a low-conductance C f channel, yet all other members of this 
gene superfamily assemble as ATP-driven membrane pumps (39). Chloride can 
move freely in either direction through the pore, governed by activation of the 
channel and the electrochemical gradient across the membrane. In contrast, the 
movement of a substrate via its ATP-driven transporter usually is unidirectional 
and is limited stoichiometrically by ATP hydrolysis. CFTR is a multifunctional 
protein with different roles ascribed to distinct domains.
6
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1.1.6 CFTR forms a functional chloride channel.
Unusually, gating of CFTR is dependent upon both ATP hydrolysis and 
phosphorylation by cAMP-dependent protein kinase A (PKA) (40;41). It is 
accepted widely that the TMs assemble into the C f channel pore and that 
positively charged residues such as Arg-352 (Figure 1.2) contribute to the 
anion-selectivity of CFTR (42). Specific residues from TM domains in both 
MSDs are involved in channel function (42).
1.1.7 Secondary functions of CFTR.
In addition to being an ion channel per se, CFTR regulates a number of other 
channels in the epithelium (35-38). CFTR modulates cell proliferation and 
differentiation (43) and may regulate vesicular traffic (44), as well as its 
potential role as an epithelial receptor for P. aeruginosa (45). CFTR prevents 
the influx of sodium across the airway epithelium by down-regulating the 
amiloride-sensitive epithelial sodium channel, ENaC, through interactions with 
NBD-1 (35), compounding the problem of dehydrated secretions at mucous 
membranes. Activated CFTR causes an efflux of ATP from the cell, which 
binds purinergic receptors on the luminal membrane face and stimulates a 
medium C f conductance through outwardly rectifying chloride channels 
(ORCC) (46). Therefore, absence or reduced expression of CFTR at the apical 
membrane can have secondary effects on transepithelial C f conductance. These 
studies illuminate potential targets for pharmacological intervention in CF.
7
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Normal Class I Class II Class III Class IV Class V
effect 110 block in block in altered reducedsynthesis processing regulation conductance synthesis
mutation
type
Nonsense Missense Missense Missense Missense
example G542X aa deletion 
AF508
G551D R117H A455E
Figure 1.1 Classes of mutation affecting CFTR. Wild-type CFTR (blue) is transcribed in the 
nucleus (black) and processed in the Golgi and ER (white), where it is inserted into vesicle 
membranes and transported to the apical epithelial cell surface to form a functional chloride 
channel (far left). Numerous mutations affect one or more steps of the biosynthetic pathway 
resulting in failed expression of functional CFTR. For example, from left to right, mutation 
Classes I and II do not allow the production o f any protein, whilst Class III produces correctly 
folded protein but dysregulation prevents its proper functioning as a Cl * channel. Class IV 
mutations produce functional protein that reaches the membrane but cannot conduct Cl * ions 
correctly, whilst Class V mutations affect the transcription or translation efficiency of CFTR so 
that fewer functional CFTR molecules are expressed at the apical membrane, compared with 
wild-type cells. Abbreviations: aa -  amino acid. Adapted from ref. (29).
8
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L ipid  b ilayer
Airway
NBD1
Figure 1.2 Membrane topology of CFTR. Two motifs, each comprising six TM regions and 
a NBD are joined by a highly charged regulatory (R) domain at the apical epithelial membrane. 
Arg-352 is a major determinant of charge selectivity of the channel. Adapted from ref.(47)
Syntaxin 1A





Figure 1.3 Interaction of CFTR with cellular components. Localization o f CFTR to the 
apical membrane is via N-terminal interactions with syntaxin 1A (48), and C-terminal 
interactions with the actin cytoskeleton, which are required for CFTR to function correctly (49) . 
EBP50 (ezrin-binding phosphoprotein 50) contains a PDZ domain t hat binds ezrin with great 
affinity, which in turn associates with cell scaffolding components such as actin (31).
9
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1.2. The Host Response to Infection.
1.2.1 The immune response and inflammation in the CF lung.
Microbial products trigger an immune response in the local environment 
beginning with a rapid but non-specific reaction from components of the 
‘natural* (innate) immune system. Extensive networks of proinflammatory 
cytokines amplify the innate response and stimulate cells of the ‘specific’ 
(acquired / adaptive) immune system. Anti-inflammatory cytokines are released 
as the infection is cleared and the stimulus is removed, switching off the 
immune response when it is no longer required.
Resolution of the inflammatory response is essential since host-derived tissue 
damage is as detrimental as that instigated by a pathogen. Indeed, inappropriate 
immunological activity coupled with intractable bacterial infection results in the 
pathophysiological scenario in the CF lung. There is much in vitro evidence 
that CF pulmonary inflammation precedes infection (50-52), including data 
from an uninfected AF508 mouse model (53) that demonstrated elevated 
respiratory levels of lymphocytes and inflammatory mediators. Contradictory 
findings state that inflammation occurs only after infection and increases 
relative to bacterial culture counts (54) but it is difficult to disregard the in vivo 
data. The inherent predisposition of the CF lung to inflammation likely is 
exacerbated by Respiratory Syncytial Virus (RSV), an important cause of 
inflammatory chest infections in very young children and particularly in those 
with CF (55). One consequence of RSV infection seen in the alveolar cell line 
A549 (56) and human macrophages (57) was increased secretion of interleukin- 
8 (IL-8), findings that have important implications for CF. Depleted or
10
Chapter 1: Introduction
inactivated mechanisms of natural immunity could allow viruses to persist in the 
CF respiratory tract and establish an early infection-inflammation cycle that 
may encourage adapted bacterial pathogens to thrive.
Recurrent respiratory infections provoke an intensive and uncontrolled attack 
from non-clonal host factors. A functional adaptive response is activated but is 
ineffective in the CF pulmonary microenvironment. Cytotoxic molecules are 
released into the lung by the host with catastrophic effects on airway tissue so 
that ironically, the host itself causes much of the lung pathology associated with 
CF. The following section describes components of the immune response and 
how each may be affected by the absence or dysfunction of CFTR.
1.2.2 Physical barriers to infection at the epithelium.
The respiratory tract is lined with polarised epithelial tissue covered by a very 
thin layer (10-15 pm deep) of airway surface fluid (ASF; also known as airway 
surface liquid, ASL) (58) and a second layer of mucus that prevents bacterial 
adherence and traps inhaled particles in the airways. Both secretions contain a 
myriad of microbicidal agents. Thousands of cilia project from the apical 
epithelial surface and beat rhythmically into these secretions. However, 
disrupted transepithelial fluid and electrolyte transport experienced in CF has 
profound effects on the mucociliary clearance capacity of the lung, resulting in 
hyper-secretion of dehydrated viscid mucus that overwhelms the cilia (59,60). 
The ‘isotonic model’ proposes that the CFTR defect reduces the volume of ASF 
that bathes the epithelium so that the cilia no longer can disengage the mucus 
bed to allow its propulsion (61). An alternative and equally widely held view of 
the situation in the CF lung is termed the “hypotonic model”. In this scenario
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the volume of fluid bathing the lung remains the same as that in the normal 
lung, but the ionic composition of this ASF is altered, inactivating certain salt- 
sensitive proteins, as discussed later.
Another cardinal feature of CF is P. aeruginosa colonisation of the lung in 90 % 
of patients (62). P. aeruginosa secretes pyocyanin and 1-hydroxyphenazine, 
both of which inhibit ciliary beating by disruption of cyclic nucleotide pathways 
(63); and the lipopolysaccharide (LPS) component of P. aeruginosa outer 
membrane induces mucin glycoprotein synthesis via upregulated MUC2 gene 
expression in the lung (64). Another barrier to the establishment o f microbes at 
the epithelial surface is desquamation of damaged or infected cells, a commonly 
used mechanism for preventing infection in the urinary tract. It has been 
proposed (45;65) that P. aeruginosa binds to CFTR and is taken up into the 
normal respiratory epithelial cell then sloughed-off for infected cells to be 
destroyed by phagocytosis. Hence, decreased pulmonary expression of CFTR 
in CF could allow the persistence of P. aeruginosa within the lung directly 
(45;66), although there is by no means agreement on this point (65;67;68). 
P. aeruginosa exacerbates and exploits many immunoregulatory features of the 
CF lung, discussed in the more specific context of bacterial infection. It is clear 
that the epithelium is not merely a physical barrier but that this structure 
actively produces and interacts with a multitude of host- and pathogen-derived 
molecules and cells and in so doing makes an important contribution during the 
immune response to infection.
12
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1.2.3 Biochemical modulators of infection and inflammation.
Many natural biocides exist at the respiratory mucosa and yet in CF, pulmonary 
infection occurs repeatedly and chronically. Mutations in cftr reduce the 
expression of some of these biochemical factors; whilst the functional integrity 
of other components may be disrupted by the abnormal tonicity of CF 
respiratory secretions (69-71). Both salt-insensitive and salt-sensitive agents are 
discussed to highlight how a failure of each mechanism potentially could affect 
CF respiratory immunology.
1.2.3.1 Complement
Complement-mediated elimination of potential pathogens is achieved by 
opsonisation, target cell lysis, chemotaxis, and immune complex removal, 
which have been ascribed to different complement factors (72). The 
intermediate C5a has inflammatory effects that include degranulation of 
basophils and mast cells; and increased vascular permeability, allowing 
extravasation of neutrophils and monocytes to the site of infection. The C5a 
fragment and its receptor (C5aR) were examined as potential culprits for the 
ineffectiveness of CF innate immunity and a local deficiency in C5a and its 
receptor in CF airways has been postulated (73). Knockout mice lacking C5aR 
were shown to suffer more severe P. aeruginosa infection than did their C5aR- 
competent littermates (74) despite normal trafficking and infiltration of 
neutrophils. Precisely why depletion of the C5a system should impair the 
clearance of P. aeruginosa from the lung is unclear. Murine models also were 
used to investigate the properties of collectins, another group of antimicrobial 




Collectins include the surfactant proteins, SP-A and SP-D, and mannose- 
binding protein (MBP), which mediate host-parasite interactions including 
opsonisation, bacterial aggregation and enhanced uptake of intracellular 
pathogens (75). Expression of SP-A and SP-D is reduced in some CF patients 
(76) which may lead to reduced clearance of both P. aeruginosa (77) and 
Staphylococcus aureus (75).
1.2.3.3 Nitric oxide
Nitric oxide (NO) regulates distinct cellular processes depending on its 
localisation and concentration, as discussed in several reviews (78;79). NO is 
synthesised from L-arginine by nitric oxide synthase (NOS) which exists in at 
least three different isoforms. The calcium-dependent isoform is expressed 
constitutively (cNOS) and the inducible isoform (iNOS) is expressed during 
inflammation (80). Usually, calcium-dependent cNOS produces NO at 
picomolar concentrations, which regulate vasorelaxation tightly. However, 
during endotoxic shock, the iNOS-derived levels of NO increase in response to 
high levels of bacterial LPS with the result that relaxation of smooth muscle and 
blood vessels becomes uncontrolled (81). Nanomolar amounts of NO are 
generated by iNOS in cells of the immune system providing an important innate 
defence mechanism against pathogens (82;83). Very recently, NO has been 
shown to potentiate killing of Burkholderia cepacia by hydrogen peroxide (84) 
and to a lesser extent, killing by superoxide. Oxidation of nitrogen species by 
superoxide generates peroxynitrite (ONOO ), a potent bactericidal molecule that 
attacks prokaryotic copper- and iron-containing proteins to release free Cu2+ and 
Fe2+ and highly toxic, oxidising hydroxyl and superoxide radicals (85). It has
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been suggested that there is a positive correlation between NO levels and 
bronchiectasis, which is probably mediated by IL-lp and TNF-a. Exaggerated 
NO production is observed in asthma but not in CF, indeed some research 
shows iNOS expression to be reduced considerably in cells displaying mutant 
CFTR (86). Other published data suggest that total exhaled oxidised nitrogen 
species are elevated in CF (87). NO activates cGMP and by doing so NO can 
regulate respiratory transepithelial Cl' currents (88), which is also of 
considerable relevance to CF.
The molecular basis for reduced expression of NOS, C5aR and surfactant in the 
CF lung has not been explained satisfactorily but several researchers have 
proposed that the impotence of some other antimicrobial agents within the CF 
lung, such as defensins, may be related to disturbed tonicity in CF pulmonary 
secretions.
1.2.3.4 Defensins
Defensins belong to a large and highly conserved family o f small (3 -  6-kDa) 
endogenous cationic antimicrobial peptides (89). Many eukaryotic species 
including plants and insects have been shown to express defensin homologues 
(see reference (90) for a recent review) and this phylogenetic conservation 
highlights the importance of such molecules in innate immunity. Peptide 
antibiotics have variable broad-spectrum activity against bacteria, fungi and 
some enveloped viruses (91). (3-defensins are synthesised locally and 
continuously by mammalian epithelial cells (71;92-95) and their expression 
may be upregulated by a local inflammatory environment. Type-1 human beta 
defensin, hBD-1, is expressed constitutively at tissue-specific levels in many
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sites including renal, intestinal and respiratory epithelia (71;92;96). In contrast, 
Type-2 beta defensins including hBD-2 (94) and mouse p defensin 3 (97) are 
expressed constitutively at much lower levels but may be induced by 
microorganisms and their products, as well as by inflammatory mediators (95). 
Reported levels of defensins may differ slightly from one study to another, but it 
is clear that these molecules play a major role in mammalian epithelial 
immunology.
Cationic defensins kill bacteria by disrupting high affinity glycolipid-ionic 
electrostatic forces in the prokaryotic membrane and creating ion-permeable 
pores (98). Electrostatic interactions with LPS confer anti-endotoxic properties 
on defensins (99), potentiating the anti-inflammatory effects of these peptides. 
Defensins have been implicated in CF as potentially major culprits o f failed 
innate respiratory defence. Seminal research in 1996 at the University of Iowa, 
USA demonstrated that ASF from non-CF airways inhibited the growth of 
clinically important CF pathogens but that hypertonic respiratory secretions 
from CF airways did not (69). This bacterial inhibition was shown to be 
reversibly salt-sensitive. Within a short time, another research group confirmed 
suspicions that hBD-1 was responsible for at least some of the salt-sensitive 
antimicrobial activity of ASF (71) and more recently, hBD-2 has been 
implicated as an additional candidate for impotence against P. aeruginosa 
infection in CF (93;100). These intriguing observations had identified a major 
and plausible link between the genetic defect and recurrent pulmonary infection 
in CF, and suggested that clinical restoration of defensin activity could be 




Chronic Granulomatous Disease (CGD) patients lack NADPH reductase so 
these individuals rely on non-oxidative antimicrobial mechanism, such as 
defensins, to kill invading bacteria (101). Interestingly, CGD patients as well as 
CF sufferers, become colonised with B. cepacia (101), suggesting that 
B. cepacia is resistant to defensin-mediated killing. This resistance was 
confirmed very recently (102) so that restoration of defensin activity will have 
little benefit for CF patients colonised with B. cepacia.
1.2.3.5 Cytokines co-ordinate the immune response
Cytokines are peptide hormones that range up to 40-kDa in size and are secreted 
by many cell types, regulating further cytokine production, cell proliferation or 
apoptosis. For example, macrophages produce IL-lp, TNF-a and IL-8 in 
response to bacterial antigens such as LPS. IL-ip and TNF-a are potent early- 
response cytokines, sharing many effects and acting on a range of cell types 
including neutrophils, epithelial cells and the vascular endothelium to attract 
neutrophils to the site of infection via IL-8 signalling, discussed later. In 
addition, IL-lp and TNF-a act in both a paracrine and an autocrine fashion on 
macrophages and this activity serves to magnify and reinforce the inflammatory 
response. Unusually high systemic levels of IL-lp and TNF-a resulting from 
chronic activation of the immune system may exacerbate cachexia, a common 
symptom of CF that stems from pancreatic insufficiency and other 
gastrointestinal complications (103; 104). Whilst high concentrations of TNF-a 
can induce apoptosis in some cell types (105), no lethal effects of IL-lp have 
been observed. Furthermore, TNF-a is not produced by epithelial or 
endothelial cells, yet both tissues synthesise IL-lp (106). Thus, despite having
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some targets and effects in common, these cytokines display some important 
differences so that neither IL-lp nor TNF-a is functionally redundant. Notably, 
B. cepacia induces human monocytes to increase their production of TNF-a 
(62), which could add significantly to CF pulmonary inflammation.
The anti-inflammatory cytokine IL-10 is produced mainly by type-2 helper T 
(Th2) lymphocytes and is an important molecule in the resolution of the 
immune response by reducing the inflammatory effects of macrophage-derived 
cytokines induced by LPS (107). Some epithelial cells also secrete IL-10 but 
the expression of this cytokine is reduced in CF in both epithelial and 
lymphocyte cells (103,108-110) and consequently the activity o f IL-lp and 
TNF-a from alveolar macrophages is not regulated. Decreased secretion of the 
anti-inflammatory IL-10 may be as important as increased pro-inflammatory 
mediator production in creating an uncontrolled inflammatory environment at 
CF respiratory epithelia.
Some cytokines, such as IL-8, induce directional chemotaxis of leukocytes, 
earning them the name chemokines (a contraction of chemot&ctlc cytokines). 
Chemokines constitute a group of 8 -  10-kDa molecules that act via subsets of 
G protein-coupled receptors on a multitude of different cell types with 
inflammatory results (see (111;112) for recent reviews). Neutrophil elastase 
and IL-lp both induce IL-8 release from respiratory epithelial cells and from 
neutrophils (113; 114), as does neutrophil-derived IL-8 (115), establishing a 
localised cycle of inflammation. Several products of P. aeruginosa and 
B. cepacia elicit IL-8 from epithelial cells and peripheral blood monocytes 
(116; 117) although the underlying molecular mechanisms have not been
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delineated. Surprisingly, recent work by Schwiebert et al. (118) challenges the 
notion that upregulated IL-8 expression correlates with defective CFTR 
expression but despite their claim that differences in IL-8 production between 
CF and non-CF tissues are insignificant, data presented in this paper show 
greater basal production of IL-8 in some CF cell lines so that their dismissal of 
CFTR-dependent IL-8 expression should be accepted with caution. Even more 
intriguing was the observation by Massengale et al. (119) that in fact IL-8 
production is decreased in CF cells compared with those that expressed wild 
type CFTR. Nevertheless, it is clear that IL-8 and other cytokines are important 
molecules that synchronise the biochemical and cellular defence systems in the 
immune response to infection.
1.2.4 Cell-mediated pulmonary immunity.
1.2.4.1 Pulmonary macrophages.
Respiratory macrophages are of particular importance as a source of pro- 
inflammatory mediators, as a link between lung and systemic responses, and in 
the removal of immune complexes from the CF lung (120). Macrophages 
constitute the major surveillance cells in host defence, patrolling the epithelial 
mucosae for foreign molecules, which they bind and remove by phagocytosis. 
Stimulated macrophages releases IL-lp and TNF-a that recruit and activate 
numerous target cells including neutrophils and the epithelium, which express 
cell adhesion molecules and secrete additional inflammatory signals. Despite 
the eventual activation of specific lymphocytes, CF pathogens are not 
eliminated and the innate responses become chronic with severe 
pathophysiological consequences. Under normal circumstances the macrophage 
would initiate wound healing, as the infection is resolved. In CF, pulmonary
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infection is not cleared so these processes are activated chronically and thick 
scars form at sites of host-derived pulmonary damage, caused mainly by 
neutrophils.
1.2.4.2 Neutrophils
By far the most abundant leukocyte in the CF lung is the neutrophil (120), or 
polymorphonuclear leukocyte (PMN), and its most potent stimulus is IL-8 
(121). IL-8 is produced by the epithelium, the endothelium and macrophages in 
response to macrophage-derived IL-lp and TNF-a (113-115). Combinations of 
IL-lp, TNF-a and IL-8 up-regulate the surface expression of adhesion 
molecules on the neutrophil, the endothelium and tissue through to the 
respiratory epithelial mucosa (120; 122) in order to facilitate this recruitment of 
neutrophils by diapedesis.
Activated neutrophils possess a variety of bactericidal mechanisms such as 
digestive enzymes, antimicrobial peptides, and the synthesis of reactive oxygen 
and nitrogen species (ROS and RNS, respectively), which are 
compartmentalised in neutrophil granulocytes to prevent host-cell damage. In 
CF, however, the activated neutrophil is unable to engulf target bacterial cells 
because of alginate production and the formation of bacterial microcolonies 
termed biofilms (7). Instead, the neutrophils empty their lysosomal contents 
including anionic radicals and elastase into the extracellular milieu where these 
molecules attack the lung epithelium. Elastin provides alveoli with their 
essential plasticity so the host secretes small amounts of anti-leukoprotease 
(ALP) (123) and ai-antitrypsin (124) to counteract spurious elastase leakage. 
However, the combined elastase derived both from neutrophils and
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P. aeruginosa overwhelms these inhibitory molecules (125). Thin, flexible lung 
tissue is replaced by thickened fibrotic material so that gaseous exchange across 
the CF lung is impaired severely. Neutrophil elastase (NE) elicits further IL-8 
release from neutrophils and from respiratory cells, as demonstrated in a cftr 
AF508/AF508 ce|j jjne (J26), establishing a local autocrine amplification cycle of 
inflammation.
1.2.4.3 Role of adaptive cellular immunity in CF.
The specific arm of host defence is provided by T lymphocytes and B 
lymphocytes, and functions normally in CF (120). Activated B cells synthesise 
and release a variety of Ig isotypes including IgA, which is important in 
eliminating respiratory infections. In support of this hypothesis, both 
Haemophilus influenzae (127) and P. aeruginosa (128) produce IgA-specific 
proteases that degrade this immunoglobulin isotype as a mechanism for averting 
the host response.
Two major populations of T cells are defined according to whether they express 
CD4 (helper T, Th cells) or CD8 (cytolytic T, Tc cells). Th2 cells secrete IL-4, 
IL-5, IL-10 and IL-13 and are associated particularly with an allergic or 
humoral (Ig-mediated) immune response against extracellular pathogens (129). 
In contrast, the predominant ThI cell-derived cytokines are IFN-y and IL-2 and 
this lymphocyte sub-population assists CD8+ T cells eliminate intracellular 
infection (129). IFN-y also activates B cells (which produce opsonising 
immunoglobulin) and macrophages to enhance phagocytosis of infecting 
pathogens. Bronchial epithelial cells stimulated with IFN-y produce 
chemokines that signal through the CXCR3 molecule found predominantly on
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ThI cells thus amplifying the ThI response (130). Neither IL-ip nor TNF-a 
induced the production of these chemokines from the bronchial cells, but 
instead elicited the detrimental production of IL-8 (130). Not only is IL-8 a 
pivotal mediator of excessive neutrophil activity in CF, but also this chemokine 
drives Th2-mediated production of antibody against extracellular organisms that 
is ineffective in CF (131).
B. cepacia has been reported to invade (132) and replicate in activated 
macrophages (133), as well as replicating in epithelial cells (134). It is possible 
therefore that ThI lymphocytes would be more effective than Th2 cells against 
CF infections with B. cepacia and recent data provided by Sauty et al. 
demonstrate that this could be achieved by stimulating epithelial cells with IFN- 
y (130). Another study by Moser et a l (135) examined CF patients with chronic 
P. aeruginosa infection and showed that these patients exhibited Th2 responses 
most frequently, and that this type of response correlated with poor lung 
function compared with those patients exhibiting TrI responses. Thus, driving 
the immune system towards TrI and away from Th2 type responses could 
benefit chronically infected CF patients.
1.2.5 Co-ordination of the response via intracellular signalling.
Cells respond to environmental stimuli, such as the presence of bacterial 
products or pharmacological agents, in a bewildering variety of ways that may 
be mediated directly, for example via protein phosphorylation, or indirectly via 
second messengers. Extracellular information is relayed to the nucleus via 
intracellular signalling cascades that begin in general with a ligand-receptor 
interaction at the membrane. Many receptor types and signalling pathways have
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been described, but discussion here is restricted to interactions that regulate two 
distinct and important airway epithelial cell responses, namely activation of the 
CFTR Cl' channel and production of inflammatory mediators.
1.2.5.1 Activation of CFTR
Pharmacological mediators that activate the CFTR Cl' channel operate by 
means of the second messenger, cAMP, as depicted in Figure 1.4, allowing 
rapid and transient control of C f efflux via CFTR. In contrast, some cellular 
effects display much slower reaction kinetics and occur over periods of minutes 
or hours. For example, transcription of inflammatory components mediated by 
a cohort of kinase and phosphatase molecules in response to IL-ip and TNF-a 
can take several hours.
1.2.5.2 Signalling via IL -lp  and TNF-a.
These pathways have been relatively well characterised and are depicted in 
Figure 1.5.
1.2.5.3 MAP kinase signalling cascades.
Mammalian cells possess three main families of MAP kinases, namely 
extracellular signal regulated kinase (ERK), and the stress-activated protein 
kinases (SAPK) p38 MAP kinase and c-Jun N-terminal kinase (JNK), which 
regulate development, growth, protection against stress, the immune response 
and prevention of damage to DNA (136-139). MAP kinase molecules respond 
synergistically to distinct extracellular cues and their complex pathways display 
a degree of overlap and redundancy, whilst allowing for amplification of the 
original signal. A bewildering amount of information has been accumulated in
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recent years regarding MAP kinase signal transduction, contributing 
significantly to the complexity of the subject, and the literature reveals some 
apparent contradictions regarding MAP kinase activity and physiological 
consequences that may be cell- or tissue-specific. For this reason, a much- 
simplified overview is presented here describing the salient features of the three 
MAP kinase signalling cascades (Figure 1.6), followed by discussion of some 
common downstream effects that culminate in the activation of gene 
transcription in the nucleus. An exhaustive and detailed discussion is outwith 
the scope of this work, but more detail is provided by several recent reviews 
(137-140).
1.2.5.4 Signalling through ERK.
ERK is probably the most well studied MAP kinase and it is activated by 
endotoxin, IL-1(3 and certain growth factors like epidermal growth factor (EGF) 
(136; 141). ERK exists as 44-kDa (ERK-1) and 42-kDa (ERK-2) isoforms and a 
specific inhibitor of the ERK cascade, PD-098059 (142), is invaluable in 
studying the cell-specific activation of ERK by numerous stimuli. As well as 
their effects on ERK signalling, IL-lp and endotoxin also may activate the 
SAPK pathways of p38 and JNK, which are less well characterised than the 
ERK pathway, although some overlap exists between these parallel cascades.
1.2.5.5 Signalling through Stress-Activated Protein Kinases (SAPK).
JNK and p38 share approximately 50 % sequence homology with ERK (138) 
and they are activated preferentially by cellular stresses and have diverse 
physiological roles in processes that include the immune response, cell 




was discovered in 1994 as a kinase that responded specifically to endotoxin and 
hyperosmolarity (143) but whilst osmoreceptors have been identified in yeast 
cells, analogous molecules have yet to be found in mammalian systems (137). 
p38 is found in evolutionarily diverse eukaryotic cells ranging from yeast to 
mammalian tissue, and much of the information regarding p38 has come from 
studies in Drosophila. Four mammalian p38 isoforms have been found that 
share 60-75 % sequence homology and show different substrate specificities in 
vitro (138). As many as twelve isoforms of JNK exist by virtue of alternative 
splicing of the three JNK genes (a ,(3 and y) (137), but all are approximately 54- 
kDa in size. The major function of JNK appears to be in stress-induced cell 
death, either by apoptosis or necrosis (137), but the lack of a specific functional 
inhibitor of the JNK pathway impedes detailed study of this cascade. In 
addition, JNK activates NFkB, whilst this transcription factor is inhibited by 
p38 kinase (138). The serine / threonine kinases MAPKAPK2 and 
MAPKAPK3 serve as additional substrates for p38 and these proteins 
phosphoiylate and activate a number of heat-shock proteins within the cell 
(138). A final point of interest regarding the physiological functions of the 
MAP kinases is their involvement in directing the immune response during 
infection. Whilst ERK cascades favour TH2-type responses, the SAPKs 
promote ThI-type responses (139) and this feature may be of clinical relevance 
in CF.
1.2.5.6 Signalling through NFkB.
The sequence of events leading to NFkB activation, including proteins involved 
in phosphorylation and activation reactions, are shown in Figures 1.6 and 1.7.
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Upon cellular activation, a MAP3K is activated and phosphorylates the IKK 
(IkB kinase) complex. Possible MAP3K candidates include MEKK-1 of the 
JNK cascade (144), although MEKK-1 was found not to be necessary for 
cytokine-induced JNK or NFkB activation in murine macrophages and 
fibroblasts (145). Mitogenic stimuli that activate the Raf pathway (upstream of 
ERK) can activate NFkB independently of ERK, diverting via MEKK1 (146). 
Cytokine induction of IKK activity may be mediated by NIK (147), another 
MAP3K. The IKK complex consists of IKKa (IKK-1) and IKKJ3 (IKK-2) 
catalytic subunits and an IKKy regulatory subunit (148). A putative kinase 
implicated in the phosphorylation of IkBgc is p90rskl (149) a serine threonine 
kinase that lies downstream of the ERK MAP kinase cascade. The IKK 
complex phosphorylates IkBcx at Ser32 and Ser36 (150) or IkBP at Ser 19 and 
Ser23 (151), the IkB protein is ubiquitinated and degraded via the 26S 
proteasome pathway (150). Both Ser32 and Ser36 residues must be 
phosphorylated to effect ubiquitination and subsequent proteolysis, since 
mutation of either one or both of these residues prevents the degradation of 
IkBcc (150,152).
In quiescent cells, IkB binds (and inhibits) via its ankyrin repeat domain (ARD) 
to NFkB (153). The mammalian transcription factor NFkB is central to the 
regulation of genes involved in numerous cellular responses, and in particular 
inflammation (154). NFkB is a dimeric protein consisting of two Rel-related 
protein subunits: a 65-kDa subunit that contains the Rel-homology domain 
(RHD) and a 50-kDa subunit (154;155). Following activation of the IKK 
complex and degradation of IkB, the NLS on NFkB is exposed and NFkB
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translocates rapidly into the nucleus (155), whereupon it binds to the DNA 
sequence 5’-GGGPuNNPyPyCC-3’ (156) present upstream of the promoter in a 
multitude of genes, to initiate their transcription. Gene transcription also 
requires phosphorylation of the NFkB p65 subunit (157) and that this moiety 
binds the phosphorylated TATA-binding protein (TBP) (156). The IkB family 
members display different affinities for NFkB and different modes of action. 
For example, hcBa is degraded rapidly but is resynthesised within an hour, 
under the control of NFkB (158), and re-complexes with NFkB to terminate 
gene transcription. However, IkBP transcription is not controlled by NFkB and 
when resynthesised, IkBP is either unphosphorylated or hypophosphorylated so 
that it does not mask the NFkB NLS or DNA-binding sites (151; 154). As such, 
NFkB cannot bind and be inhibited by IkBcc so  that iKBp-mediated NFkB 
stimulation is for a protracted period (>20 h) (154). These differences allow 
fine-tuning of gene transcription of NFkB. In CF bronchial epithelial cells, 
NFkB activation is mediated primarily by IkBP, resulting in prolonged NFkB 


























Figure 1.4 CFTR activation by cAMP. In the resting state, the CFTR Cl' channel is blocked 
sterically by its R-domain (a). Activated adenylate cyclase (AC) converts ATP to cAMP ( b) 
and this second messenger molecule amplifies the response since each molecule of adenylate 
cyclase produces many cAMP molecules during the time that G ,a-GTP remains bound. cAMP- 
dependent protein kinase (protein kinase A, PKA) then phosphorylates numerous sites in the R- 
domain o f CFTR, inducing a conformational change such that the R-domain assumes a new 
position within the cytoplasm, thus unblocking the channel (c). The effects o f cAMP are 
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Figure 1.5 Signalling via TNF-a and IL- ip . TNF-a binds to its receptor (TNF-R1 or TNF- 
R2) and recruits the protein TRAF- 2 (TNF-receptor associated factor) directly or via the ‘death- 
domain’-containing molecules, FADD (Fas-associated death domain protein) and TRADD 
(TNF receptor-associated death domain) and receptor interacting protein (RIP), which associate 
with the cytoplasmic portion of the TNF receptor. The death domain consists o f approximately 
80 amino acids and this binding site also mediates TNF-induced apoptosis. IL- 1 receptor 
activation recruits the IL-1 receptor-associated kinase (IRAK) and TRAF- 6, and the IL-1 p and 
TNF-a pathways converge on the NFkB inducing kinase (NIK) molecule, activating NFk B as 
described below. Furthermore, TRAF proteins may activate another kinase called MEKK-1, 
which forms part of the mitogen activated protein kinase (MAP kinase) cascade and ultimately 
may activate NFk B as well. LPS signalling via Toll-like receptor (TLR) shares many features 































Figure 1.6 MAP kinase cascades. Binding of a ligand, such as EGF, to its receptor tyrosine 
kinase (RTK) induces dimerisation of the receptor, followed by autophosphorylation o f tyrosine 
residues in the cytoplasmic tail o f the receptor molecule. An adaptor protein, Grb2, associates 
with the phosphorylated tyrosine residues in the receptor tail via an SH2 domain, whilst the SH3 
domain of Grb2 binds a cytosolic protein, Sos (son of sevenless), a GTP-exchange factor (GEF) 
and localises it to the plasma membrane. Sos binds and activates Ras, a small GTP binding 
protein, which exchanges GDP for GTP and in doing so becomes activated. Ras- GTP 
associates directly with Raf, a serine/ threonine kinase, and this induces a transient membrane- 
anchoring signal. The active Raf kinase binds and activates the dual specificity kin ase, MEK 1 / 
2, and this kinase activates ERK 1 / 2 in turn, via phosphorylation of Thrl83 and Tyrl85. 
Numerous downstream targets o f ERK have been identified, including the 90-kDa ribosomal S6 
kinase (pW"*1) and transcription factors such as Elk-1. By analogy with Ras that mediates ERK 
pathways, two members from another family of small GTP-binding proteins ( /?as /tomology, or 
Rho), called Racl and Cdc42, precipitate SAPK signalling. The Rho protein phosphorylates 
MAP kinase kinase kinase (MAP3K), also referred to as MEKK (p38 cascade) and PAK or 
MEKK1 (JNK cascade), which phosphorylates the dual-specificity kinases MKK3 or MKK6 
(p38 cascade) and a JNK kinase (JNKK) MKK4 or MKK7 (JNK cascade). This dual specificity 
kinase sometimes is referred to as SEK. Then, in turn, these proteins phosphorylate (activate) 
JNK or p38 at threonine and tyrosine residues, causing them to translocate to the nucleus where 
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Figure 1.7 Activation o f NFicB-mediated gene transcription. In resting cells, NFkB is 
localised in the cytosol by virtue o f its binding the inhibitory protein IkB a , but stimulation of 
the cell with any o f a number o f different agonists, such as IL - lp , precipitates phosphorylation 
of IKBa (A) or IkBP (B) and their subsequent degradation via the ubiquitin -26S proteasome 
pathway. Following its dissociation from Ik B<x/P, NFkB exposes a nuclear localisation 
sequence (NLS) and translocates into the nucleus, where it initiates transcription o f genes of a 
number of inflammatory proteins. Resynthesised IkB a  masks the NLS once more and 




1.3 The Microbiology of CF
The most striking feature of CF lung infections is that, despite the inactivation 
of a number of immune responses in the lung, only a narrow spectrum of highly 
adapted microorganisms repeatedly exploits the immunocompromised 
pulmonary environment (160). RSV is a common cause of mild lung disease in 
early childhood of CF and non-CF individuals and coupled with additional 
factors in the CF lung, pulmonary inflammation caused by RSV may encourage 
subsequent colonisation by bacterial pathogens (55; 120). Initially, S. aureus 
and then H. influenzae infect the lungs of very young CF children and these 
bacteria may continue to cause acute exacerbations throughout the disease 
course (160;161). Ironically, maintenance antibiotic treatment against these 
bacteria may help to select for the more troublesome organism P. aeruginosa, 
which is resistant to many antimicrobial agents and is acknowledged to be the 
most important pathogen in CF respiratory infections (7;160). In the early 
1980s, B. cepacia emerged as an additional and significant risk to the health of 
CF patients (162;163), causing much concern amongst patients, carers and 
microbiologists alike and serving as a warning that this brief list o f pathogens is 
expanding. In recent years, the rate of isolation of additional bacteria, fungi and 
viruses from CF sputa has increased and B. cepacia provides a paradigm of the 
newly emerging microbiological threats to the CF community. Each o f the four 
major bacterial CF pathogens will be described, followed by a brief discussion 





This Gram-positive, non-motile coccoid human commensal is carried in the 
upper respiratory tract and nasal passages of as many as 30 % of healthy 
individuals yet lower respiratory tract infections are rare in the 
immunocompetent host (164). In contrast, rates of S. aureus lower respiratory 
tract infection are as high as 36 % in the CF community (165; 166). In the post­
antibiotic era, S. aureus no longer is the major cause of mortality in CF patients 
it once was, although the current crisis with regard to strains such as methicillin- 
resistant S. aureus (MRSA), which survives treatment with most antibiotics, 
may reverse this trend. S. aureus is the first bacterial pathogen to colonise the 
CF airways and early damage caused to respiratory tissue by this bacterium may 
encourage subsequent colonisation by P. aeruginosa (167).
1.3.2 Haemophilus influenzae
The role of this non-motile Gram-negative bacillus in CF is controversial but 
probably underestimated, since H. influenzae is a normal commensal of the 
healthy upper respiratory tract (161,168). Following S. aureus infection, low 
numbers of non-capsulated H. influenzae may colonise the CF airways but this 
often remains untreated. Convincing evidence has been published that certain 
strains of H. influenzae elicit proinflammatory chemokines from the respiratory 
epithelium (169). In addition, H. influenzae LPS may damage the pulmonary 
epithelium and interfere with ciliary beat frequency (170). This latter strategy 




Without question, P. aeruginosa is the most significant and troublesome 
pathogen to infect the CF lung and it is estimated that in some CF clinics 
P. aeruginosa colonisation rates are as high as 80-90 % (168; 171). A recent 
report stated that P. aeruginosa infects approximately 21 % of CF infants within 
1 year of birth (171). This unusually high prevalence results from an impressive 
arsenal of virulence determinants secreted by P. aeruginosa combined with the 
ability of this bacterial species to adapt to the hostile environment of the CF 
lung. This ubiquitous Gram-negative motile bacillus is a common 
environmental organism (172), which also causes significant opportunistic 
infections in immunocompromised patients both systemically and locally at 
most sites of the body, in particular to the comeal epithelium and bum wounds 
(173-175). P. aeruginosa is inherently resistant to many classes of 
antimicrobial agents and it is a common cause of nosocomial infection by virtue 
o f its ability to survive on surfaces and medical instruments, even after 
treatment with some disinfectants.
There are three broad strategies by which bacteria may resist the effects of an 
antibacterial agent namely preventing the drug from reaching its target; 
modification of the target; and inactivation of the drug. All of these 
mechanisms have been reported in P. aeruginosa. For example, P. aeruginosa 
has a relatively impermeable outer membrane because of its comparative lack of 
porins as well as the small size of these membrane channels (176). In addition, 
P. aeruginosa expresses at least four tripartite efflux pumps in its outer 
membrane, which remove from the bacterial cell a wide range of structurally 
unrelated antibiotics and biocides (177). Furthermore, there is evidence that the
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outer membrane pumps act in synergy both with each other and with the 
inherently low permeability of the P. aeruginosa outer membrane (178; 179). 
Other CF pathogens such as B. cepacia and Stenotrophomonas maltophilia 
posses homologues of the P. aeruginosa efflux pumps (180), providing further 
evidence of an important role for these molecules in biocide resistance in CF 
and indicating potential targets for novel drug design. Alterations to DNA 
gyrase owing to mutations in its gene gyrA confer ciprofloxacin resistance on 
P. aeruginosa (181), whilst target modification also reduces the activity in 
P. aeruginosa of antimicrobial agents such as aminoglycosides.
Inactivation or destruction of some antibiotics by bacterial enzymes is 
particularly problematic and is exemplified by the production by P. aeruginosa 
of p-lactamases against penicillin and its derivatives (176; 182). Other 
inhibitors of cell-wall synthesis include carbapenems, which are stable to most 
p-lactamases, although the prevalence of acquired metallo-carbapenemases such 
as IMP-1 and VIM in P. aeruginosa is increasing (183). Furthermore, 
chromosomal carbapenemases have been identified in S. maltophilia (183), an 
opportunistic pathogen that poses a potential risk to CF patients. Another 
example of drug modification by P. aeruginosa is the chloramphenicol acetyl 
transferase (CAT) that adds an acetyl group to, and inactivates chloramphenicol 
(184). Genes encoding antibiotic resistance are commonly found clustered onto 
mobile genetic elements such as plasmids and transposons, which permit 
horizontal transfer of this information amongst different bacterial species. The 
alarming rate at which these genes may disseminate has prompted the use of 
combination therapy to reduce the spread of antibiotic resistance, such as an
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inhaled aminoglycoside and an oral penicillin (185). P. aeruginosa is able to 
withstand treatment with high doses of antibiotics, and this ability constitutes 
only one of the multiple and complex mechanisms by which P. aeruginosa is 
able to exploit the CF lung.
1.3.4 The pathogenesis of P. aeruginosa.
After gaining entry to the host, flagella propel P. aeruginosa through the 
respiratory tract where this bacterium induces intermittent episodes of 
pulmonary exacerbation followed by chronic asymptomatic carriage in the lung 
(160; 186; 187). P. aeruginosa adheres to the lung via several host factors, such 
as CFTR (45), ganglioside moieties (67; 188) and mucins (189) mediated by 
bacterial factors such as LPS (45), type IV pili (188) and the flagellar cap 
protein, FliD (190). Terminal sialylation is altered in the CF lung because of 
impaired pH-dependent sialyltransferase activity in intracellular glycosylation 
compartments (67) so there is an increased expression of asialo-GMl, to which 
P. aeruginosa and other CF pathogens bind with high affinity (188).
Hypersecretion of tracheobronchial mucin in CF (59;60), which is increased 
further by P. aeruginosa binding to the lung epithelium and by certain 
pseudomonal exoproducts (64; 191; 192), enhances P. aeruginosa colonisation 
of the lung either because of specific molecular adhesive interactions or simply 
because the mucin is so sticky. It has been proposed that P. aeruginosa binds 
CFTR and becomes internalised into respiratory epithelial cells and that 
subsequent epithelial desquamation serves as a bacterial clearance mechanism 
from the lung, highlighting one way in which the relative absence of CFTR 
expression on the CF lung epithelium may contribute to the persistence of this
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bacterial pathogen (45;66). This view is based on the observations that 
pulmonary epithelial tissue from CF patients bound and internalised much less 
P. aeruginosa than did non-CF epithelial cells (193) and that a synthetic peptide 
corresponding to the first extracellular loop of CFTR reduced P. aeruginosa 
internalisation by non-CF epithelial cells (45). However, this interpretation 
remains controversial (65;68).
Virulence factors such as proteases, lipases and haemolysins like rhamnolipid 
are important during the initial states of P. aeruginosa infection (7; 160; 194- 
196) and these exoproducts act synergistically to induce symptoms of acute 
infection. Elastase is a potent digestive metalloprotease that is secreted both by 
P. aeruginosa and by frustrated phagocytes in the CF lung and its substrates 
include complement components, immunoglobulin and elastin (197). Elastase 
also cleaves host transferrin and lactoferrin to release sequestered iron into the 
lung (198), where it is scavenged by P. aeruginosa pyocyanin, a siderophore 
that can also immobilise the mucociliary escalator (63). Pyochelin is another 
P. aeruginosa siderophore, which forms complexes with molecular iron called 
ferripyochelin and, together with pyocyanin, catalyses the production of 
superoxide and hydroxyl radicals thus causing significant free radical damage to 
lung tissue (199;200). P. aeruginosa produces other siderophores, including 
pyoverdin and inositol polyphosphates (201,202), which are also important to 
the pathogen during chronic infection, when the CF lung becomes particularly 
iron-deplete. Siderophores propagate the respiratory immune response for 




Exotoxin A is a potent P. aeruginosa ADP-ribosylating toxin, which is the 
product of the toxA gene (204) and it interrupts protein synthesis via ADP- 
ribosylation-mediated inhibition of elongation factor-2 (EF-2) (205). Exotoxin 
A also kills macrophages (206) and is important during initial colonisation but 
shows maximal expression during iron-limitation (160,207).
After repeated episodes of acute pulmonary exacerbation, P. aeruginosa 
becomes established chronically in the CF respiratory tract in an attenuated 
form. Flagella no longer are expressed (187;208), toxin production is reduced 
(160) and the P. aeruginosa LPS loses its O-side chains, assuming a ‘rough’ 
phenotype (209). Although the latter change renders P. aeruginosa sensitive to 
complement-mediated killing, the relative inactivity of complement in the CF 
lung negates this issue (210). Thus, initial chronic pseudomonal colonisation in 
CF is asymptomatic, although the same organism would produce significant 
clinical manifestations in an immunocompromised non-CF individual.
Attenuation of virulence correlates with the spontaneous mutation in vivo of 
P. aeruginosa into a mucoid phenotype that shows enhanced antibiotic 
resistance because of a profusely secreted polyanionic exopolysaccharide called 
alginate and the formation of adherent bacterial microcolonies or ‘biofilms’ 
(211), after which eradication of P. aeruginosa from the lung is seldom 
achieved. Alginate is anti-phagocytic and reduces neutrophil chemotaxis 
despite the potent induction of epithelial IL-8 by this exopolysaccharide (212). 
Gradually, iron-depletion from the CF lung becomes more significant until it 
reactivates virulence factor production by P. aeruginosa. The host produces 
high titres of antibodies against a wide range of these virulence determinants,
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such as alginate, LPS, iron-regulated membrane proteins and elastase (160;213), 
an event which correlates with progressive deterioration of pulmonary function 
and is associated with a poor clinical prognosis that may be caused by excessive 
immune-complex deposition (160;214).
Alginate allows community growth of a heterogeneous population of 
P. aeruginosa in adherent microcolonies, which develop into mature biofilms, 
several hundred micrometres deep, as shown in Figure 1.8. Water channels 
bring in nutrients and remove waste products and a steep oxygen gradient exists 
across the biofilm (215), determining the bacterial growth rate at different 
locations within the structure and therefore dictating in part the susceptibility to 
antibiotics of the bacterial cells within the biofilm (216). Biofilm resistance to 
biocides may also be attributed to a reduced penetration of the drugs into the 
mucoid matrix because of the impermeable nature of the structure as well as the 
production of inactivating enzymes by bacterial cells around the biofilm 
periphery (216). Biofilm growth is concurrent with a stress response that is 
mediated by the alternative bacterial sigma factors AlgU and RpoS, and is 
switched on by nutrient limitation and environmental cues via bacterial signal 
transduction (217). Alginate production, biofilm development and the secretion 
of extracellular toxins are all highly energy demanding processes so they are 
regulated tightly by specific bacterial signalling cascades (218-220).
1.3.5 Signalling in P. aeruginosa.
Effective attacks on host cells require the contribution of a critical number -  or 
quorum -  of bacteria. Gram-negative bacteria secrete small (300-700 Da) 
molecules called autoinducers (AI) and together with specific AI ‘receptors’
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(effector molecules), allow neighbouring bacteria to sense and communicate 
with the surrounding population and enable a co-ordinated attack on the host, 
once an appropriate density is attained. This signalling mechanism is therefore 
known as “quorum sensing” (QS) (221).
Chemically, AI molecules have been identified as acyl homoserine lactones 
(acyl-HSLs) and have no known function other than signalling and both acyl 
side chain length and substitutions provide specificity for the signal (215). Each 
acyl-HSL is synthesised by a specific enzyme and detected by its cognate 
effector molecule. Quorum sensing was first discovered in Vibrio fischeri more 
than 30 years ago (222), in which an acyl-HSL synthase, LuxI, catalyses the 
synthesis of the AI molecule; and the AI effector, LuxR, serves as a 
transcriptional activator of density dependent genes (218). LuxR family 
members possess an N-terminal acyl-HSL-binding domain and a C-terminal 
DNA binding domain (215). Homologues of these gene products have been 
found in many Gram-negative species including CepR and CepI in B. cepacia 
(223), as well as two different QS systems in P. aeruginosa, namely the Lasl/R 
and Rhll/R systems (224). Rhll was so-named because it regulates the rhl 
operon that controls rhamnolipid biosynthesis and this enzyme generates mainly 
butyryl HSL (BHL or C4-HSL) (215). In contrast, LasI synthesises mainly N- 
(3-oxododecanoyl)-HSL (OdDHL, or 30C12-HSL) and derives its name from 
its reported regulation of the las operon, which mediates elastase biosynthesis 
(215;224).
It is now known that these QS systems regulate the expression of many more 
bacterial genes besides, indeed it has been estimated that as many as 4% o f the
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approximately 6,000 P. aeruginosa genes are under the control of QS (220) and 
there is a strict requirement for the QS systems in virulence. In a murine model 
of pulmonary infection, LasI* mutants of P. aeruginosa were able to invade and 
survive in lung tissue but did not cause disease (225). Neither did QS mutants 
of P. aeruginosa cause infection in a burned mouse model (175). Co­
administration of OdDHL restored the virulence potential of P. aeruginosa LasI' 
mutants (175). Similarly in another study, LasI' mutants resulted in 
P. aeruginosa microcolonies that were unable to develop into a mature biofilm, 
but addition of OdDHL to the microcolony corrected this defect (226). 
Resistance to the respiratory burst is also regulated in part by QS (219).
An intriguing study by Singh et al. (227) showed that the ratio of BHL to 
OdDHL determined whether bacterial growth would tend to be planktonic or 
assume a biofilm formation and this observation could have implications for the 
treatment of Pseudomonas respiratory infection since in general, antibiotics are 
more effective against planktonic than against biofilm bacterial cells (216). 
This study was also critically important because it provided the first evidence, in 
terms of autoinducer ratios, that P. aeruginosa grows as a biofilm in the CF 
lung (227). In addition to the effects of acyl-HSLs on bacterial virulence 
products, some of these bacterial signalling molecules have direct 
immunomodulatory effects in the host. For example, there have been several 
reports that autoinducers stimulate the production of cytokines such as TNF-a 
and IL-8 (228;229), both of which play an important role in the host immune 
response to P. aeruginosa. Telford’s report also indicated that P. aeruginosa 
HSL molecules may affect lymphocyte proliferation (229).
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O f  particu lar r e le v a n c e  to  C F  w a s  th e  o b serv a tio n  that P. aeruginosa a c y l-H S L s  
a n ta g o n ise d  th e  e x p r e ss io n  o f  P 2 Y  recep to rs in C F  trach ea l g la n d  c e l l s .  A T P  
and U T P  b in d  P 2 Y  recep to rs and a c tiv a te  C a2+-m e d a ite d  C F -c h a n n e ls  in 
resp ira tory  c e l l s ,  th u s b y p a ss in g  th e  ion  ch a n n e l d e fe c t  o f  C F T R  (230). 
T h ere fo re , Q S  m o le c u le s  m ig h t co n tr ib u te  to  th e  p h y s io lo g ic a l d y sfu n c tio n  
w ith in  th e  lu n g . E x c it in g  p o ss ib il it ie s  e x is t  for n o v e l a n tim icro b ia l therapy  
d irec ted  a g a in s t  b acteria l s ig n a llin g  c a sc a d e s  and th e se  a p p ro a ch es  h a v e  b egu n  
to  b e in v e s tig a te d  (231;232). A n o th er  so p h is t ic a te d  stra teg y  for  e v a d in g  th e  
h o st  im m u n e  r e sp o n se  c o n c e r n s  th e  se c r e t io n  o f  a  su b se t o f  ‘s te a lth ’ b acteria l 
to x in s  b y  P. aeruginosa and  o th er  G ra m -n eg a tiv e  b acteria  v ia  ty p e  III secre t io n  
sy s te m s .
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Figure 1.8 Biofilm formation in the lung. Planktonic bacterial cells in the airway lumen 
attach to the pulmonary epithelium, whereupon they multiply into a monolayer. Bacterial cells 
express type IV pili, which are responsible for the ‘twitching motility’ that allows the 
development of adherent microcolonies (233). Maturation of P. aeruginosa microcolonies into 
tower and mushroom-shaped biofilm structures is dependent upon LasI to generate QS signals.
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1.3.6 Protein secretion in Gram-negative bacteria.
Gram-negative bacteria export a diverse range of proteins but utilise only four 
main pathways (234;235). Type II and type IV secretion mechanisms are 
referred to collectively as the General Secretory Pathway (GSP) and they 
employ the sec-system. Approximately 30 residues form a signal sequence in 
the amino-terminal of the protein to be secreted by the GSP. This sequence 
directs the protein to the periplasmic space, where the amino acid signal is 
cleaved by peptidases. Finally, the protein is transferred across the outer cell 
membrane into the extracellular space. Type II secretion is the major pathway 
by which Gram-negative organisms secrete extracellular degradative enzymes; 
for example, P. aeruginosa exports phospholipase C (PLC), elastase and ETA 
via this route (234).
In contrast, type I and type III mechanisms are sec-independent, they by-pass 
the periplasm and they do not require the proteins to be tagged with a cleavable 
amino-terminal signal sequence. The type I pathway mediates secretion of 
P. aeruginosa proteases (234;235) and proteins are targeted for type I secretion 
by a highly specific 60-amino acid export signal that lies in the carboxy- 
terminal region (234;235). However, the most important way by which 
pathogenic Gram-negative bacteria export protein is the type III secretion 
system, which is dedicated to the export of toxic products (234).
Type III secretion was described first in Yersinia spp. (236), although this 
protein export mechanism has been described in a number of other important 
human, animal and plants pathogens including Escherichia spp., Salmonella 
spp., Shigella spp. and Pseudomonas spp. (234). The secretion apparatus is
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highly conserved amongst bacterial species, but heterogeneity amongst secreted 
proteins creates diverse and distinct infections (234;237). Type III secretion 
requires cellular contact between the bacterium and its target eukaryotic host 
cell, resulting in the transcription and translation into protein of approximately 
twenty clustered bacterial genes, which encode the secretory apparatus, the 
energy generating system and chaperones, as well as the effector toxins 
(234;238). This precise cell-to-cell association allows the bacterial proteins to 
be ‘injected’ directly into the eukaryotic cytoplasm, circumventing the immune 
system and making the type III secretion system a highly effective virulence 
determinant. However, a critically important discovery was made recently, 
which showed that neutralising antibodies against PcrV created a significant 
reduction in the toxic effects of exoenzyme S (exoS) (239). PcrV is a 
P. aeruginosa homologue of LcrV in Yersinia, which determines the size of the 
protein translocation channel (240) so that this finding may provide a useful 
strategy for immobilising type III secreted toxins.
Proteins exported by the type III secretion mechanism in P. aeruginosa include 
exoS, exoT, and exoU (241;242), which are toxic by virtue of their remarkable 
analogy with host signal transduction components and these proteins can 
interfere with DNA synthesis, host cell viability, cytoskeletal structure and cell 
matrix adherence (243;244). Based on the genotype of the exoS locus, a recent 
report (245) distinguished invasive strains of P. aeruginosa (such as PAK and 
PAOl), which produced exoS but not exoU, from acutely cytotoxic strains 
(such as PA 103), which expressed exoU but not exoS, although long-term 
exposure to exoS causes increased tissue damage and bacterial dissemination
44
Chapter 1: Introduction
(246). Both invasive and cytotoxic P. aeruginosa phenotypes produce exoT 
(245).
The exoS locus contains several open reading frames (ORFs) and is under the 
transcriptional control of the global regulator ExsA, encoded by exsA (237), 
which is required for expression of exoS, exoU and exoT. ExoU is 
approximately 70-kDa and induces acute cytotoxicity and epithelial damage 
(242;245), although it is absent from non-cytotoxic (invasive) isolates of 
P. aeruginosa (242). ExoS is a 49-kDa, biglutamic acid ADP-ribosylating toxin
(247) that is found in approximately 90 % of clinical isolates (245), an 
observation that supports the importance of this toxin in P. aeruginosa 
pathogenesis. ExoT is a 53-kDa protein that co-immunoprecipitates with exoS 
and these proteins share approximately 75 % amino acid sequence homology 
(241). However, exoT displays only 0.2% of the ADP-ribosylating activity of 
exoS (241). Mammalian G-proteins (GTPases) are common targets of type III 
secreted toxins. ADP-ribosylation of the GTPase Ras by exoS interferes with 
its guanine-nucleotide exchange factor and locks Ras into a state of permanent 
inactivation (248) so that a multitude of host cell signalling cascades and 
physiological processes may be disrupted (243;249).
In addition to the cytotoxic ADP-ribosyltransferase activity in exoS C-terminal 
residues, its amino terminal portion is required for export and the aggregation 
properties o f this toxin (246) and induces actin rearrangements via Rho GTPase 
activation (250;251), conferring resistance to phagocytosis. The growing 
epithelium shows increased sensitivity to exoS, since cell contact and epithelial 
differentiation appear to protect against the toxicity o f this protein (252). This
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discoveiy suggests that exoS would be especially damaging to the regenerating 
epithelium following tissue injury in CF, but epithelial susceptibility to exoS is 
not related to the functional expression of CFTR (252). Virulence determinants 
such as the type III secretion system are encoded by mobile genetic elements 
called ‘pathogenicity islands’ (253). These gene clusters can move horizontally 
between species so that evolutionarily distinct organisms may share significant 
homology with respect to virulence determinants. Type III secretion has been 
described in P. aeruginosa (246) and Burkholderia pseudomallei (254), but to 
date this system has not been found in B. cepacia. However, there is a strong 
possibility that B. cepacia type III secretion systems will be discovered in the 
near future.
1.3.7 Burkholderia cepacia.
B. cepacia is a Gram-negative bacillus, which is highly motile by virtue of 
multiple peritrichious pili (255). B. cepacia has a relatively plastic genome 
consisting of up to three circular replicons, which total approximately 7-Mb of 
DNA (256). Its unusually large genome allows B. cepacia to be highly 
adaptable and exploit unfavourable environments, such as the CF lung. 
B. cepacia is not a common cause of human infection, having been described 
originally as a phytopathogen causing soft rot in onion bulbs (257) and 
environmental reservoirs of this organism include soil, water, plants and free- 
living amoebae (7;160;258). However, both CF patients and 
immunocompromised individuals, such as those with in-dwelling catheters 
(259) and CGD patients (260) may suffer from repeated respiratory or systemic 
infections with B. cepacia. Whilst B. cepacia colonisation rates are much lower 
than those of P. aeruginosa, reaching 40 % prevalence at most compared with
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more than 85 % prevalence of P. aeruginosa (7'), three salient features of 
B. cepacia infection account for the increasing anxiety that this bacterial species 
has caused within the CF community within the last two decades.
1.3.7.1 Certain strains of B. cepacia are highly transmissible.
Strain J2315, a genomovar III isolate that is often referred to as the Edinburgh- 
Toronto (ET) lineage (261), was implicated in a number of epidemic clusters 
across Europe and the North American continent (262;263). For example, one 
patient harboured two different strains of B. cepacia, but passed only the 
epidemic strain to his girlfriend (7). Enhanced person-to-person transmission of 
this epidemic strain is most likely consequent to expression of the ‘cable pilus’, 
which binds specifically to cytokeratin 13 on the host respiratory epithelium 
(264); and non-specifically to mucin (265). Unlike conventional bacterial pili, 
the cable pilus expresses adhesin proteins along its entire length, augmenting 
interaction with the uncharacteristically thick mucus blanket in the CF lung. In 
addition, adjacent bacterial cells could aggregate via cable pili interactions to 
form protective microcolonies. Globotriosylceramide (Gb?) is a good candidate 
for adhesion to host cells of B. cepacia strains that do not express the cable pilus 
strongly (266). Like P. aeruginosa, B. cepacia adheres to the lung via asialo- 
GM1, but lack of competitive binding between these two pathogens implies that 
one or both of these bacteria use additional receptors on host cells. Moreover, 
synergistic binding of B. cepacia to the host epithelium following prior 
colonisation with P. aeruginosa has been reported (267).
For many years, summer camps performed a vital role within the CF community 
but the fear of widespread B. cepacia epidemics led to the decision in 1993 to
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ban many of these important social events (268). Risk factors for the 
acquisition of B. cepacia infection include social contact with an infected 
individual (particularly a sibling), for example sharing drinking vessels, kissing 
or more intimate interactions; and recent hospitalisation possibly because of 
contaminated surfaces or respiratory equipment (7). It has been reported that 
B. cepacia may survive on environmental surfaces for as long as a week (261). 
In addition, the use of aminoglycosides, underlying pulmonary disease and 
increasing age are all factors that predispose CF patients to colonisation with 
B. cepacia (7). Furthermore, patients already colonised with B. cepacia are not 
immune from acquiring additional epidemic strains (269). This discovery 
highlights the urgent need to develop improved discriminatory typing methods 
that allow the pathogenic potential of B. cepacia to be assessed so that more 
appropriate segregation policies can be adopted.
Isolated cases of B. cepacia infection in the immunocompetent host have also 
been described, including a non-CF mother who developed B. cepacia 
pneumonia with a genomovar III cable-piliated strain, which shared the same 
pulsed field gel electrophoresis (PFGE) pattern as a strain cultured from each of 
her two CF children (270). This latter observation led to the proposal that CF 
patients colonised with the epidemic strain should be segregated further from all 
other B. cepac/a-infected individuals (269). Whilst such measures may seem 
draconian, there is good evidence that segregation has been successful in 
reducing the prevalence of B. cepacia fatalities (271;272).
Extensive efforts have been made to discriminate between virulent and less 
pathogenic strains of B. cepacia, to permit a more selective segregation strategy,
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but with only limited success. To compound the problem, patients may respond 
differently after colonisation with an identical B. cepacia strain. For example, 
although a number of patients have died within 6-12 months of becoming 
infected with the most virulent strain, J2315, the index case survived for many 
years (J.R.W. Govan, personal communication). This important caveat 
highlights the fact that host factors are as important as bacterial characteristics 
in determining the clinical progression of an infection in CF (16).
1.3.7.2 Variable pulmonary disease with B. cepacia.
The second feature of B. cepacia infection that distinguishes it from 
P. aeruginosa concerns the severity of pulmonary disease. Three possible 
clinical outcomes are observed following B. cepacia acquisition: chronic 
asymptomatic carriage, progressive deterioration over a protracted period, or 
rapid fatal decline associated with necrotising pneumonia and septicaemia, a 
condition known as ‘cepacia syndrome’ (163). Life expectancy may be reduced 
to just a few weeks after infection with a particularly virulent isolate (7). 
However, in contrast to P. aeruginosa infection, the B. cepacia factors 
responsible for the severe clinical sequelae remain poorly characterised but 
possible candidates include LPS (62;273;274), a protease that is cross-reactive 
with antibodies to P. aeruginosa elastase (275), lipase (276), exopolysaccharide 
(277) and siderophores (278).
B. cepacia LPS is more endotoxic than that of a number of other CF pathogens 
and displays similar toxicity to E. coli LPS (273). For example, B. cepacia LPS 
primed and elicited more TNF-a from monocytes than LPS from either 
P. aeruginosa or S. maltophilia (62;273;274). In addition, a specific humoral
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immune response is mounted against B. cepacia LPS that does not cross-react 
with P. aeruginosa (279). Taken together, these observations suggest a 
potentially important role for LPS in the onset of ‘cepacia syndrome’ that might 
be mediated by immune complex deposition in the lung and exacerbated by 
TNF-a. In addition to endotoxin, approximately 40 % of B. cepacia strains 
secrete proteins with haemolytic activity (276;280) and one such protein from 
the genomovar III strain, J2315, induced neutrophil degranulation at high 
concentrations and apoptosis of neutrophils at lower (1 fig/ ml) concentrations 
(280).
Mucoid isolates of B. cepacia are much less common than mucoid 
P. aeruginosa and the composition of the respective exopolysaccharides differs 
greatly. P. aeruginosa alginate consists of repeating units of P-o-mannuronic 
and a-L-guluronic acids (7), whilst B. cepacia exopolysaccharide contains 
rhamnose, mannose, galactose, glucose and glucuronic acid (281). 
Furthermore, hyperosmolarity and nitrogen limitation stimulate alginate 
production by P. aeruginosa, but these conditions do not induce B. cepacia 
exopolysaccharide production (7). Convincing data have been presented for a 
pathogenic role of P. aeruginosa exopolysaccharide, as described previously, 
but the evidence for B. cepacia exopolysaccharide as a virulence determinant 
remains circumstantial. However, a role for B. cepacia siderophores in CF lung 
disease has been demonstrated.
Four major siderophores have been identified in B. cepacia, namely omibactin, 
salicylic acid, pyochelin and cepabactin (282-285). Cepabactin appears not to 
be produced by clinical isolates from CF patients (285), whilst strong evidence
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for the virulence potential of pyochelin has been presented. Exogenous 
pyochelin augmented the virulence potential of pyochelin-negative isolates of 
B. cepacia (286), which were associated with less severe pulmonary disease 
(284). Moreover, patterns of siderophore production correlated well with typing 
fingerprints of clinical isolates, so that this family of pathogenic factors may 
help to determine the virulence of particular B. cepacia strains (278).
1.3.7.3 Multiple drug-resistance of B. cepacia.
The final alarming property of B. cepacia is its intrinsic resistance to many 
antibiotics, including several potent anti-pseudomonal drugs (185). This feature 
may be attributed in part to its impermeable outer membrane (287;288), which 
has been reported to be ten-fold less permeable than that of E. coli (289); and 
also to its altered LPS structure (288). B. cepacia possesses an antibiotic efflux 
pump analogous to the multi-drug resistance pumps of P. aeruginosa conferring 
resistance to trimethoprim, ciprofloxacin and a number of penicillins (290). In 
addition, Hancock identified a penA gene that is induced in B. cepacia by P- 
lactams (291) and allows penicillin G to be utilised as a substrate (292). 
However, B. cepacia does not produce chloramphenicol acetyl transferase 
(CAT) that is found in 50-85 % of P. aeruginosa isolates (184). The reduced 
outer membrane permeability and altered LPS composition also protect 
B. cepacia against endogenous defensins (102) whilst P. aeruginosa remains 
sensitive to these natural antibiotics (69).
Biofilm formation by B. cepacia under nutrient limiting conditions in the CF 
lung (293) provides B. cepacia with an additional anti-bactericidal mechanism 
and may contribute to poor predictive in vitro antibiotic susceptibility testing.
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This problem highlights the need for a reproducible and physiologically relevant 
model to predict the efficacy of antibiotics in vivo, a challenge that is beginning 
to be addressed (293). Conversely, lactoferrin enhanced the antibacterial 
activity of doxycycline, chloramphenicol and rifampicin against B. cepacia and 
P. aeruginosa (294,295), an important finding in light of the elevated 
production of lactoferrin in the CF lung to approximately 0.9 g/ L (294).
Intracellular growth in macrophages is an important way in which B. cepacia 
can avoid antibiotic exposure and evade the host immune response (133). The 
respiratory burst in activated macrophages generates reactive oxygen species 
such as superoxide (O2’) radicals and hydroxyl (OH*) radicals, which are potent 
bactericidal agents. However, B. cepacia secretes melanin, a brown pigment 
that scavenges and detoxifies O2* radicals (296), as well as producing catalase 
to detoxify OH* radicals (101), allowing B. cepacia to overcome this host 
defence mechanism (296).
Reports that NO production is diminished in CF (86) may begin to explain the 
affinity of B. cepacia for the CF lung, since NO may potentiate superoxide- and 
hydrogen peroxide-mediated killing of B. cepacia (84). Patients with CGD are 
unable to mount a phagocytic respiratory burst because they lack the enzyme 
NADPH reductase, relying instead on non-oxidative immune responses such as 
defensins. Since this bacterium is resistant to these non-oxidative killing 
mechanisms, CGD patients also suffer from recurrent infection with B. cepacia. 
Coupled with several observations that B. cepacia can invade and replicate 
within the respiratory epithelium (297-299), which is an immunologically- 
privileged site, a model is evolving in which B. cepacia continually stimulates
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an aggressive immune response without itself being killed, causing tissue 
destruction and impairing pulmonary function within the CF lung. This 
intracellular growth scenario highlights the potential relevance of attempting to 
modulate the immune response towards T-cell-mediated mechanisms (135).
1.3.8 The evolving microbiology of CF.
Surprisingly few microorganisms infect the CF lung and it is particularly 
noteworthy that classical respiratory pathogens such as Mycobacterium 
tuberculosis and Streptococcus pneumoniae seldom cause acute exacerbation 
(160). However, the rapid increase in B. cepacia infection in CF patients during 
recent years has alerted microbiologists and clinicians to the potential threat to 
the CF community of additional opportunist and multi-drug resistant (MDR) 
pathogens, which have been isolated with increasing frequency from CF sputa 
(168). This problem may be related in part to periods of prolonged 
hospitalisation, since repeated exposure to sub-lethal concentrations of biocides 
selects for resistant isolates and may encourage horizontal spread of antibiotic 
resistance genes. Indeed, the incidence of nosocomial infection with MDR 
pathogens has continued to escalate in recent years and is well documented. In 
the same way, aggressive antipseudomonal therapy may have accelerated the 
acquisition and spread of novel MDR organisms in CF patients.
Gram-negative S. maltophilia (formerly Xanthomonas maltophilia) is a notable 
example of an MDR nosocomial bacterial opportunist that can pose particular 
problems in the hospital setting and this organism has been isolated with 
increasing frequency from the CF lung (7). Although there is no evidence that 
S. maltophilia secretes toxic exoproducts (273) or that S. maltophilia LPS
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displays any inflammatory potential (300), long-term survival following 
S. maltophilia colonisation of CF patients with significant underlying 
respiratory disease was reduced to just 40 % in one study, compared with 72 % 
in matched non-colonised patients (168). Furthermore, S. maltophilia shows 
high rates of person-to-person transmission (273) and a retrospective study has 
revealed an inverse correlation between prolonged S. maltophilia colonisation 
and lung function (301).
Other microorganisms that have been isolated intermittently from CF sputa 
include Ralstonia pickettii, Bordetella spp., Aspergillus spp. and Alcaligenes 
xylosoxidans and their pathogenic potential has been investigated (168;300). 
For example, R. pickettii LPS increased TNF-a and IL-8 production 
significantly in whole blood and a macrophage-derived cell line, indicating the 
inflammatoiy potential of this organism (300). In light of the relatively rapid 
and significant emergence of B. cepacia, it would seem prudent to monitor these 
potential pathogens amongst the expanding CF population.
1.4 Aims and Objectives.
The main purpose for this investigation was to measure pro- and anti­
inflammatory cytokine production, and C f channel activity of the respiratoiy 
epithelium following stimulation with P. aeruginosa and B. cepacia. By 
utilising two pairs of airway epithelial cell lines, the objective was to determine 
whether any of these responses was dependent upon the functional expression of 
CFTR. In addition, attempts were made to characterise signalling pathways
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involved in IL-8 production to identify potential targets for therapeutic 









All chemicals were purchased from Sigma Chemical Co., unless stated 
otherwise, and were of Analytical Reagent Grade or equivalent.
2.2 Distilled water
Freshly double distilled water (ddtkO, referred to as Milli-Q water) was taken 
from the Milli-Q filtration unit and steam-sterilised in 500 ml volumes. Sterile 
Milli-Q water was used to prepare solutions for epithelial cell and bacterial cell 
culture and experiments.
2.3 Liquid
Liquid N2 was purchased from BOC gases, and N2 cell-storage tanks were re­
filled regularly.
2.4 Solutions
Sterile PBS (302) was purchased from Gibco at lOx and diluted aseptically into 
sterile Milli-Q as required; PBS for non-sterile use was prepared as shown in 
Table A l. Solutions used in multiple procedures are detailed in the appendix, 
whilst those solutions specific for individual experimental procedures are 
described in the appropriate sections.
2.5 General disposables
Polypropylene tubes (0.5 ml and 1.5 ml) were purchased from Elkay and 
automatic pipette tips were obtained from Greiner Labortechnik Ltd. Sterile
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Pasteur pipettes were obtained from Alpha Laboratories Ltd. Cryovials were 
from Nunc.
2.6 Epithelial Cell Culture
2.6.1 Epithelial cells
Details of epithelial cell lines are shown in Table 2.1.
2.6.2 Epithelial cell culture reagents
The following cell culture reagents were purchased from Gibco-Life 
Technologies:
• Dulbecco’s Modified Eagle Medium, DMEM (303) with 1.0 g/ L D- 
glucose, 0.11 g/ L sodium pyruvate, 0.58 g/ L L-glutamine and 4.0 mg/ L 
pyridoxine;
•  Minimum Essential Medium, MEM (304) with Earle’s salts and 
0.406 g/ L L-alanine-L-glutamine (Glutamax-I);
• MEM non-essential amino acids (lOOx -  Table A2) (304);
• Foetal bovine serum (heat inactivated);
• Penicillin (10 000 U)/streptomycin (10 mg) solution;
• Fungizone (amphotericin B, 250 pg/ ml);
• Trypsin (0.5 g/ L)/ EDTA (0.2 g/ L) solution in Modified Puck’s
Saline-A
• MEM D-Val Medium (304) with Earle’s salts,




• Dulbecco’s phosphate buffered saline (PBS) and PBS without calcium 
and magnesium (PBS-A) (302), (both lOx solution);
• HEPES (1 M) solution
Hygromycin B (400 mg/ ml) was purchased from Calbiochem-Novabiochem 
and Vitrogen 100 (bovine dermal collagen types I and III, 3.0 mg/ ml) was 
obtained from Cohesion Technologies. Gentamicin sulphate and protease type 
XIV both were from Sigma.
2.6.3 Disposable equipment for epithelial cell culture
All disposables for tissue culture had been gamma-irradiated by the 
manufacturer before purchase, unless stated otherwise. Standard vented 25 cm 
(T25), T80 and T175 tissue culture flasks were purchased from Nunc. Sterile 
150 ml, 100 ml, 60 ml, 30 ml and 7 ml containers were purchased from Bibby 
Sterilin. Falcon brand 50 ml tubes were from Becton Dickinson. Cell scrapers 
were from Costar. Non-sterile multi-well strips and frames were purchased 
from Greiner. Glass coverslips (13 mm diameter, No. 1), also non-sterile, were 
manufactured by Chance Propper and purchased from Richardson’s of 
Leicester.
2.7 Bacterial Cell Culture
2.7.1 Bacterial strains
Details of bacterial strains used in this study are shown in Table 2.2.
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2.7.2 Bacterial growth media
4-8°C.
2.7.3 Complex media
Luria Bertani (LB) Broth LB base (Difco) 25 g
ddH20 to 1 000 ml
Nutrient Agar Nutrient Agar (Difco) 28 g
ddH20  to 1 000 ml
2.7.4 Chemically defined media (CDM)
Succinate minimal medium (SMM) K2HPO4 6.0 g
(305) KH2PO4 3.0 g
(NH4)2S04 1.0 g
MgS04.7H20  0.2 g
Sodium succinate 4.0 g
ddH20  to 1 000 ml
Casamino Acids (CAA) Casamino acids (Difco) 0.1 g
ddH20  to 10 ml




(306) M9 minimal salts (Sigma) 10 g
(see Table A3)
ddH20  to 1 000 ml
[pH 7.0]
2.7.5 Disposable equipment for bacterial cell culture
Petri dishes were obtained from Bibby Sterilin and spectrophotometer 
microcuvettes were from Elkay Products Inc.
2.8 General Equipment
Automatic pipettes: Gilson pipetman P-2, P-10, P-20, P-100, P-200, P-1000, 
P-5000 (Anachem Ltd.)
Filtration equipment: 25mm Swinnex units 0.2 pm pore size (Millipore). 
Disposable 0.2 pm pore size filter bottle tops (Nalgene, purchased from BDH/ 
Merck Ltd.).
Gel electrophoresis apparatus: Bio-Rad Mini Protean II Cell (Bio-Rad 
Laboratories Ltd.).
Heated water bath: Grant JB2 (Grant Instruments)
Heating block: Techne Dri-Block DB-2A (Techne Cambridge Ltd.) 
Incubators: New Brunswick Scientific Controlled Environment Incubator 
Shaker (New Brunswick Scientific)
Magnetic stirrer: Stuart Magnetic stirrer (Stuart)
pH meter: Coming pH meter 240 (Ciba Coming Diagnostics Ltd.)
Power supply: Bio-Rad 200/ 2.0 power supply (Bio-Rad Laboratories Ltd.) 
W ater supply: Milli-Q Plus P.F. (Millipore)
Whirlimixer: Fisons Whirlimixer WM/ 250/ SC/ P (Fisons)
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Table 2.1. Details of epithelial cell lines and growth media / supplements.









AF508 / AF508 CF phenotype; 
SV40 transformed
MEM with L-alanine-L- 
glutamine
Present in all cell-line media
16-HBE 16HBE14o‘ (309) Non-CF phenotype; 
SV40 transformed
DMEM with glucose, sodium 
pyruvate, glutamine and 
pyridoxine
10 % v/v FCS 





HTE containing pCEP4P plasmid DMEM with glucose, sodium 
pyruvate, glutamine and
100 U/ml penicillin 
100 pg/ml streptomycin 
500 ng/ml amphotericin B
pCEP-RF 9HTEo'
/pCEP-RF
(310) AF508 / AF508 -like phenotype; 
HTE containing pCEP4P plasmid
pyridoxine 
+ 80 (ig/ml hygromycin
62
Chapter 2: Materials
Table 2.2. Details of bacterial strains and selective media.
Synonym Strain Reference Description Selectivity agents added to SMM + CAA
B. cepacia
JL21 J2315 (262) Highly transmissible, virulent clinical isolate None
P. aeruginosa
PAOl PAOl (ATCC 15692) (311) Invasive, non-mucoid laboratory strain None
PAK1 PAK (312) Invasive, non-mucoid laboratory strain None
PAK2 PAK exsA::Q (312) exsA mutant of PAK °200 (ig/ml St + 200 (ig/ml Sp
PAK 3 P AKexOiS:: Dexo T:: Gem (312) exoS/exoT double mutant of PAK 200 (ig/ml St + 200 (ig/ml Sp + 200 (ig/ml Gm
PAK4 PAKexoS::QexoT: :Gem( pDN 19) (312) exoS/exoT double mutant of PAK, 
containing a vector
*100 (ig/ml Tet
PAK 5 PAKexoS:: QexoT:: Gem(pH W9948) (312) exoS/exoT double mutant of PAK, 
containing exoS clone
100 (ig/ml Tet
PAK 6 PAKexoS::f2exoT::Gem(pHW9949) (312) exoS/exoT double mutant of PAK, 
containing exoT clone
100 |ig/ml Tet
aKey: St -  Streptomycin ^ e t  was added from concentrated ethanolic stock
Sp -  Spectinomycin 








3.1 Epithelial Cell Culture.
In all cases, epithelial cell culture media and supplements were purchased from 
Gibco-Life Technologies and epithelial cells were grown on collagen gels, 
except when described to the contrary.
3.1.1 Epithelial cell lines.
Two pairs of transformed, human tracheal epithelial cell lines were used 
routinely in this work. Control cells, 9HTEo* (HTE) (307), and CF-phenotype 
cells, XCFTE29o' (CFTE) (308), both were gifts from D.C. Gruenert, University 
of California, San Francisco, USA. The second pair o f cell lines was derived 
from the HTE cell line by transfection with the pCEP4p plasmid (310). Control 
cells (pCEP-2) consist of HTE cells transfected with the empty vector; whilst 
the plasmid in CF transfectants (pCEP-RF) expresses multiple copies of CFTR 
R-domain, conferring a AF508 / AF508-like CF phenotype on pCEP-RF cells. 
pCEP cells were gifts from P.B. Davis, Case Western Reserve University, Ohio, 
U.S.A. Details of epithelial cell lines are summarised in Table 2.1.
3.1.2 Maintenance of cell lines.
Epithelial cells were grown for at least 5 days in standard vented tissue-culture 
flasks (Nunc) before they were seeded for experiments. CFTE cells were 
maintained in T175 flasks to generate sufficient cells for each experiment. All 
other epithelial cells were maintained in T80 flasks. HTE and CFTE cells were 
grown in MEM (304) containing 0.406 g/ L L-alanine-L-glutamine (Glutamax- 
I); and pCEP cells were grown in DMEM (303) containing 1.0 g/ L D-glucose, 
0.11 g/L  sodium pyruvate, 0.58 g/ L L-glutamine, 4.0 mg/ L pyridoxine and
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80 jig/ ml hygromycin B (Calbiochem) to maintain the plasmid. Both MEM 
and DMEM were supplemented as shown in Table 2.1. Media containing all of 
these supplements are referred to as “ 10 % complete” and, unless stated 
otherwise, 10 % complete medium was used for all epithelial cell procedures. 
Medium was aspirated from the adherent epithelial cells every 2-3 days and 
replaced with fresh until the cells were almost confluent. The monolayer was 
harvested and seeded into dishes or multi-well plates for experiments, and 
propagated in fresh flasks.
3.1.3 Harvesting epithelial cells.
Epithelial monolayers were washed with 10-15 ml Ca2+- and Mg2+- free PBS 
(PBS-A) three times and incubated with 2-3 ml trypsin (0.5 pg/ ml) / EDTA 
(0.2 pg/ ml) at 37°C for 2-3 min until cells began to round up and dislodge. 
Volumes of PBS-A and trypsin / EDTA were adjusted according to monolayer 
unit area. Removal of epithelial cells from the flask and separation from each 
other was completed by dispersion through a Pasteur pipette. Trypsinisation 
was terminated by addition of 25 ml medium and the epithelial cell suspension 
was transferred to a 30 ml tube (Bibby Sterilin). Epithelial cells were 
centrifuged at 300 x g for 10 min and the resulting pellet was suspended in 1 ml 
medium for the cells to be counted. After counting, the epithelial cell 
suspension was diluted to the required concentration and seeded at the 
appropriate density into the relevant vessels. Culture supernatant was aspirated 
every 2-3 days, and replaced with fresh medium.
66
Chapter 3: Methods
3.1.4 Epithelial cell viable counts using a haemocytometer.
Approximately 40 pi of epithelial cell suspension was diluted with an equal 
volume of 0.4% w/v trypan blue in PBS, placed into a haemocytometer 
counting chamber and overlaid with a glass coverslip. All of the cells in 
opposing large comer squares of the haemocytometer grid were counted such 
that at least 100 viable cells had been recorded. Cell density was calculated as 
follows:
cells / ml = cells counted x dilution factor x 104
nr. squares counted
3.1.5 Cryopreservation of epithelial cells.
Epithelial cells were grown in T175 flasks until confluent. The monolayer was 
harvested and suspended in 7.5 ml medium. A volume (400 pi) of the 
suspension, containing 2x105 -  8xl06 cells, was transferred into cryovials 
(Nunc) containing 0.5 ml dimethyl sulphoxide (DMSO, Sigma) and 0.1 ml FCS. 
Cryovials were placed in a “Cryo 1°C freezing container” (Nalgene) with 
isopropyl alcohol (BDH) at -80°C overnight, which cools cells at a rate of -1°C 
per min to prevent cryolysis. Frozen epithelial cells were stored in liquid N2. 
One vial of epithelial cells from each batch was thawed the following day to 
confirm that the freezing process had been successful.
3.1.6 Thawing epithelial cells.
Epithelial cells were removed from the liquid N2 store and part-thawed quickly 
at 37°C. Cryovial contents were transferred immediately to 25 ml warmed 
medium and centrifuged at 300 x g for 10 min. The pellet was resuspended in
67
Chapter 3: Methods
10 ml medium and transferred to a coated tissue culture flask for growth to 
confluence before harvesting and re-seeding for experiments. Medium was 
changed 24 h after thawing to remove final traces of DMSO from the flasks.
3.1.7 Collagen-gel preparation.
All glassware and plasticware onto which cells would be seeded was coated 
with a solution of 0.2 mg/ ml collagen (Table 3.1). After removal of the excess 
collagen solution, vessels were left to dry overnight, wrapped aseptically and 
stored at 4-8 °C.
3.1.8 Preparation of multi-well strips for tissue culture.
Non-sterile multi-well strips and frames were placed in a laminar flow hood and 
drenched in 70 % v/v ethanol. Once the ethanol had evaporated, the strips and 
frames were exposed to UV radiation overnight. The following day, the strips 
were assembled aseptically into the frames, coated with collagen and stored at 
4-8 °C.
3.1.9 Preparation of glass coverslips for tissue culture.
Non-sterile glass coverslips were soaked in 70 % v/v ethanol overnight. The 
following day, coverslips were transferred aseptically, one each into the wells of 
a 24-well plate in a laminar flow hood. After evaporation of the ethanol, 




3.2 Bacterial Cell Culture.
3.2.1 Details of strains.
A virulent and highly transmissible clinical isolate of Burkholderia cepacia, 
strain J2315, was a generous gift from J.R.W. Govan, University of Edinburgh, 
UK. Two invasive non-mucoid laboratory strains of P. aeruginosa were used in 
this study: PAOl (ATCC 15692) (311) was obtained from American Type 
Culture Collection; and PAK and isogenic mutants derived thereof (312) were 
kind gifts from Dr. S. Jin, University of Florida, U.S.A. Mutations had been 
introduced into PAK genes encoding proteins of the Type III secretion system 
apparatus (312), and five such mutants were used in this work. Details of 
bacterial strains and selective media are summarised in Table 2.2.
3.2.2 Maintenance of bacterial strains.
3.2.2.1 Cry (preservation of bacterial cultures.
Cultures were grown overnight in Luria Bertani (LB) broth (Difco) containing 
the appropriate selective antibiotics (Table 2.2). A volume of the overnight 
culture was mixed with sterile glycerol (20% v/v), transferred into cryovials and 
stored at -80°C.
3.2.2.2 Stock plates.
Strains were cultured from frozen stocks onto nutrient agar with antibiotic 
selection as required. P. aeruginosa plates were stored at 4-8°C and B. cepacia 
plates were stored at room temperature for up to one week, before re-streaking 
from frozen. Agar plates containing light-sensitive tetracycline were wrapped 
in foil to store in the dark.
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3.2.3 Preparation of Glassware.
All glassware for bacterial culture was soaked overnight in 0.01% w/v EDTA to 
remove Fe3+ and rinsed at least three times in MilliQ water. Glassware was 
dried and oven-sterilised as usual.
3.2.4 Broth Culture of Bacteria.
All strains were grown in succinate minimal medium (SMM) supplemented 
with casamino acids (CAA, 0.01 % w/v) [detailed in the previous chapter] at 
37°C, and selected as shown in Table 2.2. The stock plate was brought to room 
temperature and used to inoculate pre-warmed culture medium. Inoculated 
cultures were grown overnight with shaking (200 rpm) in thick-walled baffled 
glass flasks and those cultures containing tetracycline were covered completely 
with foil.
3.2.5 Viable counting of stationary phase broth cultures.
Each bacterial strain culture was diluted in M9 salts (Table A3) and the 
OD550nm (optical density at 550 nm) was measured spectrophotometrically 
(Milton Roy Spectronic 601). Broth cultures were diluted in a 10-fold series 
into M9 and 100 pi were plated in triplicate onto nutrient agar, for two 
consecutive dilutions. Plates were incubated overnight (P. aeruginosa), or for 
48 h {B. cepacia), at 37°C and the mean number of colony forming units (cfu) 
from triplicate plates was noted in each case. ODssonm was calibrated against 
the corresponding mean cfu so that viable bacterial cell density (cfu/ ml) could 
be estimated from ODssonm for future cultures of each strain.
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3.3 Epithelial - Bacterial Cell Co-incubation.
OD550111T1 of an overnight bacterial culture in stationary phase was measured. 
The culture was diluted in M9 and added (10 % v/v) to sub-confluent epithelial 
cells in multi-well dishes or petri dishes, to give the required multiplicity of 
infection (moi). Epithelial cell and bacteria were transferred to a small mobile 
incubator unit (Billups Rothenberg) and gassed for 1-2 min with 5% CO2: 95 % 
air. The unit was sealed and placed on a rotating platform at no more than 25 
rpm. Co-cultures were incubated at 37°C. If bacterial cells or supernatant 
alone were to be used to stimulate epithelial cells, 1 ml of the neat whole cell 
suspension was microfuged at 5,900 x g for 10 min. The supernatant (1 ml) was 
transferred to a 1.5 ml polypropylene tube and diluted accordingly. Pellets of 
bacteria were suspended gently in 1 ml M9 and diluted as required.
3.4 Ion Channel Studies.
3.4.1 Fluorimetric analysis using PTI fluorimeter. Cells were seeded (1 x 
105) onto 13 mm diameter glass coverslips and grown for at least 4 days until 
patches of confluent cells were visible. Cells were loaded with 10 mM N- 
(ethoxycarbonylmethyl)-6-methoxyquinolinium bromide (MQAE, Molecular 
Probes) in serum-free medium for 4 h at 37°C. The principle of this assay is 
shown in Figure 3.1. As required, each coverslip was washed in C f buffer 
(Table 3.2) three times, assembled into the coverslip perfusion chamber and 
overlaid with 200 pi C f buffer. All buffers were warmed before use. Cells 
were brought into view under a x40 oil immersion objective on an inverted 
Nikon Diaphot 300 microscope attached to a Photon Technology International 
(PTI) Inc. dual-wavelength fluorimeter. The viewed area was adjusted by way
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of moveable slits to reduce background auto-fluorescence and epithelial cell 
fluorescence was measured using the PTI fluorimeter (365 nm excitation; 465 
nm emission) at room temperature, in a darkened room. Each sample was read 
for 1 min to obtain a stable baseline for comparison, corresponding to 
unstimulated cells, Fmin. Cl*-buffer was aspirated and replaced with 100 pi Cf- 
free (NO3') buffer (Table 3.2) three times, and fluorescence was measured for 
1 min to monitor C f leakage from unstimulated cells. One hundred microlitres 
of agonist were added cell fluorescence was recorded for 5 min, or for 10 min in 
the case of forskolin, which has longer reaction kinetics. Fifty microlitres of 
0.5 mg/ ml digitonin (Sigma) in 70 % ethanol were added at the end of each 
stimulation to lyse the cells and obtain a maximum fluorescence reading, Fmax, 
corresponding to [Cf]i=0. Percentage change in fluorescence, AF, was 
calculated as:
AF = (Ft - Fmjn) / (Fmax " Fmin) X 100 %
where Ft is the fluorescence at time, t; and the degree of dye loading was 
calculated as the difference between Fmin and Fmax.
3.4.2 Fluorimetric analysis using Fluoroskan Ascent plate-reader.
Cells were seeded into multi-well strips (1 x 104 / well) and grown for at least 4 
days. Once confluent patches of cells were apparent, cells were washed three 
times with 200 pi PBS and incubated with 10 mM MQAE in serum-free 
medium for 4 h. Each strip of cells was removed as required, washed three 
times with 200 pi C f buffer and overlaid with 50 pi C f buffer. Fluorescence
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was measured (355 nm excitation, 460 nm emission) using the semi-automated 
Fluoroskan Ascent 2.2 plate reader with Ascent software Version 2.4, for 2 min. 
Cells were rinsed three times with 200 pi NO3' buffer, overlaid with 50 pi NO3' 
buffer and cell fluorescence was measured for 1 min. One hundred microlitres 
of agonist were added and fluorescence was monitored for 5 min. Cells were 
lysed with 100 pi of 0.5 mg/ ml digitonin to obtain Fmax and the data were 
analysed to calculate the change in fluorescence over time, as described 
previously.
3.4.3 Radioisotopic analysis.
Cells were grown in small petri dishes for at least 4 days, rinsed three times 
with 2 ml efflux buffer (Table 3.3) and incubated at 37°C for 1 h with 5 pCi 
36C1 (Amersham) in efflux buffer. Cells were rinsed rapidly with 2 ml efflux 
buffer three times then 1 ml fresh efflux buffer was added and removed for 
scintillation counting after 1 min. Twice more, fresh efflux buffer (1 ml) was 
added for 1 min then removed for counting. One millilitre of fresh efflux buffer 
containing agonist at the required concentration was added and removed after
1 min for the next 9 min. Finally, cells were rinsed three times with 2 ml ice- 
cold Mg2+-sucrose wash buffer (Table 3.4). Cells were lysed overnight with 
0.1 M NaOH (1 ml) and the lysates were collected for counting. All samples 
were diluted with 10 ml scintillant (Optiphase Hi-safe), stored in the dark for
2 h and then read using a liquid scintillation counter (LKB Wallac Rack II beta 
(1207), Wallac), with a darkened lid, for 2 min per sample. Efflux of Cl was 








A: MQAE is loaded into the 
epithelial cell where its fluorescence 
is quenched by intracellular Ch.
The difference in CT concentration 
between the cytosol (~4mM) and 
extracellular fluid (1 l(M30mM) is 
maintained by the plasma membrane.
4 mM Cl-
Cl Cl Cl
M O M  O Cl Cl
16 mM NO, 
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B: Cf is removed from the 
extracellular fluid and replaced 








C: Activation of one or more groups 
of Cl' channel in the plasma membrane 
allows Cl' to flow out of the cell and 
NOj' to flow into the cell down their 
respective concentration gradients.
As MQAE inhibition by Cl'decreases 
so its fluorescence intensity increases.
NOj' does not quench MQAE fluorescence.
D: Digitonin permeabilises the cell 
membrane so that the intracellular 
Cl' concentration = 0 mM.
This situation corresponds to 
maximum fluorescence.
Figure 3.1 Effects of Cf on MQAE fluorescence in cells.
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3.5 MAP Kinase Pathway Studies.
3.5.1 Western blotting.
3.5.1.1 Extraction of cellular protein.
Cells were seeded into 22 cm2 petri dishes (Nunc) at lxlO5 / dish or 2xl05 / dish 
and grown for 4-7 days until almost confluent. The monolayer was washed 
three times with 2 ml PBS (Table A l) then 1.8 ml serum-free medium was 
replaced into each dish and incubated overnight at 37°C, 5 % CO2/ 95 % air. 
Four or 5 dishes at a time were removed from the CO2 incubator and agonist 
(200 pi) was added to each dish, which were swirled gently to mix. Stimulated 
cells were incubated for between 30 sec and 15 min at room temperature, with 
occasional gentle agitation to ensure adequate mixing; or for 30 min or 60 min 
at 37°C, 5 % CO2/ 95 % air in a modular incubator chamber, with rotation at 
25 rpm. The supernatant was discarded quickly by inversion and cells were 
washed once with 2 ml PBS and transferred to ice immediately, followed by the 
addition o f400 pi ice-cold lysis buffer (Table 3.5). On ice, cells were removed 
from the dish mechanically using a clean cell-scraper (Costar) and the lysate 
was homogenised by repeated dispersion through a pipette tip. The lysate was 
transferred to a clean 1.5 ml polypropylene tube and microfuged at 350 x g for 
10 min at 4°C to pellet any cell debris. Supernatants containing whole cell 
extracts (WCEs) were transferred to a fresh 0.5 ml polypropylene tube and 
stored at -80°C.
3.5.1.2 Quantification of cellular protein by Bradford Assay.
The protein content of each sample was assessed essentially by the method of 
Bradford (313). Working out of direct light, 20 pi of sample was added to 1 ml
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of protein dye reagent concentrate (Bio-Rad) that had been diluted 20 % v/v 
with MilliQ-water in a polypropylene tube. BSA stock (10 mg/ ml) was diluted 
freshly to a concentration of 1 mg/ ml from which ten standards, with protein 
concentrations between 0 pg/ ml and 20 pg/ ml, were prepared freshly for each 
plate. Analysing one set of 20 samples at a time, samples and standards were 
vortexed and 200 pi of each was transferred in duplicate to wells of a 96-well 
microtitre plate (Nunc). Samples were read immediately at 595 nm in a 
spectrophotometric plate reader (MR500, Dynatech) and protein concentrations 
of each were calculated from the standard curve, which plotted protein 
concentration against OD595nm, using BioLinx 2.10 software (Dynatech 
Laboratories). Acceptable values for protein concentration of samples were 
obtained only from plates generating a standard curve with R-square > 0.990. 
Otherwise, the preparation and analysis of samples and standards were repeated.
3.5.1.3 Protein separation by SDS-PAGE.
Protein separation was carried out based on the method of Laemmli (314). 
Polyacrylamide (Protogel 37.5:1 Acrylamide: Bisacrylamide, Flowgen) mini­
gels were prepared (0.75 mm width; 4% stacking gel, 10 % resolving gel -  
Table 3.6) using Mini Protean II apparatus (BioRad). Once set, gels were 
submerged in electrode buffer (Table 3.7) during sample preparation. An 
aliquot of broad-range molecular weight marker (BioRad), 10 % v/v, was boiled 
in 5x SDS sample buffer (Table 3.6) and 10 pi added to the first well of each 
gel. Samples containing 20 pg protein (15-25 pi of lysate) were boiled for 5 
min in 5pl of 5x SDS sample buffer in 0.5 ml polypropylene tubes and the total 
contents of each tube were transferred to the relevant well using gel-loading tips
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(Greiner) for accuracy. Samples were electrophoresed at 75 V through the 
stacking gel and at 200 V through the separating gel until the dye-front was at 
the very edge of the gel.
3.5.1.4 Immunoblotting.
Electrophoretic transfer of protein onto nitrocellulose membranes was carried 
based on the method of Towbin et al. (315). The gel containing electrophoresed 
samples, the nitrocellulose membrane (BDH) and the filter paper (3M, 
Whatman) all were soaked in transblot buffer (Table 3.7) for 10-15 min. After 
soaking, each gel was laid on top of a nitrocellulose membrane (7.5 x 10 cm). 
This arrangement was sandwiched between eight sheets o f filter paper, which, 
in turn, was sandwiched between two Scotchbrite pads and clamped into the 
Mini Transblot Cell cassette (BioRad). Electroblotting was carried out on ice 
for lh at 100 V. Transfer of protein onto the nitrocellulose was confirmed by 
staining the membrane with Ponceau S solution (Sigma). This practice allowed 
visualisation of molecular weight marker bands, which were marked onto the 
membrane in pencil. Ponceau S stain was washed away three times with TBS 
(Table A4) + 0.05 % v/v Tween-20 (polyoxyethylene (20) sorbitan 
monolaurate) and then three times with TBS alone.
3.5.1.5 Detection of protein.
Membranes were blocked overnight in BSA/ ovalbumin blocking buffer (Table 
3.8) then washed three times in TBS/ tween and three times with TBS alone for 
5 min each. Anti-phospho-p44/42 MAPK (ERK) monoclonal antibody (New 
England Biolabs) was diluted to 1: 1 000 of stock, as recommended by the
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manufacturer, with 0.2x blocking buffer in TBS and incubated with the 
membranes in heat-sealed plastic bags overnight at room temperature with 
rotation (40 rpm). Membranes were washed, as before, and incubated with 
HRP-conjugated goat anti-mouse antibody (Dako) diluted to 1: 10,000 of stock, 
as recommended by the manufacturer, in TBS/ tween for 1 h at room 
temperature, with rotation (40 rpm). Secondary antibody was washed away and 
membranes were blotted dry. Each membrane was incubated with 
chemiluminescence reagent (ECL, Amersham) for 1 min, blotted dry again and 
wrapped in cling-film. Phosphorylated ERK was detected on the membranes by 
their exposure to x-ray film (XOMAT, Kodak). Film was processed using a 
Fuji RGII x-ray film processor.
3.5.1.6 Stripping and re-probing membranes.
Membranes were re-hydrated in TBS before being baked in stripping buffer 
(Table 3.6) for 1 h at 50-55°C. Membranes then were rinsed thoroughly with 
distilled water and re-blocked for 1 h in BSA/ ovalbumin. After washing three 
times with TBS/ tween and three times with TBS alone, membranes were 
incubated with anti-pan ERK antibody (New England Biolabs), diluted 1: 1000 
in 0.2x blocking buffer, for 1 h. Membranes were washed as before and 
incubated with HRP-conjugated goat anti-rabbit antibody (Dako) diluted 1: 




3.5.2 Toxicity of dicoumarol to pCEP cells.
pCEP cells were seeded into 6-well plates (Nunc) and left to grow for at least 4 
days, until almost confluent. Confluent monolayers were washed three times 
with 2 ml PBS (Gibco) and then cells were bathed overnight in 0.9 ml serum- 
free DMEM containing only hygromycin and non-essential amino acids. The 
following day 100 pi of dicoumarol (3,3,-methylene-bis(4-hydroxycoumarin), 
Sigma) or vehicle control (Milli-Q water, adjusted to pH 9.8) was added to 
duplicate wells and incubated at 37°C, 5 % CO2: 95 % air for 30 min plus 3 h, 
8 h, 12 h, or 24 h. Alternatively, dicoumarol was left on the cells for 30 min 
then washed away three times with 2 ml PBS and replaced with 0.9 ml DMEM, 
containing only hygromycin and non-essential amino acids, for the times 
indicated. After incubation, cells were harvested using approximately 200 pi 
trypsin/ EDTA per well. Cell suspensions were centrifuged at 300x g for 10 
min and viable cells were counted as described previously.
3.6 Analysis of Cytokine Production by Epithelial Cells.
3.6.1 Stimulation of cells.
Cells were seeded into 12-well plates (Falcon) at a density of lxlO4/ well or 
2xl04/ well and grown for 4-7 days until almost confluent. Cell monolayers 
were washed three times with 1 ml PBS, and 450 pi serum-free medium was 
replaced into each well for incubation overnight. The following day, 50 pi of 
vehicle control or agonist were added and cells were incubated for up to 24 h at 
37°C in 5 % CO2 : 95 % air. For each inhibitor to be added, 50 pi of serum-free 




imidazole, Calbiochem) (316) or 50 pi of the specific ERK MAP kinase 
inhibitor PD-098590 (2’-amino-3’-methoxyflavone, Calbiochem) (142). In 
some experiments, both inhibitors were used together. The plates were wrapped 
in foil and incubated for 1 h before the addition of agonists. Alternatively, cells 
were treated with dicoumarol for 30 min and then washed three times with 1 ml 
PBS. Serum-free medium (450 pi) was replaced and 50 pi agonist was added. 
SB-203580 and PD-098590 were left in supernatants for the duration of the 
experiment. Supernatant from each well was collected into 1.5 ml 
polypropylene tubes, microfuged for 10 min, split into 2 aliquots and stored at - 
80°C. Microscopic examination after collection of supernatants allowed a gross 
assessment of whether the cells remained healthy.
3.6.2 Analysis of epithelial cell supernatants for IL-8.
Microtitre 96-well immunoplates (Nunc) were coated with 50 pi/ well of 2 ng/ 
ml anti-human IL-8 monoclonal antibody (R&D Systems) in PBS, pH 7.4, and 
incubated overnight at room temperature. Unbound antibody was washed away 
three times with 200 pi ELISA wash buffer (PBS + 0.05 % tween) per well and 
the wells were blotted dry. Plates were incubated with 100 pi/ well blocking 
buffer (Table 3.9) for 1 h at room temperature and then washed as before. 
Samples were prepared in dilution buffer (Table 3.9) and 50 pi were added in 
duplicate to the plate. Standards of nine different concentrations were prepared 
in dilution buffer from recombinant human IL-8 (R&D Systems), in the range 0- 
2 ng/ ml. Fifty microlitres per well of each standard was added to each plate in 
duplicate. Loaded plates were incubated at room temperature for 2 h and then 
washed. Addition of streptavidin peroxidase (50 pi/ well, 0.5 ng/ ml) was
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followed by an incubation period of 30 min at 37°C and further washes. HRP 
substrate was prepared by addition of OPD (o-phenylene-diamine 
(dihydrochloride), 1 tablet) and H2O2 (20 pi of 30 % v/v) to warmed substrate 
buffer (Table 3.9) and was added (100 pi/ well) for incubation at room 
temperature in the dark for approximately 30 min. The reaction was terminated 
with 150 pi/ well 1.0 M HC1 and OD450 nm for each well was measured. 
BioLinx 2.10 software (Dynatech) was used to calculate the IL-8 concentration 
in each sample by reading values from the standard curve, which plotted IL-8 
concentration against OD450 nm.
3.6.3 Selection of antibody concentrations and incubation conditions for IL- 
10 ELISA.
Two microtitre 96-well immunoplates (Nunc) were coated with either 100 pi/ 
well or 50 pi/ well of anti-human IL-10 monoclonal antibody (R&D Systems) at 
either 4 pg/ ml or 2 pg/ ml, in PBS pH 7.4, and incubated overnight at room 
temperature. Each plate was washed three times with PBS/ tween and 100 pi/ 
well of blocking buffer was added for incubation for 1 h at room temperature, 
then the plates were washed as before. IL-10 protein standard (R&D Systems) 
was diluted in dilution buffer to 0-12 ng/ ml, 50 pi was added to each coated 
well and one plate was incubated at room temperature for 1 h, whilst the other 
plate was incubated at 37°C for 1 h. Plates were washed as before and either 
100 pi/ well or 50 pi/ well of 250ng/m l biotinylated anti-human IL-10 
antibody was added to each well. Plates were incubated at 37°C for 1 h then 
washed three times. Streptavidin peroxidase, OPD/ H2O2 and H2SO4 were 
utilised as above and the OD490nm was determined for each well using the same
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BioLinx 2.0 software package. Each combination of antibody concentration 
and sample incubation conditions was assessed in duplicate.
3.6.4 Analysis of epithelial cell supernatants for IL-10.
Microtitre 96-well immunoplates (Nunc) were coated with 100 pi/ well of 2 pg/ 
ml anti-human IL-10 monoclonal antibody (R&D Systems) in PBS, pH 7.4, and 
incubated overnight at room temperature. In the same way as for IL-8 
detection, plates were washed, blocked and washed again. A range of IL-10 
protein concentrations was prepared in dilution buffer and samples were diluted 
to 20 % v/v in dilution buffer. Samples and standards were loaded onto the 
plate 50 pi/ well and incubated for 2 h at room temperature. After further 
washes, 50 pi/ well of 250 ng/ ml biotinylated anti-human IL-10 antibody was 
added to each well and the plated were incubated for 1 h at 37°C. IL-10 in each 
well was detected as described previously.
3.7 Statistical Analysis.
Statistical significances were calculated using one-way ANOVA where n > 3, 
followed by an appropriate parametric multiple comparison analysis using 
Dunnett’s test for multiple comparisons.
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Table 3.1 Collagen gel solution.
Component Volume
Vitrogen 100 (Cohesion Technologies) 1 ml
DMEM (serum-free) 1 ml
Milli-Q water 13 ml
Table 3.2 Composition of Cl'- and Cl'-free (N0 3 -) buffers.








n o 3‘ - 130.0
s o 42_ 3.0 3.0
h p o 42_ 2.4 2.4













HEPES, pH 7.4 10




HEPES, pH 7.4 50.0
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Table 3.5 Lysis buffer for WCE collection.
Component Final concentration
Tris HC1, pH 7.5 50 mM
NaCl 150 mM
NP40 (Nonidet P40) (BDH/Merck) 1 % v/v
Glycerol 10 % v/v
EDTA, pH 8.0 5 mM
Na3VC>4 (Calbiochem) 1 mM
NaMo04 1 mM
NaF 10 mM
PMSF (phenylmethylsulphonyl-fluoride) 40 pg/ ml
Pepstatin A 0.7 pg/ ml
Aprotinin 10 pg/ ml
Leupeptin 10 pg/ ml
STI (soybean trypsin inhibitor) 10 pg/ ml











Aery lam ide/ 1.33 ml 5.0 ml -
Bis soln. 
SDS 0.15 ml 0.25 ml 5g 20 ml
(10%w/v) 
Tris pH 8.8 5.6 ml
(1M) 
Tris pH 6.8 1.25 ml 10 ml 8 ml
(1M)
Milli-Q 6.36 ml 4.35 ml 11.5 ml 72 ml
TEMED 20 pi 20 pi - -
soln (10%) 
AMPS 50 pi 50 pi
(10% w/v) 
Glycerol . . 25 ml
BPB soln. - - 400 pi -
(5 % w/v) 
2-ME 2.5 ml 770 pi
Abbreviations: TEMED - N,N,N,’N’-tetram ethyl ethylene diamine; AMPS -  
ammonium persulphate (prepared freshly each week); BPB -  bromophenol 
blue; 2-ME -  2-mercaptoethanol.
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Table 3.7 Composition of electrophoresis buffers for SDS-
PAGE.
Component Electrode buffer Transblot buffer
Tris HC1 3.0 g 3.0 g
Glycine 14.4 g 14.4 g
SDS (10 % w/v) 10 ml -
Methanol - 200 ml
Milli-0 to 1 L to 1 L





Milli-Q to 100 ml







BSA 10g 0.1 g -
Sucrose 50 g - -
NaN3 0.5 g - -
Citric acid - - 7.3 g
(monohydrate)
Na2HP04 9.46 g
Tween-20 - 50 pi -
TBS - to 100 ml -
Milli-Q to 1 L - to 1 L
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C h a p t e r  4:
M odulation o f  
chloride channel activity  
in the respiratory epithelium
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4.1 Introduction.
CF is characterised by an abnormal electrolyte balance across the epithelial 
mucosae because of defective chloride transport through CFTR. Many bacterial 
species, including E. coli (19;317;318) and P. aeruginosa (319-321), have been 
shown to affect ion channel activity, although bacterial modulation of Cf 
transport in the lung has not been demonstrated directly. This chapter describes 
a series of experiments that were designed to investigate the possibility that 
clinically significant CF pathogens, P. aeruginosa and B. cepacia modulate C f 
movement across the respiratory epithelium and if so, whether any differences 
exist between the C f channel responses in CF and non-CF epithelial cells.
Chloride channel activity was measured in respiratory epithelial cell lines that 
had been stimulated either with pharmacological mediators, or with 
P. aeruginosa PAOl or B. cepacia J2315. A range of different techniques was 
used, employing either fluorescent or radioisotopic chloride probes, and several 
chloride channel agonists served as positive controls in these assays. These 
agonists are described in Table 4.1.
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Table 4.1 Pharmacological actions of agonists used to investigate Cl' efflux.
Agonist Mode of 
action
Immediate response Cellular effects Expected effect on Cl' 







Influx of extracellular 
Ca2+




















High levels of cAMP 
maintained

















IBMX Non-specific High levels of cAMP Activation o f cAMP-mediated CF - No increase
(Calbiochem) PDE inhibitor maintained Cl* channel (CFTR) normal - Increased efflux
‘ Abbreviations: CaMCC -  calcium-mediated Cl* channel; CF -  cells expressing CF mutation; cAMP -  cyclic AMP; 8-Br-cAMP - 8 bromo cyclic 
AMP; IBMX -  3-isobutyl-1-methylxanthine; PDE - phosphodiesterase
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4.2 Investigation of C1‘ Channel Activity Using the Radioisotope 
36C1.
Epithelial cells were grown in 35 mm-petri dishes and loaded with Cl for up to 
5 h (308). Unloaded radioactivity was washed away and cells were overlaid 
with efflux buffer. Supernatant was collected every minute before and after the 
addition of agonist for up to lOmin. Changes in radioactivity in the cell 
supernatant over time were analysed after the addition of a cAMP agonist 
(isoprenaline, forskolin + IBMX, or 8Br-cAMP) or addition of a calcium 
ionophore (ionomycin) and these data were compared with unstimulated cells 
and buffer control. Only ionomycin (10 jaM) increased the efflux of 36C1 from 
stimulated epithelial cells but no difference could be detected between the level 
of radioactivity in the supernatant from unstimulated cells and that from cells 
treated with a cAMP agonist (data not shown). This assay displayed low 
reproducibility because often, baseline efflux was very high, masking any 
effects that there may have been with the Cf channel agonists.
It has been reported that fluorescent probes are more sensitive that radioisotopic 
probes (322), as well as being non-toxic. To improve the sensitivity of the 
assay, and to avoid the potential hazards associated with radiolabelled 
chemicals, a fluorescent Cf sensitive dye was tested in subsequent experiments.
4.3 Analysis o f Epithelial Cl~ Transport Using a Fluorescent 
Probe.
A number of groups have used fluorescent indicators to assess C f transport in a 
variety of epithelial cell types (310,323-325). MQAE is a Cl'-sensitive dye,
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whose fluorescence is reduced by collision with halide ions in a concentration- 
dependent fashion. The sensitivity of fluorescent probes is described by the 
Stem-Volmer quenching constant, Ksv, which describes the reciprocal of the 
ion concentration that quenches 50 % of the maximum fluorescence. 
Developed by Verkman and colleagues (322;326), MQAE was selected because 
it can be loaded into the cells non-invasively, and because it is more sensitive 
(Ksv = 200 M '1) than another commonly used C f probe, SPQ (Ksv =118 M'1). 
However, both dyes are less sensitive in cells (MQAE Ksv = 64 M'1; SPQ Ksv = 
12 M’1) than in solution. MQAE was loaded into epithelial cells and measured 
using three different fluorimetric systems, and procedures adapted from several 
published methods (326-329).
4.3.1 Fluorescence measurement of C f transport in epithelial cells using a 
cuvette system.
CFTE and HTE cells were grown in T25 flasks and loaded with MQAE as 
required. Harvested epithelial cells were washed and suspended in C f free 
buffer so that C f could move out of the cell down a concentration gradient once 
the appropriate channels were opened. The extracellular anionic balance was 
restored with NO3’, which permeates C f channels readily but it does not quench 
MQAE fluorescence. The principle of this model is depicted in Figure 3.1.
Epithelial cells were stimulated with ionomycin, isoprenaline or heat-killed 
B. cepacia J2315, and the fluorescence of each sample was measured over time. 
The results are displayed graphically (Figure 4.1) and are shown in Table 4.2. 
Percentage change in fluorescence, AF, was calculated as:
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A F =  ( ( F t - F m in ) /  (Fmax " Fmin )) x 100 %
where F t is the fluorescence at time, t; and the degree of dye loading was 
calculated as the difference between F mjn and F max.
4.3.1.1 Results from MQAE cuvette assay.
Heat-killed B. cepacia J2315 seemed to increase the fluorescence of MQAE- 
loaded HTE cells (Figure 4.1 A) and CFTE cells (Figure 4.1 B) over a 5 min 
period, compared with unstimulated cells (Table 4.2), although these 
differences were not significant by ANOVA analysis. Only CFTE cells 
stimulated with 10 pM ionomycin for 5 min showed a significant increase in 
MQAE-fluorescence compared with unstimulated cells (ANOVA, p<0.05). 
B. cepacia J2315 may activate a transepithelial C f current in CF airway 
epithelial cells, but this stimulation would need to be repeated at least once to be 
sure, since only n=2 data were obtained for this stimulation using this technique.
Ionomycin, but not cAMP agonists, increased the MQAE-fluorescence of CFTE 
cells (Table 4.2; Figure 4.1 B), which is consistent with reports that Ca2+ 
ionophore-stimulation of CFTE cells induces C f efflux and lack functional 
CFTR (327). No response was seen in HTE cells to either class of agonists, 
despite the fact that these cells should respond to both. These caveats may be 
the result of physiological instabilities of adherent cells kept in suspension, 
which create high background fluorescence because of increasing membrane 
permeability. This point was addressed in the next set of experiments. Since 
epithelial cells do not grow in suspension in vivo and thus may not behave in
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suspension as they would when in an adherent monolayer, subsequent studies 
focused on analysing transepithelial Cl" flux in adherent epithelial cultures.
4.3.2 Fluorimetric analysis of cells grown on coverslips.
CFTE, HTE or pCEP cells were grown on coverslips and loaded with MQAE 
(310). A small island of epithelial cells was brought into focus. Fluorescence 
was measured first in Cl" buffer and then in NO3’ buffer, before addition of the 
agonist. Unavoidable disturbances in the fluorescence signal caused by manual 
aspiration of buffer in the dark, between measurements, affected the 
reproducibility of this assay (data not shown). Therefore, an alternative method 
for measuring MQAE fluorescence in adherent epithelial cells was adopted, 
employing a semi-automated fluorimetric system.
4.3.3 Fluorimetric analysis of CF transport using a semi-automated plate- 
reader.
Epithelial cell lines were grown in 8-well strips of a microtitre plate and loaded 
with MQAE. Baseline cellular fluorescence was measured in the presence and 
then the absence of Cl" as before, using a Fluoroskan Ascent plate reader. 
Adherent epithelial cells were stimulated with pharmacological agonists or with 
fresh stationary phase cultures of P. aeruginosa PAOl or B. cepacia J2315 (moi 
= 100).
It was found that the presence of P. aeruginosa PAOl supernatant almost 
doubled the change in fluorescence that was detected. The difference between 
the fluorescence generated using whole cell suspension PAOl and supematant-
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free PAOl is shown in Figure 4.2. Because some P. aeruginosa exoproducts 
(for example pyoverdin and pyocyanin) fluoresce at a similar wavelength to 
MQAE they interfere with the fluorescence signal, cultures of P. aeruginosa 
PAOl were pelleted then suspended in M9 and diluted in NO3’ buffer for 
stimulating epithelial cells in this assay.
4.3.3.1 Results from Fluoroskan Ascent plate reader assay with MQAE 
Data from this set of experiments are detailed in Table 4.3, and illustrated in 
Figure 4.3. P. aeruginosa PAOl enhanced MQAE fluorescence in both CF and 
normal epithelial cells, compared with negative controls. In CFTE cells, PAOl 
elicited more than a 7-fold increase in Cl* efflux after 1 min (ANOVA, p<0.01), 
which was sustained over the 5 min period (ANOVA, p<0.05) elevating the 
fluorescence to approximately 40 % of the maximum (Figure 4.3 B). This 
effect was repeated in the second CF cell line, pCEP-RF (Figure 4.3 D), in 
which PAOl induced a significantly enhanced transepithelial Cl* current 
compared with buffer alone (ANOVA, p<0.05), raising fluorescence to 
approximately 50 % of the maximum. An even greater effect was seen in 
pCEP-2 cells stimulated with P. aeruginosa, which demonstrated fluorescence 
of almost 70 % of the maximum when Cl* efflux was elevated significantly 
(ANOVA, p<0.001) compared with control cells for the duration of the 
experiment (Figure 4.3 C). After 1 min of stimulation with PAOl, pCEP-2 
fluorescence had increased 12-fold over control. No significant effect was 
observed in HTE cells (ANOVA, p>0.05).
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Furthermore, Figures 4.3 C and 4.3 B, respectively, show that the epidemic 
B. cepacia strain, J2315, activated sustained Cl' efflux both from pCEP-2 cells 
(ANOVA, pO.OOl) and from CFTE cells (ANOVA, p<0.01) within 1 min of 
stimulation, and whilst B. cepacia elevated the fluorescence of pCEP-RF cells 
(Figure 4.3 D), this increase was not considered to be significant (ANOVA, 
p>0.05). These results suggest that both P. aeruginosa and B. cepacia activate 
C f channels in respiratory epithelial cells. Although the fluorescent signal 
continued to rise in intensity over the 5 min period in all samples, the initial 
rates of increase were not sustained but they began to reach a steady state.
Activation of C f channels in CFTE cells was more pronounced after bacterial 
stimulation than after treatment with ionomycin (p(imin)< 0.01; P(5min)<0.05), and 
a similar situation was seen in pCEP-2 cells (Figure 4.3 B-C). B. cepacia 
generated a stronger C f efflux from pCEP-2 cells than did ionomycin after 5 
min (ANOVA, p<0.05) and P. aeruginosa treatment was significantly and 
consistently more effective at eliciting C f currents in this cell line (ANOVA, 
pO.OOl).
Bacterial stimulation of CFTE cells generated a similar elevation in 
fluorescence intensity regardless of the strain (p(imin)>0.48; P(5min)> 0.84). 
However, the response of pCEP-2 cells to P. aeruginosa was even greater than 
to B. cepacia (ANOVA, pO.OOl). Taken together, these observations imply 
that whilst P. aeruginosa and B. cepacia activate Cl* channels in respiratory 
epithelial cells, rates of Cl* efflux vary according to the epithelial and bacterial 
phenotype.
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Table 4.2 Effects of B. cepacia J2315 and other agonists on the 
fluorescence of MQAE in suspension epithelial cells, measured with a PTI 
fluorimeter. Changes in fluorescence 1 min (Al) and 5 min (A5) after 
stimulation are expressed as a percentage +/- SEM of the maximum 
fluorescence of each sample.
Agonist HTE CFTE
Al A5 Al A5
Nothing 9.15 ± 65.54 11.95 39.99




Buffer 10.15 75.55 13.81 45.55











Ionomycin 33.58 89.25 16.38 80.37




Isoprenaline 7.47 ± 66.95 7.35 ± 51.96
(lOpM) 7.33 ±5.00 2.70 ±9.59
(n-3) (n=3) (n=6) (n=6)
Forskolin 9.76 ± 59.63 12.95 58.03






Figure 4.1 (next page) MQAE fluorescence of epithelial cell suspensions, 
measured with a PTI fluorimeter. Error bars (SEM) that are not visible were 
smaller than the data marker.
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Table 4.3 Effects of bacteria on the fluorescence of MQAE in adherent 
epithelial cells, measured with Fluoroskan Ascent. Changes in fluorescence 
1 min (Al) and 5 min (A5) after stimulation are expressed as a percentage +/- 
SEM of the maximum fluorescence of each sample.
A: HTE and CFTE
Agonist HTE CFTE
Al A5 Al A5
Buffer 8.52 ± 11.77 4.7 ± 9.12 ±
2.59 ±2.38 8.54 10.64
(n=4) (n=4) (n=4) (i=4)
B. cepacia, 15.86 23.27 30.05 37.94
J2315 ± 1.65 ±3.21 ±2.68 ±5.80
(n=3) d=3) (n=3) d=3)
P, aeruginosa, 21.57 31.25 32.91 39.63
PAOl ± 1.70 ±4.34 ±2.56 ±5.91
(i=3) (n=3) (n=3) d=3)
Ionomycin 14.22 23.20 6.30 ± 12.86
(lOpM) ±4.30 ±2.70 0.74 ±1.33
(n=3) (n=3) d=3) d=6)
Isoprenaline -5.62 -2.66 1.76 4.53
(lOpM) (n=2) (n=2) (n=2) (i=2)
8Br-cAMP 8.78 ± 13.54 6.19 ± 11.33
(250 pM) 11.42 ±9.74 1.85 ± 1.44
(n=3) (n=3) (n=3) (n=3)
B: pCEP-2 and p<CEP-RF
Agonist pCEP-2 pCEP-RF
Al A5 Al A5
Buffer 5.09 ± 13.14 12.28 24.24
4.52 ±3.03 ±4.14 ±2.41
(n=3) d=3) d=3) (n=3)
B. cepacia, 18.66 35.82 23.16 31.32
J2315 ±3.71 ±4.70 ±9.20 ±9.07
(n=4) (n=4) d=3) ( i-3 )
P, aeruginosa, 70.92 52.56 53.47
PAOl 62.09 ±4.12 ± ±
±8.28 (n=4) 11.95 13.79
(n=4) (n=3) d=3)
Ionomycin 10.10 21.16 12.88 31.48
(lOpM) ±2.03 ±1.63 ±9.03 ±3.49
(i=3) (n=3) d=3) (n=3)
8Br-cAMP 1.98 4.46 0.57 9.89
(250 pM) (n=2) (n=2) (i=2) d=2)
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Figure 4.2 Interference of P. aeruginosa PAOl supernatant with MQAE 
fluorescence, measured with plate-reader. H T E  (b lu e ); C F T E  (red ). T r ia n g le  
-  b u ffer; sq u are -  Pseudomonas sup ernatant; c ir c le -  Pseudomonas w h o le  
cu ltu re . ( n = l )
Figure 4.3 (next two pages) Effect of PAOl and J2315 on MQAE- 
fluorescence of adherent respiratory epithelial cells measured with 
Fluoroskan Ascent plate reader. Error bars rep resen t S E M  for ea ch  sa m p le  
and w h ere  n ot v is ib le ,  error bars w e r e  sm a ller  than th e  data  p o in t.
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4.4 Discussion.
Bacterial challenge within the respiratory tract activates a plethora of signalling 
pathways in the host cell that commonly are mediated by second messengers. 
These small diffusible signalling molecules include Ca2+ and cyclic nucleotides 
and they regulate a number of important cellular processes such as the activity 
of membrane ion channels. The major physiological manifestation of CF is a 
disturbed electrolyte balance at epithelial mucosae because of reduced 
functional expression of the epithelial C f channel, CFTR. Abnormal electrolyte 
movement dehydrates the overlying mucous blanket and the mucociliary 
escalator is disabled. Highly adapted bacterial pathogens such as P. aeruginosa 
and B. cepacia can withstand this hostile, nutrient replete environment to cause 
repeated and persistent infections that contribute significantly to the 
pathophysiology of the CF lung. The aim of the work presented in this chapter 
was to determine whether these pathogens might modulate C f channels within 
the lung, and contribute to this electrolytic disruption.
Using bovine tissue and a capacitance probe technique, Evans et a l 
demonstrated recently that P. aeruginosa altered the airway fluid transport in 
bovine tissue, and that this was most likely via effects on basolateral K+ 
channels and apical Na+ channels in the respiratory epithelium (319). This 
study also suggested that P. aeruginosa may modulate other ion transport 
processes, including anionic channels. Since C f is the predominant cellular 
anion, it is likely that their observations could translate into an activation of C f 
transport by P. aeruginosa. Other research groups have shown that a secreted 
heat-stable E. coli enterotoxin hyper-activates CFTR specifically in the gut, by
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the direct activation of cAMP and cGMP production (19;196;317;330), 
resulting in enhanced transepithelial Cl" transport that causes a massive and 
constant outpouring of watery stools in vivo. This process provides E. coli with 
a mechanism of dispersal to the next host to ensure continuation of the 
infection. Similarly, Vibrio parahaemolyticus, which is another important cause 
of gastroenteritis, produces a haemolytic toxin that activates CaMCC in human 
colonic epithelial cells (331). Thus, bacterial interference with electrogenic 
processes in epithelia is an important and well-documented mechanism of 
pathogenesis and may be important in CF lung infections. In view of the 
pleiotropic effects of CFTR in the cell, this molecule would not be an 
unexpected target for bacterial disruption of host signalling pathways and 
potential diversion or inactivation of the immune response in the lung.
The primary aim of this chapter was to develop a suitable experimental system 
to assess the effects that P. aeruginosa or B. cepacia may have on 
transepithelial C f currents in the respiratory epithelium and whether any such 
effects may be mediated by CFTR. Numerous techniques are available for the 
investigation of ion channel activity in epithelial cells, including the use of 
radioactive or fluorescent intracellular probes. Both of these methods were 
tested here for use with the immortalized CF and non-CF epithelial cells.
4.4.1 Development of a sensitive and reproducible assay to measure Cl" 
efflux in respiratory epithelial cells in vitro.
36C1 efflux was measured in HTE cells and CFTE cells that had been treated 
either with the calcium ionophore ionomycin, which activates Ca2+-mediated Cl"
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channels (CaMCC); or with a cAMP-agonist such as isoprenaline, which 
activates adenylate cyclase via its G-protein coupled receptor and activates 
CFTR via PKA phosphorylation. As expected, ionomycin elicited Cl' efflux 
from both the non-CF and CF-phenotype cell lines that was higher than 
background fluctuations. This was consistent with published reports that both 
pairs of cell lines express Ca2+-mediated Cl' channels (307;308;310). However, 
it was not possible to demonstrate a clear difference between the response of 
CFTE cells and that of HTE cells to isoproterenol using 36C1 despite the fact that 
the double AF508 mutation renders CFTE unresponsive to cAMP agonists 
(308), whilst HTE cells retain C f transport activity through CFTR (307). At 
this point it is of interest to note that whilst studies in the laboratory from which 
both of these cell lines originate employed both electrophysiological and 
radioactive tracer techniques to report the Cl* transport properties of CFTE cells 
and to demonstrate a lack of responsiveness to cAMP agonists (308) 9 only 
electrophysiological demonstration of HTE Cl* transport was provided (307). 
Thus, CFTR-mediated Cl* currents had not been demonstrated previously in 
HTE cells using radioisotopic probes. There was high background noise in this 
system, which hindered the reproducibility of this assay and made it unsuitable 
in this situation. Bacteria were not tested in this system.
Subsequent experimental systems involved a fluorescence Cl* probe, MQAE, 
since it has been reported that fluorimetric techniques are more sensitive that 
assays with radioisotopes (322). Furthermore, use of these non-toxic 
fluorescent dyes circumvents the potential hazards associated with measurement 
of radioisotopic tracers. In the first instance, MQAE fluorescence was
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measured in epithelial cells in suspension in a cuvette so that the cellular 
concentration could be adjusted easily to optimise the signal, whilst a magnetic 
stirrer in the bottom of the cuvette ensured even distribution of cells and 
agonists. In addition, this procedure permitted access to the basolateral 
epithelial membrane, which is likely to occur in vivo in the event of 
inflammation or tissue damage. To maximise any change in fluorescence, Cf 
ions were removed from the extracellular fluid so that Cl' would flow out of the 
cell, and consequently the fluorescence intensity would increase, should the 
appropriate channels be activated, as depicted schematically in Figure 3.1. A 
marked change in fluorescence was detected in stimulated cells, although 
unstimulated epithelial cells in suspension also displayed increased MQAE- 
fluorescence over the 5 min duration of the experiment. Adherent cells lose 
physiological stability with time when in suspension, which may have 
contributed to the ‘leakiness’ of the epithelial cells so the protocol was adapted 
to measure cells growing on a substrate.
To begin with, epithelial cells were grown on glass coverslips and MQAE 
fluorescence was measured in response to Cl' channel agonists using a PTI 
fluorimeter. Experiments were performed with and without extracellular Cl' but 
neither approach generated a particularly strong signal. Thus, for a number of 
reasons, the most useful fluorescence-based system with which to monitor 
epithelial Cl' currents was the semi-automated Fluoroskan Ascent plate reader. 
Firstly, Cl' efflux could be measured in adherent epithelial monolayers, which 
reduced the baseline efflux of unstimulated cells that was seen in the cuvette 
system quite considerably (compare Figure 4.1 A with Figure 4.3 A, for
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example). In addition, multiple replicates could be performed for each sample, 
providing a more accurate representation of the data. Finally, in contrast to the 
coverslip assay, samples could be mixed thoroughly and signals were detected 
with relatively small numbers of cells.
4.4.2 Bacterial modulation of Cl' channels in airway epithelial cells.
Both P. aeruginosa and B. cepacia, two important pathogens associated with 
CF pulmonary infection displayed the potential to interfere with C f channel 
activity in vitro. For example, P. aeruginosa PAOl increased the fluorescence 
signal from the CF-phenotype cell lines CFTE and pCEP-RF, as well as from 
the normal pCEP-2 cells (Figure 4.3 B-D, respectively). Possible candidates 
for the activated Cf channel include cAMP-activated CFTR; ORCC, which is 
regulated by CFTR expression and cell swelling (46;332)\ and CaMCC that is 
activated by ionomycin (333). It has been reported that pCEP-RF and CFTE 
cells do not express functional CFTR activity and CFTE cells may exhibit lower 
activity of CaMCC, whilst pCEP-2 cells retain sensitivity towards agonists of 
the cAMP pathway (308;310). In order to determine precisely the identity of 
the channel targeted by PAOl, each C f current would need to be inhibited 
specifically and selectively. Since there appears to a slight difference between 
the efflux rates in CF and non-CF epithelial cells stimulated with P. aeruginosa 
PAOl, but this difference just failed to be significant (ANOVA, p<0.074), the 
possibility that more than one group of C f channels is activated in response to 
P. aeruginosa infection should not be ruled out.
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Three important features of the results presented here are in agreement with the 
report that P. aeruginosa induces fluid secretion at the respiratory epithelium. 
To begin with, the data presented here show that PAOl activates C f currents in 
epithelial cells, which was implied by Evans et al. with the use of C f channel 
inhibitors that blocked the effects of P. aeruginosa on fluid absorption in their 
electrophysiological assay. Secondly, in none of the C1‘ transport methods 
described here was it possible to detect the effects of cAMP agonists on C f 
transport, yet strong signals were obtained in response to bacterial stimulation. 
This discrepancy is consistent with the idea that a channel other than CFTR was 
activated although this evidence is circumstantial and does not exclude a role 
for CFTR. Evans et al. showed the effects of P. aeruginosa on fluid movement 
to be abrogated by the Cl" channel inhibitors H2-DIDS and NPPB yet the 
inhibitory potential of these compounds against airway CFTR channel activity 
is disputed (332;334-336). Again, the implication is that CFTR is not involved 
in bacterial-induced Cl" currents in epithelial cells. Finally, because the PAOl 
pigments secreted under iron-limited growth conditions fluoresce at a similar 
wavelength to that of MQAE so that PAOl supernatant may interfere with the 
MQAE signal, stimulations were performed with supernatant-free cultures of 
P. aeruginosa.
Therefore, it can be concluded from this result that the Cl" current measured 
fluorescently was not induced by a secreted P. aeruginosa component, but 
required the presence of bacterial cells. In the same way, the 
electrophysiological studies had shown that the altered epithelial fluid transport 
was dependent upon cell-to-cell contact between P. aeruginosa and the bovine
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epithelium, since mutants defective in expression of RpoN did not generate the 
same response in bovine tracheal epithelial cells as the wild-type P. aeruginosa 
cultures (319). RpoN is an alternative sigma factor of RNA polymerase that is 
required for the expression of certain bacterial adhesins (337). This observation 
suggests either that a direct and specific bacterial interaction with a host cell 
surface receptor is required to initiate the enhanced fluid secretion, or that a 
toxin secreted via the cell-to-cell contact dependent Type III pathway may be 
involved.
To date, no other studies have examined the potential effects of B. cepacia on 
the electrolytic composition of airway surface fluid, despite the clear relevance 
that such a finding would have for CF lung disease. The results presented here 
show that an epidemic strain of B. cepacia activated Cl' channels in normal and 
CF airway cells, independently of CFTR. Using the cuvette model, strain J2315 
generated a Cf current rapidly in HTE cells that followed closely the pattern of 
ionomycin-induced fluorescence, which could suggest CaMCC as a target of 
B. cepacia. However, the initial rate of 30 % efflux per min was not sustained 
and after 5 min, the fluorescence traces generated by ionomycin and J2315 
began to diverge. Thus whilst B. cepacia elicited C f efflux in both CF and 
normal tracheal epithelial cells, the kinetics of these currents appeared to differ 
slightly between the two cell lines. This potential discrepancy was investigated 
more closely using the Fluoroskan Ascent system.
B. cepacia J2315 activated Cf currents in both CFTE (ANOVA, p<0.01) and 
pCEP-2 cells (ANOVA, p<0.01), but no significant change was seen in either
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HTE or pCEP-RF cells in response to this pathogen. Cl' channel activity was 
induced within 1 min and sustained in CFTE cells, but the difference was only 
detectable in pCEP-2 cells after 5 min. This caveat would support the 
hypothesis that the Cl* currents in response to B. cepacia display different 
kinetics in CF and normal cells, suggesting that different Cl* channels may be 
involved in each cell line, although the overall effects after 5 min show no 
difference between the increased fluorescence in CFTE and pCEP-2 cells 
(ANOVA, p>0.78).
It is difficult to speculate about the molecular interactions that are important for 
these bacterial-induced Cl' currents. Indeed, more than one family of anion 
channels may be involved, and the potential involvement of CFTR cannot be 
excluded. Activation of CaMCC would require an intracellular Ca2+ flux, which 
could be measured fluorescently. Alternatively, a selective inhibitor of CaMCC 
and ORCC, such as H2-DIDS (331) could be used to assess the contribution of 
these channels to bacterial-induced Cl* currents in airway epithelial cells. 
Similarly, specific and selective inhibition of CFTR using glibenclamide (331) 
might determine whether this channel conducts Cl' currents as a result of 
stimulation with B. cepacia or P. aeruginosa. In view of the inconsistencies 
surrounding channel blockers, an alternative approach would be to examine the 
effects of these bacteria in A549 lung epithelial cells, which are known not to 
express CFTR mRNA (338). A requirement for cell-to-cell contact between 
P. aeruginosa and the host cell has been demonstrated modulation of epithelial 
fluid transport (319). To elucidate the bacterial factors that are important for the 
observed effects on epithelial Cl* transport, it would be of great interest to test
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bacterial mutants, such as the Type III secretion system mutants of 
P. aeruginosa PAK strain in the fluorimetric system that was described in this 
chapter. In this respect, supernatant-free cultures of B. cepacia J2315, could be 
examined to identify whether secreted factors may be important in the 
instigation of C f efflux at the respiratory epithelium, since the pathways of 
channel activation may differ between these two CF pathogens.
C f is the most abundant intracellular and extracellular anionic species in most 
tissues and, as such, is pivotal in regulating physiological parameters such as 
cell volume, pH, and secretion and reabsorption o f salt and fluid across the 
epithelial membrane. Exaggerated transepithelial C f currents could confer a 
survival advantage upon bacterial pathogens in a number of ways, which would 
enhance pulmonary infection in the CF lung. Currently there remains 
considerable debate about the precise effects of CFTR mutations on the tonicity 
and hydration of ASF in the CF lung compared with normal tissue, partly as a 
consequence of the very low yield of ASF obtainable for in vitro studies. For 
example, at least two different groups have reported that there is no difference 
between the salinity of ASF in normal tissue compared with CF (61;339), 
although the exact values for Na+ and C f concentration differed substantially in 
each case. Matsui et al. proposed that the distinction between CF and normal 
ASF concerned the volume rather than the salinity of ASF (61). Based on the 
model of hyperabsorption of fluid by the respiratory epithelium in CF, these 
researchers state that reduced ASF volume prevented the disengagement of the 
overlying blanket of mucus by the epithelial cilia during the ratchet process of 
mucociliary clearance. Equally, if the ASF were too deep, because of excessive
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Cl' and fluid secretion, the protruding cilia would be unable to engage the 
mucous blanket, again preventing the removal of aspirated and ensnared 
bacteria by the mucociliary escalator.
An alternative hypothesis arose from an illuminating study by Smith and 
colleagues (69), who provided compelling evidence that Na+ and Cl' 
concentrations were elevated in CF airways and displayed reduced antibacterial 
activity compared with normal tissue, which could be reversed by restoring 
normal salinity to the CF cell supernatant. Thus, disturbed electrolyte balance 
may enhance bacterial survival in the CF lung by inactivating salt-sensitive 
components of the immune system, such as defensins and lysozyme.
A third mechanism by which elevated Cf efflux might augment pulmonary 
colonisation involves the effects of Cl' concentration on neutrophils. CF lung 
disease is characterised by excessive neutrophilia and yet P. aeruginosa and 
B. cepacia flourish, despite exaggerated activation of these immune cells. The 
molecular basis of this caveat has not been elucidated fully. An enlightening 
study, carried out by Tager et al. (340), found that PMN exposed to elevated 
concentrations of Cl' were impaired in their ability to kill P. aeruginosa, and 
these immune cells displayed enhanced apoptosis and lysis. Therefore, bacterial 
elevation of Cl' efflux from airway epithelial cells could disarm and kill 
infiltrating neutrophils. Furthermore, this same investigation showed that 
release of the neutrophil chemoattractant IL-8 was potentiated by an abnormally 
high Cl' concentration in the extracellular fluid. This observation also has 
important implications for CF.
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In conclusion, the data presented here demonstrate clearly that both 
P. aeruginosa and B. cepacia activated a transepithelial Cl' current in tracheal 
epithelial cells in vitro. However, the questions regarding which Cl' channels 
are activated by each pathogen, and whether any differences may be linked with 
the functional expression of CFTR, remain to be answered completely. 
Nevertheless, these observations are of great interest and potential significance 
toCF.
I l l
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5.1 Introduction.
Destruction to the pulmonary tissue in CF is mediated largely by the host and 
the situation is exacerbated by repeated and chronic bacterial infection. Much 
of this inflammation is the result of an abnormally high influx of neutrophils, 
which release cytotoxic metabolites into the extracellular milieu with 
devastating effects on the respiratory epithelium. The most potent 
chemoattractant for neutrophils is IL-8 (121), which is released by monocytic 
cells and epithelial cells alike, particularly in response to the pro-inflammatory 
cytokines IL-lp and TNF-a (341). The anti-inflammatory cytokine IL-10 is 
produced in the airways by T lymphocytes to switch off the inflammatory 
response once the infection is resolved (342-344). A recent study (109) 
indicated that IL-10 might also be produced by bronchial epithelial cells, 
although the capacity of tracheal epithelial cells to secrete IL-10 has not been 
examined. Several in vitro studies have shown that CF-derived primary and 
transformed epithelial cell lines express elevated levels of IL-8 mRNA and 
protein compared with non-CF tissue (50;52;345;346), suggesting that IL-8 
makes a central and significant contribution to the early inflammatory 
environment within the CF lung. In addition, there is evidence that the 
clinically important bacteria P. aeruginosa and B. cepacia intensify this 
situation further by up-regulating IL-8 production in the lung (117;347-350). 
Furthermore, it has been suggested that pulmonary levels of IL-10 are reduced 
in CF compared with the normal lung (108-110). The aim of this section of 
work was to investigate the differential effects on IL-8 and IL-10 production in 
CF- versus non-CF epithelial cells in response to bacterial and pharmacological 
stimuli, using ELIS As specific for IL-8 and IL-10 proteins.
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5.2 Analysis of Epithelial Cell Supernatants Using an ELISA 
Specific for IL-8 or IL-10.
Epithelial cells were grown in 12-well plates and stimulated in serum-free 
conditions with bacterial or pharmacological agonists. Supernatant from 
unstimulated epithelial cells was analysed to investigate any phenotype-specific 
differences in IL-8 or IL-10 production by CF- and normal epithelial cells 
before and after stimulation. Epithelial cells were stimulated with the 
proinflammatory cytokines IL-ip or TNF-a, or with 10-fold serial dilutions of 
bacterial preparations that consisted of culture supernatant only (S), bacterial 
cells only (C), or whole bacterial suspensions (W). LPS from P. aeruginosa 
was also tested in this assay at a range of different concentrations, since 
bacterial endotoxin has been shown to modulate many immune responses 
(64;349;351).
5.3 Basal Production of IL-8 by CF- and Normal Epithelial 
Cells in Culture.
Figure 5.1 shows the relative levels of IL-8 that each of the four cell lines 
produces in the absence of stimulation, or when treated for 24 h with vehicle 
controls. It can be seen that CFTE cells secreted greater basal levels of IL-8 
than normal HTE cells (ANOVA p<0.05). In contrast, there was no significant 
difference between IL-8 production from normal and CF phenotype pCEP cells 
in the absence of agonist stimulation (ANOVA p>0.05). Vehicle controls were 
assessed for their effect on each of the four cell lines, with respect to IL-8 
production. No significant difference was found compared with unstimulated 
cells (ANOVA, p>0.05 in each cell line).
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5.4 IL-8 Production by Proinflammatory Cytokine-Stimulated 
Epithelial Cells.
Both CF- and normal airway epithelial cell lines secreted elevated levels of IL-8 
in response to IL-ip treatment in a dose-dependent manner (Figure 5.2). The 
most productive IL-lp concentration in each case was 10 ng/ ml, which induced 
a mean IL-8 concentration of approximately 30 ng/ 106 cells in HTE and pCEP- 
RF cultures, and 20 ng/106 cells in pCEP-2 cells, although less than 8 ng IL-8/ 
106 cells was released into CFTE culture supernatant. IL-lp concentrations as 
low as 0.3 ng/ ml elevated IL-8 secretion from HTE and pCEP cells, although 
significant stimulation was observed only at a concentration of 3 ng/ ml in non- 
CF cells (Dunnett’s test p<0.01), and at 10 ng/ ml IL-lp in pCEP-RF cells 
(Dunnett’s test p<0.05). A minimum IL-ip concentration of 3ng/m l was 
required to cause a significant increase in chemokine secretion from CFTE cells 
(p<0.01), although the maximum IL-8 production was less than a third of that 
observed in HTE- or pCEP epithelial supernatants.
Similarly, a dose response curve of IL-8 secretion was constructed for cells 
stimulated with TNF-a and the results are shown in Figure 5.3. These 
histograms demonstrate that IL-8 was secreted in a dose dependent manner in 
TNF a-induced cells and that in three of the cell lines (HTE, CFTE and pCEP- 
RF), 30 ng/ ml TNF-a was the optimum stimulatory concentration. In pCEP-2 
cells lOOng/ml TNF-a elicited further IL-8 secretion. As with IL-lp 
stimulation, the strongest responses to TNF-a were seen in pCEP-RF cells, 
which produced 15 times more IL-8 than unstimulated controls; and in HTE
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cells, which upregulated IL-8 production 14-fold in the presence of 30 ng/ ml 
TNF-a. Non-CF phenotype pCEP-2 epithelial cells displayed more than 10- 
fold upregulation of IL-8 secretion. However, CFTE cells secreted only three 
times more chemokine than controls. Since the most efficient induction of IL-8 
was observed with 10 ng/ ml of IL-lp and 30 ng/ ml TNF-a in most of the cell 
lines, these optimum concentrations were selected for subsequent 
proinflammatory cytokine-stimulation of respiratory epithelial cell lines.
The kinetics of IL-8 production by CF and normal epithelial cells in response to 
the proinflammatory cytokines IL-lp and TNF-a were investigated and the 
results are displayed in Figure 5.4. IL-8 secretion from CFTE and HTE cells 
followed similar kinetics over the first 8 h after treatment with both IL-lp and 
TNF-a (Figure 5.4 A). Initially secretion was low but within 3 h, the rate of 
IL-8 production began to rise until approximately 8 h after stimulation. CFTE 
cells produced IL-8 in response to IL-ip for 8-12 h only, but TNF induced IL-8 
from CFTE cells twice within 24 h, first at 3 h and then at 12-18 h post 
stimulation. HTE cells responded in a similar manner throughout the duration 
of the time course to both TNF and IL-lp stimulation. A second phase of IL-8 
production was induced approximately 18 h after HTE treatment with 
proinflammatory cytokines.
Biphasic IL-8 production after IL-ip and TNF-a stimulation was also seen in 
pCEP epithelial cells. Both cytokines induced IL-8 within 3 h. The second 
wave of IL-8 production came approximately 18 h after cytokine stimulation, 
although this effect was more rapid and stronger in pCEP-RF cells treated with
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IL-lp (12 h post stimulation), as shown in Figure 5.4 B. In common with HTE 
and CFTE cells, the first IL-8 secretion phase lasted until 8-12 h after initial 
stimulation, whilst the second wave of chemokine production continued to rise 
24 h after the start of the time course.
5.5 Effect o f P. aeruginosa on airway epithelial cell IL-8 
secretion.
Two invasive laboratory strains of P. aeruginosa were used to stimulate the 
epithelial cell lines. Figure 5.5 shows that strain PAOl did not augment IL-8 
levels in the culture supernatant of normal or CF epithelial cells after 
stimulation for 24 h. In fact, PAOl-treated respiratory cells produced less IL-8 
than the controls and this reduction in chemokine synthesis was statistically 
significant in CFTE cells (Dunnett’s test p<0.05) that had been stimulated with 
whole-bacterial suspension (moi = 200).
In contrast, PAK had a more pronounced effect on the IL-8 production from 
airway epithelial cells (Figure 5.6). Compared with PAOl-treated cells and 
unstimulated controls, CFTE cells (p<0.01), HTE cells (p<0.05), and pCEP-2 
cells (p<0.05) responded only to PAK supernatant, whilst pCEP-RF cells 
responded to both bacteria and supernatant from PAK cultures either alone or in 
combination (p<0.01).
It can be seen from Figure 5.7 that P. aeruginosa LPS had no significant effect 
on the degree of IL-8 secretion by CFTE cells (p>0.9) HTE cells (p>0.9) or
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pCEP-2 cells (p>0.2) compared with controls, although pCEP-RF cells 
responded to P. aeruginosa LPS at 300 ng/ ml (Dunnett’s test, p<0.05).
5.6 The P. aeruginosa type III secretion system does not mediate 
epithelial IL-8 production.
ADP-ribosylating toxins such as exoS, exoT and exoU are secreted by 
P. aeruginosa via type III secretion, which requires contact between cells of the 
host and the infecting pathogen. Whole cell cultures of PAK wild-type and 
PAK mutants lacking either exoS (PAK 6) or exoT (PAK 5) or both toxins 
(PAK 3 and PAK 4) and a mutant lacking the type III secretion system global 
regulator gene exsA (PAK 2) were used to stimulate the airway epithelial cell 
cultures at a high infective ratio (moi = 200). IL-8 production more than 
doubled in HTE cells to a maximum of 4.5 ng/ 106 cells (PAK 3 stimulation); 
and increased 3-fold in pCEP-2 cells to a maximum of almost 5 ng/ 106 cells 
following stimulation with PAK 4. In pCEP-RF cells the IL-8 response was up- 
regulated almost 7-fold to approximately 7.5 ng IL-8/ 106 cells (p<0.001; 
ANOVA). In contrast, CFTE cells did not secrete any more IL-8 than control 
populations (Figure 5.8). Mutants lacking exoS or exoT were not impaired in 
their abilities to stimulate epithelial cell IL-8 production and no difference was 
detected in any cell line after treatment with a type III secretion system- 
deficient P. aeruginosa mutant (PAK 2) compared with WT PAK-induced 
chemokine production. Some slight differences in IL-8 induction were 
observed amongst PAK mutants, although none was significant (p>0.05; 
ANOVA). These effects were similar in all cell lines tested.
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When bacterial cells and supernatant were tested separately for chemokine- 
inducing potential, three of the cell lines showed similar and significant 
responses to both fractions (Figure 5.9 and Figure 5.10). Interestingly, CFTE 
cells secreted as much as 4.8 ng IL-8/106 cells, which equates to more than 
twice as much IL-8 secretion in response to PAK supernatant stimulation as in 
control cells (p<0.05; ANOVA), but neither whole cell culture nor PAK cells 
alone had any effect in this cell line (Figure 5.8 A, Figure 5.9 A and Figure 
5.10 A). In the presence of bacterial supernatant, IL-8 production increased in 
HTE by as much as 4-fold to approximately 8.5 ngIL-8/106 cells (p<0.01; 
ANOVA); in pCEP-2 cells approximately 2-fold to more than 3.4 ng/106 cells 
(p<0.05; ANOVA); and in pCEP-RF cells to almost 4.7 ng/106 cells, which was 
more than four times greater than unstimulated controls (p<0.0001; ANOVA). 
However, none of the PAK mutations affected the IL-8 inducing potency of 
either supernatant or bacterial cells in any of the cell lines (p>0.05; ANOVA).
5.7 IL-8 response to B. cepacia by respiratory epithelial cells.
Ten-fold serial dilutions were prepared of a genomovar III isolate of B. cepacia, 
strain J2315, and incubated with epithelial cells for 24 h. Resultant IL-8 
concentrations in epithelial supernatants are shown in Figure 5.11. B. cepacia 
induced significant IL-8 secretion by HTE and both pCEP cell lines (ANOVA 
pO.OOl), but failed to elevate IL-8 production in CFTE cells. At a high 
bacterial cell to epithelial cell ratio (moi = 200), HTE-derived epithelial cells 
responded more strongly to a combination of B. cepacia supernatant and cells 
together than to either fraction alone, although at a lower ratio (moi = 2), both 
cellular and supernatant B. cepacia fractions increased HTE IL-8 production in
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comparison with resting cells. Compared with unstimulated controls, epithelial 
cells treated with B. cepacia produced up to 8-fold (pCEP-2) or 14-fold (HTE, 
pCEP-RF) more IL-8 (Dunnett’s test, p<0.01). This trend was repeated at a 10- 
fold lower bacterial dilution (moi = 20) although less IL-8 was produced than at 
the higher infection ratio. In normal and CF-phenotype pCEP epithelial cells, 
B. cepacia cells alone or supernatant alone each induced IL-8 secretion, but 
only some of these effects were significant (Figure 5.11).
5.8 Summary of IL-8 induction from airway epithelial cells.
The responses of airway epithelial cells towards bacterial and pharmacological 
agonists are compared in Figure 5.12. A remarkable similarity can be seen 
between the responses of HTE cells towards IL-lp and B. cepacia, which both 
elevated IL-8 production by approximately 15-fold. CFTE cells also responded 
in a similar manner to these agonists in that neither induced IL-8 from this cell 
line. B. cepacia also mimicked the potent effect of IL-ip in pCEP-RF cells, 
whilst pCEP-2 cells produced slightly more IL-8 after stimulation with cytokine 
treatment than after stimulation with bacteria. It is also of interest to note that 
whilst P. aeruginosa supernatant alone was a potent inducer of epithelial cell 
IL-8, cellular and supernatant factors from cultures of B. cepacia were required 
in combination to increase epithelial IL-8 production maximally. Furthermore, 
the relative effects of P. aeruginosa and B. cepacia differed amongst the 
epithelial cell lines. CFTE cells responded only to P. aeruginosa, whilst HTE 
cells responded only half as strongly to P. aeruginosa as to B. cepacia. pCEP- 
RF cells produced more IL-8 than pCEP-2 cells in response to P. aeruginosa
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supernatant, and this difference was augmented in cells stimulated with 
B. cepacia.
5.9 IL-10 could not be detected in supernatant from CF- or 
normal epithelial cells in culture.
It was found that coating the 96-well plates overnight with 4 pg/ ml anti-human 
IL-10 monoclonal antibody gave a stronger signal than a concentration of only 
2 pg/ ml in the presence of a range of concentrations of human recombinant IL- 
10, so the higher concentration of coating antibody was utilised. Since an 
equally strong signal was obtained on plates coated with 50 pi/well or 
100 pi/ well, the smaller volume was selected. Finally, plates were incubated at 
room temperature, rather than at 37°C, since this procedure gave the stronger 
responses over a wide range of concentrations of primary and secondary anti- 
IL-10 antibodies (data not shown). However, no IL-10 was detected in 
supernatant from any of the epithelial cell lines used in this work, regardless of 
phenotype with respect to CFTR (data not shown).
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Figure 5.1 IL-8 production by unstimulated airway epithelial cells and 
24 h after treatment with vehicle controls. S ta tis t ica l a n a ly s is  w a s  p erform ed  
u s in g  A N O V A  to  co m p a re  v e h ic le  co n tro ls  w ith  u n stim u la ted  c e l l s  for  IL -8  
p ro d u ctio n . C o m p a r iso n  w a s  a ls o  m ad e b e tw e e n  C F T E  c e l l s  and  H T E  c e l l s  (A), 
and  b e tw e e n  p C E P -R F  c e l l s  and p C E P -2  c e l l s  (B). p < 0 .0 5  w a s  c o n s id e r e d  
s ig n if ic a n t , n = 2 6 .
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Figure 5.2 IL-8 production by CF- and non-CF- airway epithelial cells 
after 24 h stimulation with IL-ip in vitro. A: CFTE and HTE ; B: pCEP-RF 
and pCEP-2. Statistical analysis was performed using ANOVA to compare data 
with untreated controls (0 ng/ml), followed by Dunnett’s test for multiple 
comparisons where p<0.05 was considered significant. (* p<0.05; ** p<0.01). 
“0 ng/ml” n=26; “10 ng/ml” n=l 1; all others n=3.
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Figure 5.3 IL-8 production by CF- and non-CF- airway epithelial cells 
after 24 h stimulation with TNF-a in vitro. A: CFTE and HTE ; B : pCEP-RF 
and pCEP-2. Statistical analysis was performed using ANOVA to compare 
stimulated cells with untreated controls (0 ng/ml), followed by Dunnett’s test 
for multiple comparisons where p<0.05 was considered significant. (* p<0.05; 
** p<0.01). “0 ng/ml” n=26; “30 ng/ml” n=10; all others n=3.
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Figure 5.4 Kinetics of IL-8 production in airway epithelial cells after 24 h 
in response to pro-inflammatory cytokines in vitro (mean + /-  SEM). A:
C F T E  and  H T E ; B: p C E P -R F  and p C E P -2 . C ir c le  w ith  d o tted  lin e , IL-1(3; 
sq u are w ith  so l id  lin e , T N F -a .  t= 0 h , n = 2 6 ; t = 6 h - l8 h  n = 3 ; t= 2 4 h  n = 2 6 .
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Figure 5.5 Effect of stimulation with P. aeruginosa PAOl for 24 h on IL-8 
production by airway epithelial cells in vitro. A: C F T E  and  H T E ; B: p C E P - 
R F and  p C E P -2 . [W : w h o le  b acteria l su sp e n s io n ; S: c e ll - f r e e  b acter ia l cu ltu re  
supernatant; C: su p ern atan t-free  b acter ia l c e lls .  N u m b e r  in d ic a te s  ratio  o f  
b acter ia l to  ep ith e lia l c e lls ] .  S ta tis t ica l a n a ly s is  w a s  p er fo rm ed  u s in g  A N O V A  
to  co m p a re  st im u la ted  c e l l s  w ith  u ntreated  c o n tr o ls , fo l lo w e d  b y  D u n n e tt’s te s t  
for  m u ltip le  c o m p a r iso n s  w h ere  p < 0 .0 5  (* )  w a s  c o n s id e r e d  s ig n if ic a n t . M ean  
v a lu e s  +  S E M  are sh o w n . “N o th in g ” n = 2 6 ; a ll o th ers n = 3 .
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Figure 5.6 Comparison of the effects of stimulation with P. aeruginosa 
strains PAOl and PAK for 24 h on the production of IL-8 from airway 
epithelial cells in vitro. A: C F T E  and H T E ; B: p C E P -R F  and  p C E P -2 . [W : 
w h o le  b acteria l su sp e n s io n ; S: c e ll - fr e e  bacteria l cu ltu re  supernatan t; C: 
su p ern atan t-free  b acter ia l c e l ls .  N u m b er  in d ica te s  ratio  o f  b acter ia l to  ep ith e lia l 
c e l l s ] .  S ta tis t ica l a n a ly s is  w a s  p erform ed  u s in g  A N O V A  fo l lo w e d  b y  D u n n e tt’s 
m u ltip le  co m p a r iso n s  te s t, co m p a r in g  s t im u la ted  c e l l s  w ith  u n treated  c o n tro ls , 
w h e r e  p < 0 .0 5  w a s  c o n s id e r e d  s ig n if ic a n t, (*  p < 0 .0 5 ;  **  p < 0 .0 1 ) .  M ea n  v a lu e s  
+  S E M  are sh o w n . “N o th in g ” n = 2 6 ; a ll o th ers n = 3 .
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Figure 5.7 Comparison of effects of stimulation with P. aeruginosa LPS 
and strains PAOl and PAK for 24 h on the production of IL-8 from airway 
epithelial cells in vitro. A: C F T E  and H T E ; B: p C E P -R F  and  p C E P -2 . 
S ta tis t ica l a n a ly s is  w a s  p erform ed  u s in g  A N O V A  fo l lo w e d  by  D u n n e tt’s 
m u ltip le  co m p a r iso n s  te s t , co m p a r in g  st im u la ted  c e l l s  w ith  u n treated  c o n tro ls ,  
w h e r e  p < 0 .0 5  w a s  c o n s id e r e d  s ig n if ic a n t. (*  p < 0 .0 5 ) .  M ea n  v a lu e s  +  S E M  are 
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Figure 5.8 Comparison of the effects of stimulation with whole bacterial
cell suspensions (W) of P. aeruginosa PAK mutants for 24 h on the
production of I L -8  from airway epithelial cells in vitro. A: C F T E  and  H T E ; 
B: p C E P -R F  and  p C E P -2 . S ta tist ica l a n a ly s is  w a s  p er fo rm ed  u s in g  A N O V A
fo l lo w e d  b y  D u n n e tt’s m u ltip le  c o m p a r iso n s  te s t , c o m p a r in g  s t im u la ted  c e lls  
w ith  untreated  co n tro ls , w h ere  p < 0 .0 5  w a s  c o n s id e r e d  s ig n if ic a n t . (*  p < 0 .0 5 ;
** p O .O l) .  M ea n  v a lu e s  +  S E M  are sh o w n . “N o th in g ” n = 2 6 ; a ll o th ers n = 3 . 
N o  s ig n if ic a n t  d if fe r e n c e  w a s  d e tec ted  b e tw e e n  m u tan ts, A N O V A  p > 0 .0 5  for  
e a c h  c e ll  lin e .
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Figure 5.9 Comparison of the effects of stimulation with P. aeruginosa 
PAK mutant bacterial cells (C) for 24 h on the production of IL-8 from 
airway epithelial cells in vitro. A: C F T E  and H T E ; B: p C E P -R F  and  p C E P -2 . 
S ta tis t ica l a n a ly s is  w a s  p erform ed  u s in g  A N O V A  fo l lo w e d  b y  D u n n e tt’s 
m u ltip le  co m p a r iso n s  te s t, co m p a r in g  st im u la ted  c e l l s  w ith  untreated  co n tro ls ,  
w h e r e  p < 0 .0 5  w a s  c o n s id e r e d  s ig n if ic a n t  (*  p < 0 .0 5 ;  **  p O .O l) .  M ea n  v a lu e s  
+  S E M  are sh o w n . “N o th in g ” n = 2 6 ; a ll o th ers n = 3 . N o  s ig n if ic a n t  d if fe r e n c e  
w a s  d e te c te d  b e tw e e n  m u tan ts, A N O V A  p > 0 .0 5  for  e a c h  c e ll  lin e .
130

















*  *  *  ii J  A
N o th in g  PAK 1 PAK 2 PAK 3 PAK 4  PAK 5 PAK 6
pO.OOl
p<0.05
■ f c  ^  f c  f c
N o th in g  PAK 1 PAK 2 PAK 3 PAK 4  PAK 5 PAK 6
CF cells non-CF cells
Figure 5.10 Comparison of the effects of stimulation with P. aeruginosa 
PAK mutant bacterial supernatant (S) for 24 h on the production of IL-8 
from airway epithelial cells in vitro. A: CFTE and HTE; B: pCEP-RF and 
pCEP-2. Statistical analysis was performed using ANOVA followed by 
Dunnett’s multiple comparisons test, comparing stimulated cells with untreated 
controls, where p<0.05 was considered significant. (* p<0.05; ** p<0.01). 
Mean values + SEM are shown. “Nothing” n=26; all others n=3. No significant 
difference was detected between mutants, ANOVA p>0.05 for each cell line.
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Figure 5.11 Effect of stimulation with B. cepacia J2315 for 24 h on IL-8 
production by airway epithelial cells in vitro. A: C F T E  and  H T E ; B: p C E P -  
R F  and  p C E P -2 . [W : w h o le  b acteria l su sp e n s io n ; S: c e ll - f r e e  b acter ia l cu ltu re  
supernatant; C: su p ern atan t-free  b acter ia l c e l ls .  N u m b e r  in d ica te s  ratio  o f  
b acter ia l to  ep ith e lia l c e lls ] .  S ta tis t ica l a n a ly s is  w a s  p er fo rm ed  u s in g  A N O V A  
to  co m p a re  stim u la ted  c e l l s  w ith  untreated  c o n tro ls , fo l lo w e d  b y  D u n n e tt’s te s t  
for  m u ltip le  c o m p a r iso n s  w h e r e  p < 0 .0 5  w a s  c o n s id e r e d  s ig n if ic a n t  (*  p < 0 .0 5 ;  
* * p < 0 .0 1 ) .  M ea n  v a lu e s  +  S E M  are sh o w n . “N o th in g ” n = 2 6 ; a ll o th ers  n=3.
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Figure 5.12 Comparison of IL-8 production in vitro by airway epithelial 
cells following stimulation for 24 h with bacterial and pharmacological 
agonists. A: C F T E  and H T E ; B: p C E P -R F  and  p C E P -2 . (*  p < 0 .0 5 ;
* * p < 0 .0 1 ) .  S ta tis t ica l a n a ly s is  w a s  p erform ed  u s in g  A N O V A  to  co m p a re  
s t im u la ted  c e l l s  w ith  untreated  c o n tro ls , fo l lo w e d  by  D u n n e tt’s te s t  for  m u ltip le  
c o m p a r iso n s  w h e r e  p < 0 .0 5  w a s  c o n s id e r e d  s ig n if ic a n t  (*  p < 0 .0 5 ;  * * p < 0 .0 1 ) .  
M ea n  v a lu e s  +  S E M  are sh o w n . “N o th in g ” n = 2 6 ; IL-1 (3 n =  a ll o th ers n=3.
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5.10 Discussion.
It is now accepted widely that an ineffective and exaggerated inflammatory 
response as a result of mutations in the CFTR gene underscores chronic lung 
disease in CF. Much of the inflammation can be attributed to an abnormally 
high influx of neutrophils, which release cytotoxic metabolites into the 
extracellular milieu and destroy pulmonary tissue. IL-8 is strongly chemotactic 
for neutrophils and several groups have reported elevated concentrations of 
inflammatory markers in culture negative airway tissue derived from CF 
patients (50-53;352). To compound this abnormally high production of the pro- 
inflammatory cytokine IL-8, it has been reported that levels of the anti­
inflammatory cytokine IL-10 are reduced in CF (109). Unfortunately, it was not 
possible to detect IL-10 in the experiments in this study, despite the potential of 
this ELISA kit to detect as little as 31.25 pg IL-10/ ml. This negative result 
indicates that very low levels of IL-10, if any at all, are secreted by tracheal 
epithelial cells and therefore clearly, it was not possible to determine whether 
lack of functional expression of CFTR reduced the anti-inflammatory potential 
of this region of the lung. However, it would not be unreasonable to speculate 
that IL-10 may be more important in the distal rather than proximal airways, 
which could account for the negative result obtained in this study.
Data from the present study corroborated the idea that certain cftr mutations are 
associated with a hyper-inflammatory phenotype, showing that CFTE cells 
produced more IL-8 than HTE cells under unstimulated conditions (Figure 5.1). 
Unexpectedly, but of significant interest is that overexpression of the CFTR- R 
domain in the HTE-derived cell line pCEP-RF did not cause this effect, since
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quiescent pCEP-RF and pCEP-2 cells did not secrete different levels of IL-8 
(Figure 5.1). This finding is consistent with a recent report by Kube et al. 
(353), which demonstrated that unstimulated pCEP-2 and pCEP-RF cells 
produce similar concentrations of IL-8. Therefore, it is likely that a 
physiological function of CFTR other than its chloride channel activity is 
responsible for the excessive inflammatory phenotype of the CF lung. 
However, some differences were detected between CF and normal pCEP cells 
after stimulation.
The inflammatory phenotype in naive respiratory CF tissue is exacerbated by 
repeated and chronic infection with bacteria, viruses and fungi, which activate 
the immune systems further. Localised activated macrophages and the airway 
epithelium secrete both IL-1 p and TNF-a into the airway lumen activating the 
respiratory epithelium in a time- and dose-dependent manner, which was 
reflected in the current studies with these epithelial cells (Figure 5.2, Figure 5.3 
& Figure 5.4). IL-1 (3 caused dramatic elevation in IL-8 production by HTE, 
pCEP-2 and pCEP-RF cells but had little effect in CFTE cells (Figure 5.2); 
whilst TNF-a enhanced production of this chemokine in each of the four cell 
lines (Figure 5.3). Cytokine-induced IL-8 secretion occurred at a similar rate in 
both HTE and CFTE cell lines within the first 12 h of stimulation, but IL-ip- 
induced IL-8 secretion ceased after this time (Figure 5.4). In contrast, a second 
elevation in IL-8 production began approximately 18 h after initial stimulation 
in pCEP-RF cells treated with TNF-a and in both non-CF cell lines treated with 
TNF-a and IL-1 p. Discrepancies between the responses towards the two 
cytokines may be the result of variable degrees of receptor expression or
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differences in the activities of downstream signalling cascades in each cell line. 
In common with the work presented here, studies by Palfreyman et al. (117) and 
Chen et a l (354) demonstrated biphasic IL-8 mRNA production in the 
respiratory epithelial cell line A549. Increased mRNA synthesis could explain 
reasonably the biphasic IL-8 protein secretion displayed in Figure 5.4 in this 
study and may reflect two different types of IL-8 regulation, at the 
transcriptional and post-transcriptional levels.
Several studies have demonstrated that the concentrations of both IL-lf3 and 
TNF-a are increased in the BALF of CF patients (103;173;355), which could 
enhance neutrophil influx via epithelial cell stimulation. Epithelial cells are not 
the only source of IL-8 in the lung since serous gland cells, macrophages and 
neutrophils themselves are rich producers of this chemokine at rest and 
following cytokine or bacterial activation (345;356-359). Regardless of 
whether this elevation of IL-8 is the result of respiratory infection or a 
consequence of the underlying cftr mutation, it is clear that increased 
proinflammatory cytokine release into the pulmonary environment will have 
important ramifications for chemokine secretion, precipitating the infiltration of 
neutrophils into the CF lung via autocrine and paracrine IL-8.
Examination of the effects of the CF pathogens P. aeruginosa and B. cepacia 
revealed some important differences between the patterns and modes of IL-8 
induction in the lung by these bacteria. Two different isolates of P. aeruginosa 
were employed, namely PAOl and PAK, and both are non-invasive laboratory 
strains. Unexpectedly, even when there were 200-fold more bacterial cells than
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epithelial cells, PAOl did not induce IL-8 production and in fact, there was 
reduced IL-8 secretion by CFTE cells at this infective ratio. One possible 
explanation for this observation is epithelial cells were being killed by PAOl at 
this multiplicity of infection. It has been reported widely that certain strains of 
P. aeruginosa may precipitate epithelial cell death (312;360-363) and clearly, 
this would result in reduced IL-8 output over 24 h. PAOl toxicity towards the 
respiratory epithelial cells was not measured, although gross microscopic 
examination of the monolayers after 24 h suggested that epithelial cell viability 
may have been compromised by PAOl co-incubation (data not shown). Indeed, 
a recent study examining the effects of this strain of P. aeruginosa on epithelial 
IL-8 secretion co-incubated pCEP epithelial cells with PAOl for only 60 min 
(353)t suggesting that epithelial cell viability may be reduced by prolonged 
exposure to this strain of P. aeruginosa. A brief exposure to PAOl at infective 
ratios between 0.1 and 100 bacteria per epithelial cell, elicited significant IL-8 
release from both pCEP-RF and pCEP-2 epithelial cells after 24 h (353). The 
data presented here do not support these observations, but they were generated 
using a modified incubation strategy. Therefore, it is possible that whilst basal 
levels of IL-8 were still detected in pCEP cells, further IL-8 release was 
prevented because of toxic effects of PAOl. Alternatively, PAOl may inhibit 
host intracellular signalling cascades that lie upstream of IL-8 production. This 
effect was not observed at lower infective ratios or in cells treated either with 
supernatant or with bacterial cells alone, so that inhibition of IL-8 production in 
CFTE cells by PAOl required a synergistic combination of both secreted and 
structural bacterial factors. Only CFTE cells produced less IL-8 than controls 
after PAOl-treatment, so the inhibitory effects of PAOl on IL-8 production
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may relate to CFTR genotype. In contrast, P. aeruginosa PAK elevated IL-8 
secretion from all four of the cell lines (Figure 5.6), suggesting either that the 
rate of IL-8 induction was greater or the rate of PAK-induced cell death was 
lower - if at all - than with PAOl stimulation.
Many P. aeruginosa factors have been implicated in the generation of an 
inflammatory response in the lung via IL-8 secretion, including structural 
components such as flagella (116) and LPS (349;364); and secreted products 
including nitrate reductase (357) autoinducers (116), haemolytic phospholipase 
C (195), pyocyanin (203,365), 1-hydroxyphenazine (365) and alginate (212). 
Furthermore, several studies describe the effects of P. aeruginosa products, 
such as exotoxin A, on IL-8 secretion by neutrophils and monocytic cells of the 
blood and airways (212;359;366;367), and this secondary source of IL-8 could 
also contribute to pulmonary neutrophilia. The immunogenic role of 
P. aeruginosa LPS is controversial, however, since this and other work have 
shown that P. aeruginosa LPS does not elevate epithelial IL-8 (359), although 
these differences may be related to the specific strains of P. aeruginosa from 
which the LPS was obtained. An interesting investigation by Ernst et a l (351) 
identified aminoarabinose and palmitate in the lipid A component of LPS from 
CF isolates of P. aeruginosa. This unusual composition conferred a resistance 
to defensins upon these bacterial strains and made the LPS more immunogenic 
than that from non-CF P. aeruginosa strains. Thus, whilst the LPS serotype 
tested here did not augment airway epithelial IL-8 production in vitro, the 
situation may be different in the CF lung in vivo.
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In addition to these virulence factors, P. aeruginosa produces toxins such as 
exoS and exoT, both of which possess ADP-ribosylating activity that can 
interfere with host intracellular signalling cascades (244;249;363;368). These 
enzymes are secreted directly into host cells via type III secretion system 
apparatus. It has been reported that P. aeruginosa exoS induces the secretion of 
proinflammatory mediators from peripheral blood mononuclear cells (PBMCs) 
(369) although no published data are available concerning the effects of exoS on 
epithelial IL-8 release. However, the results presented here lend strong support 
to the idea that P. aeruginosa exoS does not interfere with the regulated 
production of IL-8 by respiratory epithelial cells since PAK mutants lacking 
exoS (PAK 3, PAK 4 and PAK 5) did not differ in their abilities to induce IL-8 
from epithelial cells, compared with the parental PAK strain. In the same way, 
PAK mutants lacking exoT (PAK 3, PAK 4 and PAK 6) were not affected in 
their potency to induce epithelial IL-8 (Figure 5.8 & Figure 5.9). This 
hypothesis was strengthened by the observation that a type III secretion system 
knockout (exsA mutant, PAK 2) elicited similar IL-8 to wild-type PAK, 
demonstrating that P. aeruginosa induced IL-8 production via a type III 
secretion system-independent mechanism.
Evidence for a type III secretion system-independent induction of IL-8 was 
reinforced by the results shown in Figure 5.10 that bacterial-free supernatant 
from each of the PAK mutants elevated IL-8 production from all of the cell 
lines. Indeed, CFTE cells responded only to bacterial supernatant and IL-8 
release was not elevated in the presence of PAK cells (compare Figure 5.8 A, 
Figure 5.9 A and Figure 5.10 A). Furthermore, there was no significant
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difference amongst supernatants from mutant and wild-type PAK P. aeruginosa 
to elicit IL-8 from the respiratory epithelial cultures. Since the type III secretion 
system requires cell-to-cell contact, bacterial supernatant alone would not 
mediate type III secretion system effects.
It is interesting to note that no inhibition of IL-8 production was observed after 
CFTE stimulation with PAK cells at the same infective ratio as PAOl (moi = 
200). Since PAK mutants lacking exoS are defective in the induction of 
epithelial apoptosis (312), any inhibitory effects on chemokine production that 
were related to epithelial cell death would almost certainly have been obvious in 
the cell lines treated with PAK 3, PAK 4 or PAK 5, compared with wild-type 
stimulated cells. No significant difference was observed between the potency of 
PAK 1 and exoS mutants, illustrating that epithelial cell apoptosis could not 
explain the lack of response of CFTE cells to P. aeruginosa PAK stimulation.
Immune cell death has been noted previously in the presence of B. cepacia 
(280;370) but the data presented in Figure 5.11 suggest that this bacterial strain 
was not cytotoxic towards epithelial cell lines in this study. HTE and pCEP cell 
lines all responded significantly to B. cepacia stimulation, whilst CFTE cells 
produced slightly more IL-8 at a high infective ratio of B. cepacia (moi = 200) 
than unstimulated controls. Although this latter increase was not significant, it 
is unlikely that the unresponsiveness was the result of CFTE cell apoptosis. A 
synergistic effect of B. cepacia bacteria and supernatant was observed in non- 
CF epithelial cells and was particularly striking in HTE cells, implying the 
involvement of both secreted and structural B. cepacia factors. Similarly, CFTE
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cells only increased IL-8 secretion after stimulation with a combination of 
bacteria and supernatant, and both fractions elevated IL-8 in pCEP-RF cells. 
Previous reports allude to the involvement of a heat-labile secreted B. cepacia 
factor in IL-8 generation in airway cells, whose identity was not determined but 
was not related to AHLs (117); and to the possible role of B. cepacia LPS in IL- 
8 generation in the lung, via the release of TNF-a from neutrophils (62). This 
latter possibility is especially intriguing given that the IL-8 response to 
stimulation with cytokines and B. cepacia was similar in three of the cell lines 
(Figure 5.11). An alternative explanation might be that B. cepacia activates the 
same epithelial cell cytokine receptors or convergent signalling cascades. For 
example, the Toll-like receptor, which mediates endotoxin recognition in the 
lung (371-373), shares many features with the IL-1 receptor (374). The data 
presented here do not exclude a role for AHLs in IL-8 induction but other 
secreted factors such as siderophores, melanin or digestive enzymes may also be 
involved. In particular, haemolysin has been shown specifically to modulate the 
pulmonary immune response by inducing the degranulation of neutrophils 
(280). Likely candidate structural components of B. cepacia that may activate 
epithelial chemokine production include LPS and adhesion proteins.
In conclusion, CFTE cells and pCEP-RF cells generally displayed the most 
extreme IL-8 responses to stimulation, although the former were weak and the 
latter were strong; and normal airway epithelial cells responded mostly at a 
level in between. In addition, the likelihood that a complex and synergistic 
interaction exists between bacteria and biochemical mediators of inflammation 
in the induction of IL-8 should not be discounted although this possibility was
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not investigated. Differentiation between the CF and normal phenotypes with 
respect to IL-8 production is not straightforward, although it is clear that some 
differences do exist.
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C h a p t e r  6:
The role of MAP kinase 
cascades in airway epithelial 
cell IL-8 production
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6.1 Introduction
It is clear from the previous chapter and from other investigations that IL-8 
plays a pivotal role in the inflammatory process and tissue pathology of CF. 
However, the nature of the upstream signalling events that lead to the 
production of respiratory IL-8 are complex and remain incompletely 
characterised. Delineation of these cascades could identify targets for 
therapeutic intervention that might alleviate the host-derived symptoms 
associated with chronic lung disease, whilst maintaining protection against the 
spread of infection. This chapter aims to address this issue and describes a 
number of approaches used to investigate potential events in pulmonary signal 
transduction.
Several published observations suggest that IL-8 secretion may be mediated at 
least in part by the activation of NFkB or the activation of MAP kinase 
signalling cascades (347;354;364;375-378). In order to determine the role of 
MAP kinases in normal and CF-respiratoiy IL-8 production, two strategies were 
adopted. Firstly, IL-8 production was measured by ELISA in epithelial 
monolayers stimulated with B. cepacia or with the pro-inflammatory cytokines 
IL-1 p or TNF-a, in the presence of specific inhibitors o f components of the 
MAP kinase pathway. In addition, the activation of ERK in response to 
bacterial stimuli was investigated by Western blotting using anti-sera specific to 
phosphorylated (active) ERK. Measurement of phosphorylated ERK is an 
indirect method of assaying ERK activity.
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6.2 Effect o f MAP Kinase Inhibitors on Airway Epithelial Cell 
IL-8 Production.
6.2.1 Reduced IL-8 production by airway epithelial cells following specific 
antagonism of p38 MAP kinase.
Epithelial cells were incubated for 1 h with SB-203580, a specific inhibitor of 
p38 MAP kinase (379), and then stimulated with 10 ng/ml IL-1 p, 30 ng/ml 
TNF-a, or B. cepacia J2315 (moi = 200) for 24 h. In the presence of SB- 
203580, IL-1 p induced similar levels of IL-8 in CFTE cells to those detected in 
the supernatant from uninhibited CFTE cells (Figure 6.1 A). However, SB- 
203580 diminished IL-8 production significantly (p<0.05; ANOVA) in IL-lp- 
stimulated HTE cells compared with HTE cells treated with IL-1 p alone 
(Figure 6.1 A). Maximal inhibition of IL-8 production in IL-ip-stimulated 
HTE cells was achieved with 10 pM SB-203580, which reduced the amount of 
IL-8 in epithelial supernatant by 70% from 30.0 ng/ 106 cells to 7.0 ng/ 106 
cells. This value corresponds to an 82 % reduction in induced IL-8. In 
addition, both 30 pM and 1 pM SB-203580 displayed potent inhibitory 
activities, each decreasing stimulated IL-8 production by approximately 63 % to
13.0 ng/ 106 cells, compared with IL-ip-stimulated cells alone. At this 
concentration of IL-ip, 3 pM SB-203580 had less effect on chemokine 
secretion.
Both pCEP-RF and pCEP-2 cells also produced less IL-8 in the presence of SB- 
203580 after stimulation with IL-1 P and this effect was dose dependent (Figure
6.1 B). IL-1 p induced 30.0 ng IL-8/ 106 cells in pCEP-RF cells but this was
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reduced to 5.0 ng/ 106 cells by 10 pM SB-203580, equivalent to approximately 
87 % inhibition. IL-8 secretion was also diminished by more than 50 % in the 
presence of either 30 pM or 3 pM SB-203580 in pCEP-RF cells. In the same 
way, both 30 pM and 10 pM SB-203580 decreased IL-8 production in pCEP-2 
cells by approximately 70%  following stimulation with IL-1 (3. Lower 
concentrations (0.3 pM -  3 pM) of this p38 MAP kinase antagonist also 
displayed some inhibitory potential in both pCEP cell lines.
A stronger effect of SB-203580 pre-treatment on IL-8 production was seen in 
epithelial cell lines that had been stimulated with TNF-a. CFTE cells produced 
almost 20 ng IL-8/ 106 cells after stimulation with TNF-a, but this chemokine 
production was decreased by 98 % to 3.2 ng IL-8/ 106 cells in the presence of 
30 pM SB-203580 (Figure 6.2 A). This residual IL-8 secretion was only 
slightly higher than basal production. Even 0.3 pM of this inhibitor diminished 
the TNF-a-induced secretion of IL-8 in CFTE cells. HTE cells also responded 
to the presence of SB-203580 in a dose dependent manner, as shown in Figure
6.2 A. IL-8 production was inhibited by 82 % in TNF-a-stimulated HTE cells 
that had been pre-treated with 30 pM SB-203580 and again, even 0.3 pM SB- 
203580 decreased production of the chemokine by 50 % in these cells. 
Antagonism of IL-8 secretion by this p38 MAP kinase inhibitor at each 
concentration was similar in both pCEP-RF and pCEP-2 cells, as shown in 
Figure 6.2 B. In these epithelial cells, the strongest inhibitory effect of SB- 
203580 was detected at 30 pM, causing a reduction of 78 % and 75 % in IL-8 
secretion from pCEP-RF and pCEP-2 cells, respectively.
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The slight increase in IL-8 production by CFTE cells following B. cepacia 
stimulation was antagonised by the p38 MAP kinase inhibitor, SB-203580 
(Figure 6.3 A). Concentrations of both 30 pM and 10 pM caused a visible 
decrease in B. cepacia-induced IL-8 secretion to 3.0 ng/ 106 cells and 2.8 ng/ 
106 cells, respectively. These values are still marginally higher than in 
quiescent CFTE cells, which generated 2.6 ng IL-8/ 106 cells but they 
correspond to the fact that SB-203580 abrogated more than 90 % of the IL-8 
response to B. cepacia in CFTE cells. However, since B. cepacia did not 
increase CFTE IL-8 production visibly these findings may not be relevant and 
indeed, were not statistically significant (ANOVA, p>0.05).
A pronounced effect of p38 inhibition was seen also in HTE and pCEP cells. 
After bacterial stimulation, almost 28 ng IL-8/ 106 cells was detected in HTE 
supernatant but this value was reduced to just 4.6 ng IL-8/ 106 cells in the 
presence of 30 pM SB-203580 (90 % inhibition); and to 6.0 ng IL-8/ 106 cells 
with 10 pM inhibitor (Figure 6.3 A). Even 0.3 pM SB-203580 abrogated some 
of the bacterial-induced IL-8 production in these cells. The dose-dependent 
inhibition of IL-8 production in pCEP cell lines by SB-203580 was striking 
(Figure 6.3 B). Bacterial stimulation elevated chemokine synthesis from 
approximately 1.2 ng IL-8/ 106 cells in pCEP-RF cells and 1.6 ng IL-8/ 106 
pCEP-2 cells to 15.8 ng/106 cells and 7.8 ng/ 106 cells, respectively. However, 
pre-incubation with 30 pM SB-203580 decreased these values to 1.4 ng IL-8/ 
106 pCEP-RF cells and 0.6 ng IL-8/106 pCEP-2 cells. These values are lower 
than in unstimulated cells, corresponding to 100% inhibition of bacterial-
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induced chemokine in pCEP cells. IL-8 production increased gradually as the 
inhibitor concentration was reduced and once again, 0.3 pM antagonist was 
sufficient to prevent maximal induction of IL-8 in these cells. Fifty percent less 
IL-8 was formed in pCEP-RF cells that had been pre-treated with 0.3 pM SB- 
203580 then stimulated with B. cepacia, compared with stimulated control cells. 
Similarly, this concentration of inhibitor was sufficient to reduce pCEP-2 IL-8 
secretion to 4.4 ng/ 106 cells, representing 54%  less chemokine induction 
(Figure 6.3 B).
6.2.2 Reduced IL-8 production by airway epithelial cells following specific 
antagonism of ERK MAP kinase.
Epithelial cells were incubated for 1 h with PD-098059, a specific inhibitor of 
ERK MAP kinase (142), and then stimulated with 10 ng/ml IL-ip, 30 ng/ml 
TNF-a or B. cepacia J2315 (moi = 200) for 24 h. IL-8 concentration in the 
epithelial supernatant was measured by ELISA and the results are displayed in 
Figures 6.4-6.6. Pre-treatment with PD-098059 caused a visible reduction in 
IL-lp-induced IL-8 production in both pCEP and HTE cells in a dose- 
dependent manner, and these effects were significant in pCEP cell lines 
(p<0.05; ANOVA). Both 10 pM (p<0.05 in pCEP-2; Dunnett’s test) and 3 pM 
PD-098059 decreased IL-ip-induced chemokine production by at least 50 % in 
pCEP cells from 30.0 ng IL-8/ 106 cells (pCEP-RF) and 20.0 ng IL-8/ 106 cells 
(pCEP-2) as shown in Figure 6.4 B. A similar degree of inhibition was seen in 
HTE cells that had been pre-treated with 10 pM PD-098059 before stimulation 
with IL-1 p (Figure 6.4 A), in which IL-8 secretion was reduced from 32 ng/106 
cells to 15 ng/106 cells. Essentially, IL-ip-induction of IL-8 in CFTE cells was
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unaffected by the ERK inhibitor PD-098059 at these concentrations (Figure 6.4 
A).
However, Figure 6.5 A shows that PD-098059 did reduce TNF-a-induced IL-8 
secretion by CFTE cells significantly (p<0.05; ANOVA). The most potent 
inhibitory concentration of PD-098059 was 0.1 pM, which eliminated 
approximately 88 % of TNF-a-induced IL-8 production in CFTE cells and 
approximately 60 % inhibition of chemokine production was provided by higher 
concentrations of this compound. High (10 pM) levels of PD-098059 caused a 
clear reduction of TNF-a-induced chemokine secretion by HTE and pCEP-RF 
cells by 50 % and 67 %, respectively; and as little as 1 pM reduced IL-8 
production following stimulation with TNF-a in the pCEP-RF and HTE cell 
lines (Figure 6.5 A and B). Significant inhibition of IL-8 production was seen 
in TNF-a-stimulated pCEP-2 cells (p<0.05; ANOVA) that had been pre-treated 
with the ERK inhibitor, diminishing chemokine production by 48%  from 
18 ng/ 106 cells to less than 10 ng/ 106 cells in the presence of 10 pM or 1 pM 
PD-098959 (Figure 6.5 B).
B. ce/rac/fl-stimulated HTE cells secreted less than a third as much IL-8 in the 
presence of either 10 pM or 3 pM PD-098059 as did uninhibited controls 
(Figure 6.6 A). However, this apparently striking inhibition was not 
statistically significant (p>0.3; ANOVA). PD-098059 inhibited B. cepacia- 
induced IL-8 production by 71 % in CFTE cells to 3.2 ng IL-8/ 106 cells, 
compared with CFTE cells treated with B. cepacia J2315 alone and control cells 
(Figure 6.6 A). Both pCEP-2 and pCEP-RF cell lines secreted significantly
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less IL-8 after stimulation with B. cepacia J2315 if they had been treated first 
with PD-098059, compared with uninhibited epithelial cells (p<0.05; ANOVA) 
as illustrated in Figure 6.6 B and this effect was significant at 10 pM PD- 
098059 in those cells expressing a normal phenotype. B. cepacia induced
16.0 ng IL-8/106 cells in pCEP-RF cells, which was reduced by approximately 
75 % to less than 4 ng/ 106 cells in the presence of either 10 pM or 3 pM PD- 
098059. Bacterial-induced IL-8 was inhibited by more than 85 % in pCEP-2 
cells, after pre-treatment with 10 pM PD-098059, to only 2.8 ng/ 106 cells. 
Similarly, 3 pM PD-098059 inhibited IL-8 production in pCEP-2 cells, reducing 
IL-8 induction by B. cepacia to less than 50 % of uninhibited levels.
6.2.3 Assessment of the toxicity of dicoumarol to airway epithelial cells.
Specific and selective inhibitors of extracellular regulated kinase (ERK) and 
p38 MAP kinase cascades are available commercially (142;379)t although an 
equivalent compound has not been reported for antagonising the c-Jun N- 
terminal kinase (JNK/SAPK) MAP kinase pathway. A recent study by 
Templeton et a l (380) described the potential of dicoumarol to fulfil this role. 
In their experiments, 150 pM dicoumarol reduced the activity of JNK by at least 
90 %, whilst dose dependent inhibition was also displayed at lower dicoumarol 
concentrations (380). However, dicoumarol also potentiated the induction of 
apoptosis by TNF-a (380) suggesting that dicoumarol is toxic to some 
mammalian cells.
To assess whether this coumarin derivative might be useful for examining the 
role of MAP kinase pathways in IL-8 production, dicoumarol toxicity towards
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pCEP cells was investigated. To determine whether the epithelial cell lines 
were resistant to dicoumarol-induced cell death, pCEP-2 and pCEP-RF cells 
were grown in 6-well plates until almost confluent and incubated with 
dicoumarol for 24 h. Epithelial cell viability was assessed by trypan blue 
exclusion and the results are displayed in Figure 6.7.
After 3 h, only 85 % of pCEP-RF cells remained viable following treatment 
with 150 pM or 75 pM dicoumarol, respectively (Figure 6.7 A and B). Five 
hours later, only 60-70 % of the original pCEP-RF population had survived. 
After 12 h incubation, 25 % of cells had survived 150 pM dicoumarol, whilst 
40 % of pCEP-RF cells retained an intact membrane in the presence o f 75 pM 
dicoumarol at this time point. Similar trends were observed in pCEP-2 cells. 
Neither cell population survived a 24 h-incubation period with either 150 pM or 
75 pM dicoumarol. Figure 6.7 C shows that even 38 pM dicoumarol killed 
25 % of pCEP-RF and 30 % pCEP-2 cells after 8 h, and 50 % of pCEP-RF cells 
were dead within 12 h. pCEP-2 cells appeared slightly more recalcitrant to 
dicoumarol toxicity at this concentration however, since more than 65 % of the 
pCEP-2 population survived 12 h incubation with 38 pM dicoumarol. In 
contrast to samples treated with higher concentrations of dicoumarol, 20 % of 
each cell population remained viable in the presence of 38 pM dicoumarol after 
24 h. Dicoumarol vehicle control (MilliQ adjusted to pH 9.8) had no effect on 
epithelial cell viability (Figure 6.7 D). Clearly, these data suggest that it would 
be difficult to distinguish between the toxic effects of dicoumarol and any 
inhibitory effects on MAP kinase signalling. Therefore, the potential of an 
alternative incubation strategy was assessed.
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Epithelial cells were grown as before and then treated with dicoumarol for only 
30 min before washing away excess dicoumarol and replacing with dicoumarol- 
free medium. After 24 h, epithelial cell viability was determined by trypan blue 
exclusion and the results are shown in Figure 6.8. A striking increase in 
viability was observed in the pCEP-2 cell line following only 30 min treatment 
with either 150 pM or 75 pM dicoumarol (Figure 6.8 A and B), compared with 
cells that had been treated for 24 h with the inhibitor. At no time during the 
24 h period did pCEP-2 viability drop below 75 % if cells had been incubated 
with dicoumarol for only 30 min, regardless of the concentration used. 
Although pCEP-RF cells did not resist the toxic effects of a 30 min exposure to 
150 pM dicoumarol to the same extent as pCEP-2 cells, at least 50 % viability 
was observed in the pCEP-RF population even after 24 h. Furthermore, at least 
75 % of the pCEP-RF population survived a 30 min exposure to 75 pM 
dicoumarol (Figure 6.8 B). In view of these data, cells were exposed to 
dicoumarol for only 30 min in order to assess its potential as an inhibitor of IL-8 
production in stimulated epithelial cells.
6.2.4 Reduced IL-8 production by airway epithelial cells following pre­
treatm ent with dicoumarol.
Both CF and normal epithelial cells were incubated with dicoumarol for 30 min. 
Unabsorbed dicoumarol was washed away and replaced with dicoumarol-free 
medium containing IL-lp, TNF-a or B. cepacia J2315 as described previously. 
Figures 6.9-6.11 show that IL-8 production was reduced considerably and in a 
dose-dependent manner by dicoumarol. IL-1 p elicited 30.4 ng IL-8/106 pCEP-
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RF cells and 19.6 ng IL-8/106 pCEP-2 cells and these values were diminished 
in the presence of 150 pM dicoumarol to 16.4 ng/ 106 pCEP-RF cells (48 % 
inhibition) and 8.6 ng/ 106 pCEP-2 cells (61 % inhibition) as shown in Figure 
6.9. At a concentration of 38 pM, dicoumarol reduced pCEP-RF chemokine 
production further to 13.2 ng IL-8/ 106 cells, which is equivalent to 72 % 
inhibition; and this dose of dicoumarol inhibited IL-8 secretion by pCEP-2 cells 
by approximately 45 % to 11.4 ng/106 cells.
Similarly, TNF-a-induced IL-8 production by pCEP epithelial cells showed 
dose-dependent inhibition in those cells that had been treated with dicoumarol. 
TNF-a induced comparable levels of IL-8 in CF and non-CF pCEP cells 
(16.6 ng and 17.2 ng/ 106 cells, respectively), which were reduced by 
approximately 64%  of the induced in each case after exposure to 150 pM 
dicoumarol for 30 min. Figure 6.10 illustrates that the same level of inhibition 
was observed in pCEP-RF cells at 75 pM dicoumarol, although TNF-a- 
stimulated pCEP-2 cells produced slightly more IL-8 at this inhibitor 
concentration (9.8 ng IL-8/ 106 cells, representing 54%  inhibition). The 
strongest effect that dicoumarol had on IL-8 secretion was in cells stimulated 
with B. cepacia. Bacterial stimulation of pCEP-2 cells with strain J2315 
elicited 7.8 ng IL-8/ 106 cells. However, pre-treatment for 30 min with either 
150 pM or 75 pM dicoumarol abrogated this induction completely, restoring 
pCEP-2 IL-8 secretion to resting cell levels (Figure 6.11). Similar inhibition 
was achieved with 38 pM dicoumarol pre-treatment, which limited IL-8 
production in bacterial-stimulated pCEP-2 cells to 2.0 ng IL-8/ 106 cells.
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6.3 Bacterial Activation of MAP Kinase in Airway Epithelial 
Cells.
To investigate the effects of bacterial stimulation on MAP kinase cascade 
activation, epithelial cells were grown in 35cm2 petri dishes and stimulated with 
B. cepacia J2315 or with P. aeruginosa PAOl for up to 1 h. Epithelial proteins 
in the whole cell lysates were separated by SDS-PAGE and blotted onto 
nitrocellulose membranes. Blots were probed with monoclonal phospho- 
specific anti-ERK antibody and detected with chemiluminescence. Finally, 
blots were stripped and re-probed with polyclonal non-phospho-specific ERK 
antibody. The activation of ERK was quantified by densitometry. ERK-1 was 
not detected in all of the cell lines so that it was not possible to quantify changes 
in the level of activation of this protein. For this reason, only ERK-2 activation 
was examined.
6.3.1 Effects of P. aeruginosa on ERK-2 activity in airway epithelial cells.
All of the epithelial cell lines showed some change in activation 
(phosphorylation) of ERK-2 following stimulation with P. aeruginosa PAOl, 
although the kinetics varied amongst cell lines. Phosphorylated ERK-2 was 
detected in quiescent HTE cells but the strength of this signal was reduced at 
early time points (30 sec -  2 min) following bacterial stimulation (Figure 6.12). 
ERK-2 activity peaked approximately 5 min post stimulation, almost returning 
to unstimulated levels. Despite the observed reduction in phosphorylated ERK- 
2 in HTE cells after PAOl-stimulation, some degree of activity was detected 
throughout the experiment. In contrast, P. aeruginosa PAOl elevated ERK-2 
activation in CFTE cells (Figure 6.13), peaking at more than a 7-fold increase
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by 2 min and this level of ERK-2 phosphorylation was still present 10 min after 
stimulation. A slight decrease was observed at the 5 min time point, but still 
ERK-2 phosphorylation was approximately 5 times its level in quiescent cells. 
ERK-2 activity dropped below unstimulated levels during the next 20 min 
before increasing again during the final 30 min of the experiment. 
Phosphorylated ERK-2 was present in resting pCEP cell lines and had begun to 
increase 5 min after PAOl-stimulation. This upregulation was sustained in 
pCEP-RF cells (Figure 6.15) reaching almost 4 times the level of 
phosphorylated ERK-2 that was observed in unstimulated controls, whilst ERK- 
2 activity declined after 15 min in pCEP-2 cells (Figure 6.14).
6.3.2 Effects of B. cepacia on ERK-2 activity in airway epithelial cells.
Within 30 sec of exposure to B. cepacia J2315, pCEP-RF cells had increased 
ERK-2 phosphorylation by 200 % (Figure 6.17), an effect that was mimicked at 
5 min post bacterial stimulation. ERK-2 phosphorylation began to increase 
above unstimulated levels again at 10 min, until 30 min after initial stimulation, 
when pCEP-RF cells expressed twice as much phosphoiylated ERK-2 as did 
quiescent cells. One hour after stimulation with J2315, the degree of ERK-2 
phosphorylation in pCEP-RF cells had returned almost to constitutive levels. 
The initial increase in phosphorylated ERK-2 in B. cepacia-stimulated pCEP-2 
cells displayed slightly different kinetics from pCEP-RF cells. ERK-2 
phosphorylation had doubled 30 sec post stimulation, which rose to almost a 4- 
fold increase compared with quiescent cells by 2 min (Figure 6.16). Five 
minutes post stimulation some depletion of phosphorylated ERK-2 was noted 
but a second peak in expression was seen 10 min after initial stimulation of
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pCEP-2 cells with B. cepacia J2315, when phosphorylated ERK-2 was more 
than three times its original concentration. ERK-2 phosphorylation decreased to 
less than double its original concentration by 15 min, and had returned almost to 
basal level 30 min post stimulation. ERK-2 activity began to increase again 60 
min after initial stimulation of pCEP-2 cells with B. cepacia J2315.
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Figure 6.1. IL-8 production in epithelial cells after 24 h stimulation with 
10 ng/ ml IL-lp following 1 h pre-treatment and 24 h antagonism with the 
p38 inhibitor SB-203580 (mean + SEM). A : C F T E  and  H T E  c e lls ;  B: 
p C E P -R F  and p C E P -2  c e l ls .  S ta tis t ica l a n a ly s is  w a s  p er fo rm ed  u s in g  A N O V A  
fo l lo w e d  b y  D u n n e tt’s te s t  for m u ltip le  c o m p a r iso n s  w h e r e  p < 0 .0 5  w a s  
c o n s id e r e d  s ig n if ic a n t  (*  p < 0 .0 5 ;  **  p < 0 .0 1 ) . “N o th in g ” n = 2 6 ; “ IL -1 ” n = l  1; a ll 
o th ers n = 3 .
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Figure 6.2. IL-8 production in epithelial cells after 24 h stimulation with 
30 ng/ ml TNF-a following 1 h pre-treatment and 24 h antagonism with the 
p38 inhibitor SB-203580 (mean + SEM). A : C F T E  an d  H T E  c e lls ;  B: 
p C E P -R F  and p C E P -2  c e l ls .  S ta tis t ica l a n a ly s is  w a s  p erform ed  u s in g  A N O V A  
fo l lo w e d  b y  D u n n e tt’s te s t  for m u ltip le  c o m p a r iso n s  w h e r e  p < 0 .0 5  w a s  
c o n s id e r e d  s ig n if ic a n t  (*  p < 0 .0 5 ) .  “N o th in g ” n = 2 6 ; “T N F ” n = 1 0 ; a ll o th ers n = 3;  
h a tch ed  bars in d ica te  n < 3 .
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Figure 6.3. IL-8 production in epithelial cells after 24 h stimulation with 
B. cepacia J2315 (moi = 200) following 1 h pre-treatment and 24 h 
antagonism with the p38 inhibitor SB-203580 (mean + SEM). A: CFTE and 
HTE cells; B: pCEP-RF and pCEP-2 cells. Statistical analysis was performed 
using ANOVA followed by Dunnett’s test for multiple comparisons where 
p<0.05 was considered significant (* p<0.05; ** p<0.01). “Nothing” n=26; 
“J2315” n=6; all others n=3.
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Figure 6.4. IL-8 production in epithelial cells after 24 h stimulation with 
10 ng/ ml IL -ip following 1 h pre-treatment and 24 h antagonism with the 
ERK inhibitor PD-098059 (mean + SEM). A : C F T E  and  H T E  c e lls ;  B: 
p C E P -R F  and p C E P -2  c e lls .  S ta tis t ica l a n a ly s is  w a s  p er fo rm ed  u s in g  A N O V A  
fo l lo w e d  b y  D u n n e tt’s te s t  for m u ltip le  c o m p a r iso n s  w h e r e  p < 0 .0 5  w a s  
c o n s id e r e d  s ig n if ic a n t. (*  p < 0 .0 5 ) . “N o th in g ” n = 2 6 ; “ IL -1 ” n = l  1; h a tch ed  bars 
in d ica te  n < 3 ; a ll o th ers n = 3 .
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Figure 6.5. IL-8 production in epithelial cells after 24 h stimulation with 
30 ng/ ml TNF-a following 1 h pre-treatment and 24 h antagonism with the 
ERK inhibitor PD-098059 (mean +  SEM). A : C F T E  and  H T E  c e lls ;  B: 
p C E P -R F  and  p C E P -2  c e l ls .  S ta tis t ica l a n a ly s is  w a s  p er fo rm ed  u s in g  A N O V A  
fo l lo w e d  by  D u n n e tt’s te s t  for m u ltip le  c o m p a r iso n s  w h e r e  p < 0 .0 5  w a s  
c o n s id e r e d  s ig n if ic a n t. “N o th in g ” n = 2 6 ; “T N F ” n = 1 0 ; a ll o th ers  n = 3 .
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Figure 6.6. IL-8 production in epithelial cells after 24 h stimulation with 
B. cepacia J2315 (moi = 200) following 1 h pre-treatment and 24 h 
antagonism with the ERK inhibitor PD-098059 (mean + SEM). A : C F T E  
and  H T E  c e lls ;  B: p C E P -R F  and p C E P -2  c e l ls .  S ta tis t ica l a n a ly s is  w a s  
p erform ed  u s in g  A N O V A  fo l lo w e d  b y  D u n n e tt’s te s t  for  m u ltip le  c o m p a r iso n s  
w h e r e  p < 0 .0 5  w a s  c o n s id e r e d  s ig n if ic a n t. (*  p < 0 .0 5 ) .  “N o th in g ” n = 2 6 ; J 2 3 1 5  
n = 6 ; a ll o th ers n = 3 .
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Figure 6.7. Toxicity of dicoumarol (24 h exposure) to pCEP airway 
epithelial cells. p C E P -R F  (o ra n g e ) and p C E P -2  (b lu e )  e p ith e lia l c e l l s  w e r e  
treated  w ith  d ico u m a ro l and v ia b ility  w a s  a s s e s s e d  at in terv a ls  up  to  2 4  h. A : 
150  p M ; B: 75  p M ; C: 3 8  p M ; D : v e h ic le  co n tro l. ( n = l ) .
0 a
Duration of Stimulation
5^  100 l i d
Duration of Stimulation
^  100 n mO 80
Duration of Stimulation
163












8h 12h 24h 
jration of Stimulation
d  100 






3h 8h 12h 24h
Duration of Stimulation
b  100 






3h 8h 12h 24h
Duration of Stimulation
b  100
|  80 
<o 60
a  40
I  20 gong
3h 8h 12h 24h
Duration of Stimulation
Figure 6.8. Toxicity of dicoumarol (30 min exposure) to pCEP airway 
epithelial cells. p C E P -R F  (o ra n g e ) and p C E P -2  (b lu e )  e p ith e lia l c e l l s  w ere  
trea ted  w ith  d ico u m a ro l for 3 0  m in , w a sh e d  and th en  v ia b ility  w a s  a s s e s s e d . A : 
150  p M ; B: 75  p M ; C: 3 8  p M ; D : v e h ic le  co n tro l. ( n = l ) .
164
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Figure 6.9. IL-8 production in pCEP epithelial cells after 24 h stimulation 
with 10 ng/ ml IL-ip following 30 min antagonism with dicoumarol (mean















CF cells non-CF cells
Figure 6.10. IL-8 production in pCEP epithelial cells after 24 h stimulation 
with 30 ng/ ml TNF-a following 30 min antagonism with dicoumarol (mean
+  S E M ) . “N o th in g ” n = 2 6 ; “T N F ” n = 1 0 ; h a tch ed  bars in d ica te  n < 3 .
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Figure 6.11. IL-8 production in pCEP-2 epithelial cells after 24 h 
stimulation with B. cepacia J2315 following 30 min antagonism with 
dicoumarol (mean + SEM). H atch ed  bars in d ica te  n < 3  [p resen t in a ll e x c e p t  
“N o th in g ” (n = 2 6 )  and  “J 2 3 1 5 ” (n = 6 )] .
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Figure 6.12 Phosphorylation (activation) of ERK in HTE cells following stimulation with P. aeruginosa PAOl.
A: Western blot with anti-phospho-ERK antibody (top panel) and anti-pan-ERK antibody reprobe (bottom panel).
B: Histogram depicting % change in ERK activity following analysis o f  western blots using densitometry. (n= l).
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Figure 6.13 Phosphorylation (activation) of ERK in CFTE cells following stimulation with P. aeruginosa PAOl.
A: Western blot with anti-phospho-ERK antibody (top panel) and anti-pan-ERK antibody reprobe (bottom panel).
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Figure 6.14 Phosphorylation (activation) of ERK in pCEP-2 cells following stimulation with P. aeruginosa PAOl.
A: Western blot with anti-phospho-ERK antibody (top panel) and anti-pan-ERK antibody reprobe (bottom panel).
B: Histogram depicting % change in ERK activity following analysis o f  western blots using densitometry. (n=l).
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Figure 6.15 Phosphorylation (activation) of ERK in pCEP-RF cells following stimulation with P. aeruginosa PAOl.
A: Western blot with anti-phospho-ERK antibody (top panel) and anti-ERK antibody reprobe (bottom panel).
B: Histogram depicting % change in ERK activity following analysis o f  western blots using densitometry. (n=l).
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Figure 6.16 Phosphorylation (activation) of ERK in pCEP-2 cells following stimulation with B. cepacia J2315.
A: Western blot with anti-phospho-ERK antibody (top panel) and anti-pan-ERK antibody reprobe (bottom panel).
B: Histogram depicting % change in ERK activity following analysis o f  western blots using densitometry. (n=l).
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Figure 6.17 Phosphorylation (activation) of ERK in pCEP-RF cells following stimulation with B. cepacia J2315.
A : W estern  b lo t w ith  a n ti-p h o sp h o -E R K  an tib od y  (top  p a n e l) and a n ti-p a n -E R K  a n tib o d y  rep rob e (b o tto m  p a n e l) .
B: H isto g ra m  d e p ic t in g  % c h a n g e  in E R K  a c tiv ity  fo l lo w in g  a n a ly s is  o f  w este r n  b lo ts  u s in g  d e n s ito m e tr y . ( n = l ) .
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6.4 Discussion.
Pulmonaiy disease in CF is characterised by an excessive influx of neutrophils 
into the lung, which is mediated primarily by the inflammatory cytokine IL-8 
(121;381). Several groups have observed elevated IL-8 production by CF 
respiratory epithelial cells in the absence of infection (50;52;345;34t) and this 
situation is exacerbated both directly and indirectly by subsequent exposure to 
pathogens. The biochemical pathways leading to IL-8 have not been 
characterised completely, although some studies have identified a role for the 
transcription factor NFkB, which regulates the expression of many other 
mediators of immunity such as defensins, MHC-II and iNOS (154;382-385). 
IL-1 p and TNF-a as well as viral and bacterial products induce IL-8 secretion 
from a range of cell types, for example see references 
(56;57;114;116;117;203;348;386-388) and these stimuli may also activate 
members of the serine / threonine MAP kinase family (362, 389-393) although 
there have been conflicting reports regarding the molecular route of these 
signals. NFkB is not the only transcription factor that regulates IL-8 gene 
expression (376;394;395). Furthermore, whilst NFkB and MAP kinases can be 
activated independently of each other, they also share some distal signalling 
components as illustrated in Figure 1.6. In light of these facts, it seemed 
reasonable to investigate a possible involvement of MAP kinase cascades in the 
upregulation of IL-8 in airway epithelial cells and to identify potential 
differences in the regulation of IL-8 in CF versus normal cells.
173













osm otic shock U V , LPS
IL -ip , LPS IL -ip




sm all G T Pases |
(licoiim nrol
apoptosis  
im m u n e response  
proliferation  
etc.
Figure 6.18 Inhibitors of MAP kinase signalling cascades . Dicoumarol prevents the 
activation o f MEKK1, a membrane shuttle kinase that lies upstream of JNKK, MEK and also 
may regulate the NFkB pathway. SB-203580 is highly specific for p38 MAP kinase and 
prevents it from phosphorylating its downstream targets, such as the transcription factors ATF -2 
and AP-1. PD-098059 antagonises MEK selectively and, until recently, this inhibitor was 
thought to be specific for ERK. However, a recent report has suggested that MEK may also 
phosphorylate JNK so that PD-098059 may inhibit JTNK activation in some cell types.
T h ere  are three m ajor M A P  k in a se  fa m ilie s  in m a m m a ls , n a m e ly  E R K , p 3 8  and  
J N K /S A P K . N u m e r o u s  and varied  un related  ex tra ce llu la r  c u e s  can  in itia te  
in trace llu lar  s ig n a llin g  c a sc a d e s  that resu lt in th e  p h o sp h o ry la tio n  o f  o n e  or  
m o re o f  th e s e  M A P  k in a se s , c a u s in g  th em  to  b e c o m e  a c tiv a ted . In turn, M A P  
k in a s e s  p h o sp h o ry la te  - and th u s a c tiv a te  -  tran scr ip tion  fa c to rs su ch  a s  A T F -2
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and Elk-1 (373;396;397), that control the expression of subsets of genes. 
Specific and selective antagonists of MAP kinase pathways were assessed for 
their effects on basal and stimulated IL-8 production in vitro using an ELISA 
specific for IL-8. Although ERK and p38 inhibitors are available commercially, 
an equivalent antagonist of the JNK pathway has not been characterised. 
However, a recent study by Templeton et al. revealed that dicoumarol inhibited 
JNK MAP kinase (380) in CHO and HEK-293 cells. Dicoumarol is a derivative 
of coumarin, which has been used clinically as an oral anti-coagulant and this 
compound inhibits quinone reductase, an enzyme that lies downstream of the 
TNF receptor signalling complexes but upstream of the membrane shuttle 
kinase, MEKK1 (Figure 6.18). Therefore, dicoumarol was selected as an 
antagonist of the JNK signalling cascade.
Unfortunately, in their report Templeton et al. demonstrated that dicoumarol 
induced apoptosis in HeLa cells after 8 h, which was exacerbated in the 
presence of TNF-a (380) so that using a similar approach in this study would 
make it difficult to distinguish between any direct inhibitory effects of 
dicoumarol on IL-8 production, and an inhibition resulting from epithelial cell 
death. The toxicity of dicoumarol towards pCEP cells after 24 h was confirmed 
at a range of concentrations that inhibit quinone reductase (Figure 6.7). 
However, cell viability was compromised by less than a third in any pCEP cell 
population following exposure to dicoumarol for only 30 min (Figure 6.8). In 
general the most potent concentration of dicoumarol was 150 pM, which 
abrogated almost two thirds of cytokine-induced IL-8 production in pCEP-2 
cells and three-quarters of IL-8 induced in pCEP-RF cells by TNF-a. However,
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pCEP-RF cells stimulated with IL-1 p and bacterial-stimulated pCEP-2 cells 
were inhibited most effectively by 38 pM dicoumarol: B. cepacia-induced IL-8 
production was reduced below basal levels. It is unlikely that the inhibition 
resulted only, if at all, from epithelial cell death since inhibition values were 
greater than the corresponding cell death values at relevant concentrations of 
dicoumarol. Rather, it is probable that the effects of dicoumarol were caused by 
specific inhibition of one or more signal transduction pathways upstream of IL- 
8 induction in the respiratory epithelial cells. However, it should be stressed 
that these concentrations of dicoumarol are still relatively high and as such 
introduce a risk of non-specific inhibitory effects within the epithelial cells. The 
specific target of dicoumarol is MEKK1, a kinase that can activate either JNK 
MAP kinase or NFkB (145;146;398), as shown in Figures 1.7 and 6.18. Thus, 
the observed effects of dicoumarol on stimulated epithelial IL-8 production may 
be mediated via inhibition of one or both of these signalling cascades. 
Although it has been reported that dicoumarol does not inhibit signalling 
pathways activated by mitogens (380), some cross talk does exist between 
MEKK1 and MEK, which lies upstream of ERK MAP kinase (Figure 1.6), so 
the additional possibility that dicoumarol diminished IL-8 production because of 
ERK antagonism should not be discounted.
The role of p38 MAP kinase in epithelial IL-8 secretion was examined using the 
specific pharmacological inhibitor, SB-203580, a compound that blocks the 
kinase activity of p38 but has little or no detectable effect on ERK or JNK 
pathways (316), as shown in Figure 6.18. Stimulated epithelial cells produced 
much less IL-8 if they had been pre-treated with SB-203580 than did
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uninhibited controls and this antagonism was dose-dependent (Figures 6.1-6.3). 
In general, 10 pM SB-203580 was the most potent inhibitory concentration in 
IL-l[3-stimulated cells and 30 pM SB-203580 inhibited TNF-a-induced IL-8 
most effectively, reducing induced IL-8 by at least 70 % and by as much as 
100 % in both CF and normal epithelial cells, with one exception. Since IL-1J3 
had little stimulatory effect on IL-8 secretion from CFTE cells, an inhibitory 
effect of SB-203580 was less obvious in these cells. In contrast, TNF-a 
signalling pathways leading to the secretion of IL-8 were inhibited almost 
completely (98 %) in CFTE cells by this pharmacological antagonist, implying 
that p38 was an essential mediator of IL-8 induction in this cell line. In each 
cell line pair in the presence of TNF-a, antagonism of p38 MAP kinase had a 
greater effect in CF- than in normal cells (Figure 6.2). In agreement with other 
reports (399-402), 75-80 % of TNF-a-induced IL-8 in all of the other cell lines 
could be abrogated with this MAP kinase antagonist, strengthening the idea that 
p38 is critically important in IL-8 upregulation following TNF-a-stimulation of 
the pulmonary epithelium. SB-203580 also reduced bacterial-induced IL-8 
production and again the optimum antagonist concentration was 30 pM in most 
cases, reducing IL-8 production in B. cepacia-stimulated HTE cells by the 
greatest amount (Figure 6.3).
Finally, the role of ERK in epithelial cell IL-8 production was investigated and 
was found to vary according to both cell line and stimulus. Inhibiting ERK 
activation with PD-098059 eliminated approximately 50 %, 70 % and 80 % of 
induced IL-8 expression in HTE cells that had been stimulated with TNF-a, IL- 
1 p or B. cepacia, respectively. The opposite trend was observed in CFTE cells,
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however, in which ERK antagonism caused a striking reduction in the amount 
of IL-8 secreted in response to TNF-a; but this compound did not interfere as 
much in the levels of IL-8 induced by B. cepacia and had almost no effect in IL- 
lp-stimulated CFTE cells. These differences may be related to the distinct 
effects of each agonist on IL-8 induction in each cell population. Secretion of 
IL-8 was compromised by PD-098059 to a similar degree in both normal and 
CF pCEP cells stimulated with IL-1 p, suggesting that the contribution of IL-1 p 
signalling via ERK was the same in each case.
A greater effect of inhibiting ERK was seen in pCEP cells stimulated with 
B. cepacia, but again the degree of inhibition did not differ between cell 
populations expressing CF and normal phenotypes indicating that bacterial 
signalling to ERK may proceed in part via the TLR/ IL-1 pathway, perhaps 
through ligation of LPS receptors, but that another molecular route may also be 
involved in the activation of ERK by B. cepacia and that this alternative 
signalling pathway is active in CF and normal cells. Importantly, TNF-a- 
stimulated pCEP cells showed different responses towards PD-098059 
according to their phenotype. In common with the first pair of cell lines (CFTE 
and HTE), IL-8 secretion was affected by ERK antagonism much more in 
pCEP-RF cells than in normal (pCEP-2) cells, in the presence of TNF-a. 
Again, it should be noted that TNF-a induced more IL-8 in cells with a CF 
phenotype than in normal cells and the elevation of TNF-a in the CF lung has 
been well documented (103;403;404). These differences may relate to the 
efficiency of TNF-a to activate ERK or p38 in each case.
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Table 6.1 summarises the relative inhibition of induced IL-8 in each cell line in 
the presence of different agonists. It can be seen from the data presented here 
that each of the inhibitors affected IL-8 induction to some extent in all of the 
cell lines, suggesting that all three MAP kinases and NFkB can mediate IL-8 
production in airway epithelial cells. This apparent redundancy may provide 
alternative routes to regulate chemokine secretion in case one pathway becomes 
disrupted.
When used alone, both dicoumarol and SB-203580 completely ablated the 
induction of IL-8 by B. cepacia and this fact suggests that these signalling 
pathways are connected since dicoumarol does not affect p38 activity (405) and 
SB-203580 is a specific antagonist of p38 (316). Hunninghake and co-workers 
reported that p38 is required for NFKB-dependent gene expression in endotoxin- 
stimulated monocytic cells, although p38 does not affect the activation of NFkB 
itself (406). If NFKB-mediated transcription in tracheal epithelial cells 
stimulated with bacteria was also dependent upon p38 activity then inhibiting 
either of these signalling cascades would interfere with the expression of genes 
for proteins such as IL-8, consistent with the data presented here. Antagonism 
of the ERK pathway with PD-098059 also reduced the up-regulation of IL-8 
although this inhibitor was not as efficacious as SB-203580 or dicoumarol. This 
finding suggests that ERK is responsible for at least some of the IL-8 production 
via an unknown transcription factor. Since MEKK1 is the molecular target of 
dicoumarol and some cross talk exists between this MAP3K and the ERK 
signalling cascade it might be expected that dicoumarol would also prevent the 
stimulation of IL-8 via ERK, despite the implications in Templeton’s study that
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ERK signalling remains unaffected by this inhibitor (380). Taken together the 
effects of antagonising either ERK or p38 suggest that a common IL-8 
transcription factor can be activated by both of these MAP kinases, and a 
possible candidate is AP-1 (376,407-411).
The p38 MAP kinase appears to play the most important role in IL-8 secretion 
in both CF and non-CF cell lines regardless of the inflammatory signal. This 
conclusion is consistent with several published reports that describe the found 
p38 to play a central role in IL-8 production. It is also noteworthy that SB- 
203580 had the same or greater effect in epithelial cells expressing a CF 
phenotype than in normal cells, reflecting the relative importance of p38 in each 
cell type. Since one of the major extracellular stimuli for p38 signal 
transduction is osmotic stress (138), it is perhaps not surprising that p38 might 
have a dominant role in CF cells, in which there is a pronounced disruption to 
electrolyte and fluid movement across the respiratory epithelium.
ERK activation was also measured indirectly in the epithelial cells following 
stimulation with either B. cepacia J2315 or P. aeruginosa PAOl. Whilst these 
studies give a good indication that ERK is enzymatically active, it should be 
appreciated that this approach measures only ERK phosphorylation, and does 
not measure the enzyme activity directly, such as could be achieved with an ‘w 
vitro kinase assay’. Even in the absence of bacterial stimulation, some 
phosphorylated (activated) ERK was observed in all of the cell lines, which may 
contribute to the production of IL-8 in unstimulated epithelial cells. Both 
bacterial strains activated ERK in pCEP-2 cells to a similar degree, peaking at
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more than a 3-fold increase 10 min after stimulation compared with 
unstimulated cells, although B. cepacia activated ERK more rapidly than 
P. aeruginosa in this cell line (Figure 6.19 A and B). Approximately 20 min 
after stimulation with either bacterial strain ERK activity was reduced to basal 
levels, dephosphorylation continued for a further 10 min and began to rise again 
for the final 30 min of the experiment but did not quite return to unstimulated 
levels. In contrast, P. aeruginosa caused a delayed but sustained increase in 
phosphorylated ERK-2 in pCEP-RF cells, whilst B. cepacia elicited a biphasic 
and slightly lower elevation in the activity of this MAP kinase. Unexpectedly, 
P. aeruginosa induced dephosphorylation of ERK-2 in HTE cells with a rapid 
but transient 3-fold decrease in ERK-2 phosphorylation. The most dramatic 
change in ERK-2 activity was detected in P. aeruginosa-stimuXdXedi CFTE cells 
in which a rapid activation of ERK-2 was maintained for approximately 10 min, 
followed by an equally rapid dephosphorylation of ERK-2 below unstimulated 
levels. One hour after stimulation with P. aeruginosa, the level of 
phosphorylated ERK-2 in CFTE cells had returned to almost twice that in 
unstimulated control cells. It is particularly interesting to note that the pattern of 
ERK-2 activity in CFTE cells was the inverse of that seen in HTE cells (Figure 
6.19 C).
The biphasic nature of ERK-2 activation within one hour of bacterial 
stimulation of respiratory epithelial cells has been reported previously following 
RSV infection (354) and may have a number of important physiological 
consequences. In addition to the involvement of ERK-2 in IL-8 production that 
has been demonstrated in this work and elsewhere (354;412), ERK has also
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been implicated in the upregulation of the MUC1 gene for mucus production 
and in the prevention of immune cell apoptosis (413-415), both of which are 
important during pulmonary infection in CF. However, it was not possible to 
identify any difference between CF and non-CF epithelial cells with regard to 
the activation of ERK-2.
Table 6.1 Summary of the effects of pharmacological inhibitors on IL-8 
secretion in stimulated respiratory epithelial cells. Figures shown represent 
percentage inhibition of induced IL-8 production. Numbers in parentheses 
indicate the minimum concentration of inhibitor to mediate this inhibition.
Inhibitor Cell L ine
and CFTE HTE pCEP- pCEP-
STIMULUS RF 2
Dicoumarol








B. cepacia - - " 100 %
(38 uM)
SB-203580
IL-lp No 82% 87% 70%
effect (10 uM) (10 uM) (10 uM)
TNF-a 98% 82 % 78% 75%
(30 uM) (30 uM) (30 uM) (30 uM)
B. cepacia 92 % 90% 99.6 % 100 %
(10 UM) (30 uM) (io m ) (30 uM)
PD-098059
IL-ip No 68% 67% 68%
effect (3pM ) (10 uM) (10 uM)
TNF-a 88% 50% 67% 55%
(0.01
uM)
(10 uM) (10 uM) (10 |iM)
B. cepacia 71 % 79% 84% 85%
(10 UM) ( 3 mM) (10 UM) (10 UM)
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Figure 6.19 Kinetics of ERK-2 activation by bacteria in epithelial cells. A :
p C E P -R F  (red ) and p C E P -2  (b lu e )  c e l l s  s t im u la ted  w ith  P. aeruginosa P A O l;  
B: p C E P  c e l l s  s t im u la ted  w ith  B. cepacia J 2 3 1 5 ; C: C F T E  (red ) and  FITE  
(b lu e )  c e l l s  s t im u la ted  w ith  P. aeruginosa P A O l ( n = l ) .
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C h a p te r  7: 
Concluding Discussion
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7.1 Concluding Remarks.
An inherently exaggerated inflammatory environment underscores the 
pathophysiology of the CF lung. Subsequent infection in most CF patients by 
highly adapted pathogens, which can resist the unfavourable conditions of the 
CF lung such as dehydration and nutrient limitation, exacerbates this situation 
further. However, whilst many theories have been proposed, the relationship 
between the primary genetic defect in the apical CFTR chloride channel, and the 
pre-disposition towards pulmonary infection and inflammation has not been 
determined satisfactorily and many questions remain unresolved. For example, 
it is curious that excessive inflammation and subsequent infection are restricted 
to the lung when multiple organs are affected by the CF gene mutation, and this 
caveat implies a failure of critical lung-specific innate defence mechanisms; and 
yet more curious is the fact that these infections are caused by so few species.
The present study was undertaken with two broad aims, namely to investigate 
whether CF pathogens are capable of regulating Cl' channel activity in the lung 
and to evaluate the mechanisms by which bacteria induce epithelial cytokine 
production. Using a number of in vitro techniques, this study has examined 
both chloride channel activity and cytokine production in airway epithelial cells 
expressing either a CF- or a normal phenotype. In light of the data obtained in 
this and other studies, a potential connection between disrupted ion channel 
activity and the immune response within the CF lung is discussed.
Bacterial modulation of epithelial ion channels, including activation of CFTR 
by E. coli (19:196:330), had been reported previously and in the latter example
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CFTR stimulation promotes bacterial dissemination from the gut. It has been 
demonstrated in the work presented here that both P. aeruginosa and B. cepacia 
induce transepithelial chloride transport in airway epithelial cells, which may 
promote bacterial colonisation of the CF lung in a number of ways. For 
example, increased mucus viscosity, inactivation of salt-sensitive bactericidal 
agents in ASF (69); or inactivation of neutrophils (340) would each facilitate 
survival of the pathogens in the lung. Alternatively, regulating electrolyte and 
fluid movements within the respiratory tract may allow the colonising bacteria 
to control the influx of antibacterial cells and biochemical mediators to the site 
of infection.
The mechanisms by which chloride transport processes were altered in the 
present work remain to be determined, but since no CFTR-dependent 
differences were identified, it is likely that another group of C f channels was 
responsible for these observations, such as those regulated by Ca2+ (CaMCC) or 
ATP. P. aeruginosa binds via bacterial flagella to abundant asialo-GMi 
residues, which function as bacterial receptors, on CF airway epithelial cells and 
mobilises intracellular Ca2+ stores (416), sometimes via ATP release (417), with
many potential physiological consequences, such as modulation of ciliary
• 2+beating and mucus production. Furthermore, respiratory epithelial Ca 
signalling may also be disrupted by P. aeruginosa pyocyanin (320). 
Stimulation of Cf channels via bacterial-induced ATP release or intracellular 
waves of Ca2+ was not investigated by these research groups, but both remain 
enticing possibilities. It was observed in the current work that a structural,
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rather than a secreted bacterial factor, induced the observed ion-channel 
modulation.
IL-8 production, as well as ion channel activity, was upregulated following 
stimulation with P. aeruginosa or B. cepacia although in contrast to results from 
the ion-channel studies, both isolated cells and supernatant from bacterial 
cultures elicited epithelial IL-8 secretion. Much of the pulmonary damage in 
CF is host-derived and results from an unusually high influx of neutrophils into 
the lung, recruited potently by IL-8 (121) that is secreted by epithelial cells and 
activated monocytic cells alike. As such, IL-8 is responsible for the initiation 
and maintenance of airway inflammation (418). Subsequent release of ROS and 
proteolytic enzymes such as elastase from activated neutrophils is extremely 
damaging to the respiratory epithelium. Therefore, it is essential to elucidate 
upstream signalling pathways leading to IL-8 synthesis in order to identify 
potential targets for treatments to attenuate respiratory pathology. Increased 
pulmonary secretion of IL-lp and TNF-a during bacterial infection add to the 
upregulation of IL-8, and has been shown here and elsewhere to be mediated at 
least in part by MAP kinase cascades.
MAP kinase inhibitors afforded variable levels of protection against IL-8 
induction by B. cepacia, which implicates MAP kinase signalling cascades in 
bacterial regulation of IL-8 and although an involvement of MAP kinases has 
been observed by other groups using P. aeruginosa, it is thought that this is a 
novel finding with respect to B. cepacia. Levels of phosphoiylated ERK-2 were 
shown to be increased in the presence of P. aeruginosa, particularly in the
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AF508 / AF508 cell line. Binding of P. aeruginosa via its flagella to asialo- 
GMi residues on the epithelial cell surface precipitates signalling via Ca2+, 
which leads to the activation of ERK 1 / 2 (321). ERK phosphorylates pp90rsk 
(419), which in turn stimulates degradation of IicBa (149) and liberates NFkB 
from its cytosolic constraints. NFkB translocates into the nucleus and activates 
the transcription of many genes encoding proteins that are important in the host 
response to infection, such as IL-8, defensins, and iNOS. There is good 
evidence, presented both here and elsewhere, that ERK activation is pivotal in 
the induction of IL-8 by some agonists, but whether this MAP kinase always 
signals through NFkB has not been established. Moreover, ERK and IL-8 
direct the immune system towards a Th2 type response, which would encourage 
the intracellular survival of B. cepacia and seems to correlate with reduced 
clearance of P. aeruginosa as well as more rapid decline in CF lung function 
(131;135).
Additional pathways of IL-8 regulation have been described in relation to other 
bacterial and viral respiratory pathogens including mediation via p38 MAP 
kinase, which has many downstream transcription factor targets. Interestingly, 
p38 seemed particularly important for IL-8 secretion in CF cells (Chapter 6). 
One of the major stimuli for p38 activation is osmotic stress (143) and in view 
of the characteristic osmotic dysregulation in CF, there is a very strong 
possibility that p38 is over-activated in CF. It is possible that hyper-activation 
of p38 contributes to elevated IL-8 production in quiescent epithelial cells. 
NFkB activation may also be mediated by p38 (406) and this MAP kinase has
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been implicated specifically in further transcription of IL-lp (420), and iNOS 
genes (421).
During the course of this work, a non-toxic assay was developed by which 
dicoumarol could be used in vitro as a pharmacological tool to dissect 
intracellular signalling pathways. Dicoumarol is a specific inhibitor of quinone 
reductase (380), an enzyme that gates redox activation of MEKK1. In turn, 
MEKK1 is a fundamental component of c-Jun and NFkB responses (398), lying 
upstream of JNK MAP kinase and activating NFkB directly and independently 
of MAP kinase cascades (146). Therefore, the observation that dicoumarol 
reduced stimulated IL-8 secretion from airway epithelial cells implicates one or 
both of JNK and NFkB in the regulation of expression of this chemokine. 
NFKB-regulated IL-8 secretion by epithelial tissue has been observed by several 
groups (321;347;416;422), but the precise nature of events upstream of gene 
transcription have not been defined clearly. Results of experiments showing 
that dicoumarol inhibited IL-8 induction in airway epithelial cells (Chapter 6) 
suggest that JNK MAP kinase may also mediate IL-8 synthesis, although these 
effects could also have been caused by inhibition of NFkB. The specific roles 
of JNK and NFkB in IL-8 production in these epithelial cells were not assessed 
directly.
Work carried out in a number of laboratories has shown excessive activation of 
NFkB in naive and stimulated cells expressing a range of CF phenotypes 
(159;422;423). Both ER overload with mis-folded CFTR and a lack of 
functional CFTR expression have been implicated in this situation (423;424).
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More specifically, one group measured the level and type of IkBP in CF versus 
normal cells and discovered that IkBP is abnormally high in quiescent CF cells 
(159). Furthermore, these researchers found that stimulated CF cells 
synthesised an unusually high proportion of the hypophosphorylated form of 
IkBP, which remains in the nucleus and does not mask the NLS of NFkB. Thus 
NFkB activation is prolonged in CF compared with normal cells (159). These 
observations might also account in part for the excessive production of IL-8 in 
quiescent and stimulated CF epithelial cells. Consensus binding sites for 
several other transcription factors have been located upstream of the IL-8 gene 
promoter so that NFkB may not be the sole regulator of expression of this gene. 
Indeed, AP-2 is also activated by P. aeruginosa, contributing to IL-8 expression 
(416).
Bacterial factors that could be responsible for induction o f this chemokine 
include LPS, flagella, autoinducer molecules or proteases. The endotoxic 
potential of B. cepacia LPS has been demonstrated in more than one study 
(62;273;274;425) and although P. aeruginosa LPS alone did not potentiate 
significant IL-8 release in the current work, other studies have shown 
endotoxicity to vary considerably amongst P. aeruginosa serotypes. Quorum 
sensing has been observed in both bacterial species and elevated levels of 
autoinducers have been detected in BAL from CF patients (227). Furthermore, 
it was demonstrated very recently that the P. aeruginosa autoinducer molecule 
3-0-C12-HSL elicits IL-8 secretion from host cells via ERK signalling to NFkB 
and AP-2 (416). Signalling via ERK also elevates production of mucin (419), 
which serves as a respiratory epithelial receptor for both P. aeruginosa (189)
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and B. cepacia (265). Synergistic interactions between P. aeruginosa and
B. cepacia binding to respiratory epithelial cells have also been described (267), 
although this concept was not investigated here. Manipulation of host cell 
signalling is a common and highly successful strategy in microbial 
pathogenicity, which includes many other examples such as ADP-ribosylation 
mediated by type III secretion system toxins (244;248;250), and alteration of 
cytokine production to subvert the immune response (426-428).
Currently, there is much interest surrounding the possibilities for treating CF at 
a very early age by correcting the underlying genetic defect. However, this 
approach would not be appropriate for all patients, such as those with 
established pulmonary inflammation and infection. Several studies have shown 
that the immune response in the CF lung is excessive and the regulation of this 
inappropriate inflammatory activity remains an important focus for clinical 
intervention in the treatment of CF. It is especially encouraging that treatment 
of rodent models of infection with anti-inflammatory agents such as ibuprofen 
or prednisolone ameliorated bronchiectasis without resulting in an increased 
bacterial load (429-431). The reported hyperactivity of NFkB in the CF lung 
(159;356;423;432) makes this transcription factor an obvious target for 
therapeutic intervention to reduce bronchiectasis and improve lung function. It 
is intriguing to note that p-adrenergic agonists comprise a class of potent NFkB 
inhibitors (433,434). These compounds have obvious beneficial effects 
regarding CFTR activation in the lung but p-adrenergic agonists may have 
additional clinical relevance to CF if they can be used in vivo to suppress 
excessive inflammatory responses via activation of NFkB. Natural dietary
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products have also been used successfully in vitro to block NFkB activation 
(435,436) and many synthetic NFkB antagonists have been reported (437).
In the wider context of CF, the data presented here have identified a number of 
potential targets that could be blocked to reduce inflammation, and these data 
corroborate other recent reports. Attempts to assess the relative contributions of 
each antimicrobial agent, defence strategy or signalling cascade must be 
considered in the context of the whole microenvironment within the lung since 
there is considerable intercommunication and redundancy in various aspects of 
respiratory immunology. Deletion of a single factor likely will be compensated 
by other local mechanisms although it is clear that respiratory infections persist 
in CF because of a combination of failed immunological mechanisms and 
disrupted signal transduction as well as the physiological adaptations of the CF 
microflora. The information presented here suggests that CF bacterial 
pathogens do indeed affect electrolyte transport and signal transduction in the 
lung and these disturbances could explain some but not all o f these host-derived 
problems. Furthermore, such findings contribute to a more thorough molecular 
understanding of the host responses that operate in the respiratory tract, and how 
they are disturbed, which may permit the development of more effective 
treatments to prevent or alleviate symptoms associated with the progressive and 
ultimately fatal pulmonary disease that defines CF.
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A irw a y  lu m e n
IL-8
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ERK JNK
CFTR CaM CC
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E p ith e l ia l  ce ll
C l' ch a n n e l a c tiv ity C h e m o k in e  p ro d u ction
Figure 7.1 Summary of data presented in this thesis. Both B. cepacia (Be) and 
P. aeruginosa (Pa) were found to activate chloride channel activity and IL-8 production in 
airway epithelial cells in vitro. The activated channels were not identified, although it is 
possible that CFTR is not implicated since CF flux was measured in both CF and normal 
epithelial cells. Other possible candidates include the ORCC, which is also activated by CFTR; 
and CaMCC, which can be stimulated by waves o f intracellular calcium. Similarly, both Be and 
Pa induced IL-8 production by respiratory epithelial cells, independently o f functional CFTR 
expression. In this study, the use of specific inhibitors of MAP kinases (ERK, p38 and JNK) 
suggested that each of these enzymes had a greater or lesser involvement in the up-regulation of 
IL-8 secretion following stimulation with bacteria or with the pro- inflammatory cytokines IL-ip 
or TNF-a, although the nature of the bacterial components and epithelial cell receptors 
responsible have not been determined in this work. It is possible that bacterial flagella binding 
to asialo-GMl (aGM l) residues could mediate ERK activation and CF channel activity. 
Another possibility is that LPS or secreted bacterial components activate IL-8 production via 
receptors similar to the TNF-receptor (TNF -R) or the TLR, since the kinetics o f some bacterial 
responses were similar to those seen following stimulation with IL- 1P or TNF-a.
193
Chapter 7: Concluding discussion
7.2 Future Work
Exciting observations made during the work presented in this study could be 
followed up in several ways. In particular, it would be interesting to investigate 
the following points:
• Characterise epithelial cell ion channel responses more closely in 
response to bacterial stimulation, using specific inhibitors of different 
chloride channels
• Employ specific antibodies against activated forms of JNK and p38 
MAP kinases in experiments, with and without specific MAP kinase 
inhibitors, to clarify their respective roles in IL-8 production
• Establish the relative cellular effects of dicoumarol on NFkB and JNK 
signalling with respect to IL-8 production
• Examine NFkB activity in relation to B. cepacia stimulation and IL-8 
production in these cell lines
• Investigate these responses in additional pairs of CF- and normal- 
epithelial cells to confirm current findings and how they relate to the 
functional expression of CFTR
194
Appendices
A p p e n d ix  I:
Solutions for  
M ultip le Procedures
195
Appendices
Table A l. Dulbecco’s phosphate buffered saline (PBS) (302)
Component Final concentration, g/L
CaCl2.2H20 1.32
KC1 0.20




Table A2. MEM non-essential amino acids (304)
Amino acid Concentration in 100 x liquid
L-Alanine 0.89 g/L
L-Asparagine 1.32 g/L
L-Aspartic acid 1.33 g/L




Table A3. M9 minimal salts
M9 component Final concentration, g/L
Na2H P 0 4.7H20 17.0








Milli-Q to 1 L
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A p p e n d ix  II:
A ddresses o f  Suppliers
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Alpha Laboratories Ltd., 40 Parham Drive, Eastleigh, Hampshire, SO50 4NU, 
U.K.
American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, 
MD 20852, U.S.A.
Amersham Pharmacia Biotech U.K. Ltd., Amersham Place, Little Chalfont, 
Buckinghamshire, HP7 9NA, U.K.
Anachem Ltd., 20 Charles Street, Luton, LU2 OEB, U.K.
BDH/Merck Ltd., Merck House, Poole, Dorset, BH15 1TD, U.K.
Becton Dickinson (U.K.) Ltd., Between Towns Road, Cowley, Oxfordshire, 
0X4 3LY, U.K.
Bibby Sterilin Ltd., Tilling Drive, Stone, Staffordshire, ST15 OSA, U.K.
Bio-Rad Laboratories Ltd., Bio-Rad House, Maylands Avenue, Hemel 
Hempstead, Hertfordshire, HP2 7TD, U.K.
BOC Gases, The Priestly Centre, 10 Priestly Road, Surrey Research Park, 
Guildford, Surrey, GU2 5XY, U.K.
Boehringer Mannheim -  Roche Diagnostics Ltd., Bell Lane, Lewes, East 
Sussex, BN7 1LG, U.K.
Buchi Labortechnik AG, Meierseggstrasse, CH-9230 Flawil, Switzerland
Calbiochem-Novabiochem (U.K.) Ltd., Boulevard Industrial Park, Padge Road, 
Beeston, Nottingham, NG9 2JR
Ciba Coming Diagnostics Ltd., Colchester Road, Halstead, Essex, C09 2DX, 
U.K.
Clonetics Corporation, 9620 Chesapeake Drive, San Diego, CA 92123, U.S.A.
Cohesion Technologies Inc., 2500 Faber Place, Palo Alto, CA 94303, U.S.A.
Costar U.K. Ltd., 10 The Valley Centre, Gordon Road, High Wycombe, 
Buckinghamshire, HP 13 6EQ, U.K.
Dako Ltd., Denmark House, Angel Drove, Ely, Cambridgeshire, CB7 4ET, 
U.K.
Difco Laboratories, Detroit, MA, U.S.A. (supplied by Becton Dickinson (U.K.) 
Ltd.)
Dynatech Technologies -  Dynex Technologies (U.K.), Action Court, Ashford 
Road, Ashford, Middlesex, TW15 IX B, U.K.
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Elkay Laboratory Products (U.K.) Ltd., Unit 4, Marlborough Mews, Crockford 
Lane, Basingstoke, Hampshire, RG24 8NA, U.K.
Fisons (Fisher Scientific), Bishop Meadow Road, Loughborough, 
Leicestershire, LEI 1 ORG, U.K.
Gibco-Life Technologies: Life Technologies Ltd., 3 Fountain Drive, Inchinnan 
Business Park, Paisley, PA4 9RF, U.K.
Grant Instruments (Cambridge) Ltd., Shepreth, Cambridgeshire, SG8 6GB, 
U.K.
Greiner Labortechnik Ltd., Station Road, Cam, Dursley, Gloucestershire, GL11 
5NS, U.K.
Jouan Ltd., Merlin Way, Quarry Hill Road, Ilkeston, Derbyshire, DE7 4RA, 
U.K.
Millipore (U.K.) Ltd., The Boulevard, Blackmoor Lane, Watford, Hertfordshire, 
WD1 8YW, U.K.
Milton Roy Company (U.K.) Ltd., DMR House, Wokingham, Berkshire, RG11 
2FD, U.K.
Molecular Probes Inc., 4849 Pitchford Avenue, Eugene, OR 97402-9165, 
U.S.A.
New Brunswick Scientific (U.K.) Ltd., Edison House, 163 Dixons Hill Road, 
North Mymms, Hartfield, Hertfordshire, AL9 7JE, U.K.
Nikon U.K. Ltd., Nikon House, 380 Richmond Road, Kingston upon Thames, 
Surrey, KT2 5PR, U.K.
Nunc, Life Technologies Ltd., 3 Fountain Drive, Inchinnan Business Park, 
Paisley, PA4 9RF, U.K.
Perkin-Elmer Applied Biosystems (ABI), Kelvin Close, Birchwood Science 
Park North, Warrington, WA3 7PB, U.K.
PTI Inc., 1009 Lenox Drive, Suite 104, Lawrenceville, New Jersey 08648, 
U.S.A.
R&D Systems Europe Ltd., 4-10 The Quadrant, Barton Lane, Abingdon, 
Oxfordshire, OX14 3YS, U.K.
Sigma-Aldrich Chemical Company Ltd., Fancy Road, Poole, Dorset, BH12 
4QH, U.K.
Stuart, U.K. (division of Bibby Sterilin)
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Techne (Cambridge) Ltd., Duxford, Cambridge, CB2 4PZ, U.K.
Tel-test, P.O. Box 1421, Friendswood, Texas 77546, U.S.A.
Wallac, Finland (supplied by Perkin Elmer Applied Biosystems)
Whatman International Ltd., Whatman House, St. Leonard’s Road, 20/20 
Maidstone, Kent, ME 16 OLJ, U.K.
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